+

WO2007117371A2 - Listeria de fabrication humaine et ses procédés d'utilisation - Google Patents

Listeria de fabrication humaine et ses procédés d'utilisation Download PDF

Info

Publication number
WO2007117371A2
WO2007117371A2 PCT/US2007/005455 US2007005455W WO2007117371A2 WO 2007117371 A2 WO2007117371 A2 WO 2007117371A2 US 2007005455 W US2007005455 W US 2007005455W WO 2007117371 A2 WO2007117371 A2 WO 2007117371A2
Authority
WO
WIPO (PCT)
Prior art keywords
acta
nucleic acid
polynucleotide
listeria
listeria bacterium
Prior art date
Application number
PCT/US2007/005455
Other languages
English (en)
Other versions
WO2007117371A3 (fr
Inventor
Thomas W. Dubensky, Jr.
Justin Skoble
Peter M. Lauer
David N. Cook
Original Assignee
Anza Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anza Therapeutics, Inc. filed Critical Anza Therapeutics, Inc.
Publication of WO2007117371A2 publication Critical patent/WO2007117371A2/fr
Publication of WO2007117371A3 publication Critical patent/WO2007117371A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Definitions

  • the invention provides engineered Listeria bacteria, useful for stimulating the immune system and treating cancers and infections. Also provided are polynucleotides, fusion protein partners, and integration vectors useful for modifying Listeria and other bacterial species.
  • Cancers and infections can be treated by administering reagents that modulate the immune system.
  • reagents include vaccines, cytokines, antibodies, and small molecules, such as CpG oligodeoxynucleotides and imidazoquinolines (see, e.g., Becker (2005) Virus Genes 30:251-266; Schetter and Vollmer (2004) Curr. Opin. Drug Devel. 7:204-210; Majewski, et al. (2005) Int. J. Dermatol. 44: 14-19), Hofmann, et al. (2005) J. Clin. Virol. 32:86-91; Huber, et al. (2005) Infection 33:25-29; Carter (2001) Nature Revs.
  • Vaccines including classical vaccines (inactivated whole organisms, extracts, or antigens), dendritic cell (DC) vaccines, and nucleic acid-based vaccines, are all useful for treating cancers and infections (see, e.g., Robinson and Amara (2005) Nat. Med. Suppl. 1 1:S25-S32; Plotkin (2005) Nat. Med. Suppl. 1 1 :S5-S1 1 ; Pashine, et al. (2005) Nat. Med. Suppl.
  • Another reagent useful for modulating the immune system is Listeria monocytogenes (JL. monocytogenes), and this reagent has proven to be successful in treating cancers and tumors (see, e.g., Brockstedt, et al. (2004) Proc. Natl. Acad. Sci. USA 101 :13832-13837; Brockstedt, et al (2005) Nat. Med. 11:853-860); Starks, et al. (2004) J. Immunol. 173:420- 427; Shen, et al. (1995) Proc. Natl. Acad. Sci. USA 92:3987-3991).
  • L. monocytogenes has a natural tropism for the liver and spleen and, to some extent, other tissues such as the small intestines (see, e.g., Dussurget, et al. (2004) Ann. Rev. Microbiol. 58:587-610; Gouin, et al. (2005) Curr. Opin. Microbiol. 8:35-45; Cossart (2002) Int. J. Med. Microbiol. 291:401-409; Vazquez-Boland, et al. (2001) Clin. Microbiol. Rev. 14:584-640; Schluter, et al. (1999) Immunobiol. 201:188-195).
  • listerial proteins such as ActA and internalin A (see, e.g., Manohar, et al. (2001) Infection Immunity 69:3542-3549; Lecuit, et al. (2004) Proc. Natl. Acad. Sci. USA 101 :6152-6157; Lecuit and Cossart (2002) Trends MoI. Med. 8:537-542).
  • L. monocytogenes' escape from the phagolysosome is mediated by listerial proteins, such as listeriolysin (LLO), PI-PLC, and PC-PLC (see Portnoy, et al. (2002) J. Cell Biol. 158:409-414).
  • Vaccines for treating cancers or infections are often ineffective because of a lack of appropriate reagents.
  • the present invention fulfills this need by providing polynucleotides, fusion protein partners, plasmids and bacterial vaccines, useful for enhancing the expression or immune processing of antigens, and for increasing survival to cancers and infections.
  • the present invention is based, in part, on the recognition that administering an attenuated Listeria to a mammal bearing a tumor results in enhanced survival, where the Listeria was engineered to contain a nucleic acid encoding an ActA-based fusion protein linked to a tumor antigen.
  • the invention provides a polynucleotide comprising a promoter operably linked to a nucleic acid sequence encoding a fusion protein, wherein the fusion protein comprises (a) modified ActA and (b) a heterologous antigen.
  • the promoter is a bacterial promoter (e.g., a Listeria! promoter).
  • the promoter is an ActA promoter.
  • the modified ActA comprises at least the first 59 amino acids of ActA.
  • the modified ActA comprises more than the first 59 amino acids of ActA.
  • the modified ActA comprises less than the first 380 amino acids or less than the first 265 amino acids.
  • the modified ActA comprises more than the first 59 amino acids of ActA, and less than the first 380 amino acids of ActA.
  • the modified ActA comprises at least about the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA.
  • the modified ActA comprises more than about the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA.
  • the modified ActA comprises more than the first 59 amino acids of ActA, and less than the first 380 amino acids of ActA.
  • the modified ActA comprises at least the first 85 amino acids of ActA and less than the first 125 amino acids of ActA.
  • the modified ActA comprises amino acids 1-100 of ActA. In some embodiments, the modified ActA consists of amino acids 1-100 of ActA.
  • the heterologous antigen may be non-Listerial. Tn some embodiments, the heterologous antigen is from, or is derived from, a cancer cell, tumor, or infectious agent. In some embodiments, the heterologous antigen is immunologically cross-reactive with, or shares at least one epitope with, the cancer, tumor, or infectious agent. In some embodiments, the heterologous antigen is a tumor antigen or is derived from a tumor antigen. In some embodiments, the heterologous antigen is, or is derived from, mesothelin.
  • the heterologous antigen is, or is derived from, human mesothelin.
  • the Listeria is hMeso26 or hMeso38 (see Table 1 1 of Example VII, below).
  • the heterologous antigen comprises an EphA2 antigenic peptide.
  • the heterologous antigen does not comprise an EphA2 antigenic peptide.
  • the nucleic acid sequence encoding the fusion protein is codon-optimized for expression in Listeria. The invention provides plasmids and cells comprising the polynucleotide.
  • the invention further provides a Listeria bacterium (e.g., Listeria monocytogenes) comprising the polynucleotide, as well as vaccines comprising the Listeria.
  • the Listeria bacterium may be attenuated (e.g., an actA deletion mutant or an actA insertion mutant).
  • the bacterium may comprise an attenuating mutation in actA and/or inlB.
  • the Listeria comprises the polynucleotide in its genome.
  • the polynucleotide has been integrated into a virulence gene in the Listerial genome.
  • a polynucleotide (or nucleic acid) has been integrated into a virulence gene in the genome of the Listeria, wherein the integration of the polynucleotide (a) disrupts expression of the virulence gene and/or (b) disrupts a coding sequence of the virulence gene.
  • the virulence gene is prfA-dependent. In other embodiments, the virulence gene is prfA-independent.
  • the nucleic acid or the polynucleotide has been integrated into the genome of the Listeria at the actA locus and/or inlB locus.
  • the Listeria comprises a plasm id comprising the polynucleotide.
  • the invention further provides immunogenic and pharmaceutical compositions comprising the Listeria.
  • the invention also provides methods for stimulating immune responses to the heterologous antigen in a mammal (e.g., a human), comprising administering an effective amount of the Listeria (or an effective amount of a composition comprising the Listeria) to the mammal.
  • the invention also provides methods for stimulating immune responses to an antigen from, or derived from, a cancer or infectious agent, comprising administering an effective amount of the Listeria (or a composition comprising the Listeria) to a mammal having the cancer or infectious agent, wherein the heterologous antigen shares at least one epitope with or is immunologically cross-reactive with the antigen from, or derived from, the cancer or infectious agent.
  • inclusion of the modified Act A sequence in the fusion protein enhances the immunogenicity of the Listeria comprising the polynucleotide (e.g., relative to the immunogenicity of Listeria comprising a polynucleotide encoding a fusion protein comprising the heterologous antigen and a non-ActA signal sequence and/or leader sequence, instead of the modified ActA).
  • inclusion of the modified Act A sequence in the fusion protein enhances expression and/or secretion of the heterologous antigen in Listeria (e.g., relative to the expression and/or secretion in Listeria of the heterologous antigen fused to a non-ActA signal sequence and/or leader sequence instead of the modified ActA).
  • the invention provides a polynucleotide comprising a first nucleic acid encoding a modified ActA (e.g., actA-N-100), operably linked and in frame with, a second nucleic acid encoding a heterologous antigen.
  • the modified ActA comprises at least the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA.
  • the modified ActA comprises more than the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA.
  • the first nucleic acid encodes amino acids 1 -100 of ActA.
  • the polynucleotide is genomic.
  • the polynucleotide may be integrated into the actA or inlB gene.
  • the polynucleotide is plasmid-based.
  • the polynucleotide is operably linked with one or more of the following: (a) actA promoter; or (b) a bacterial promoter that is not actA promoter.
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is immunologically cross-reactive with, or shares at least one epitope with, the cancer, tumor, or infectious agent.
  • the heterologous antigen is, or is derived from, mesothelin (e.g., human mesothelin).
  • the invention further provides & Listeria bacterium e.g., Listeria monocytogenes) comprising the polynucleotide, as well as vaccines comprising the Listeria.
  • the Listeria is hMeso26 or hMeso38 (see Table 11 of Example VFI, below).
  • the invention also provides methods for stimulating immune responses to an antigen from, or derived from, a cancer (e.g., a tumor or pre-cancerous cell) or infectious agent (e.g., a virus, pathogenic bacterium, or parasitic organism), comprising administering the Listeria to a mammal having the cancer or infectious agent, wherein the heterologous antigen shares at least one epitope with or is immunologically cross-reactive with the antigen from, or derived from, the cancer or infectious agent.
  • the stimulating is relative to immune response without administering the Listeria.
  • the heterologous antigen is from, or is derived from, the cancer cell, tumor, or infectious agent.
  • the invention provides a polynucleotide comprising a first nucleic acid encoding a modified actA, wherein the modified actA comprises (a) amino acids 1-59 of actA, (b) an inactivating mutation in, deletion of, or truncation prior to, at least one domain for actA-mediated regulation of the host cell cytoskeleton, wherein the first nucleic acid is operably linked and in frame with a second nucleic acid encoding a heterologous antigen.
  • the modified ActA comprises more than the first 59 amino acids of ActA.
  • the domain is the cofilin homology region (KKRR (SEQ ID NO:23)).
  • the domain is the phospholipid core binding domain (KVFKKIKDAGKWVRDKI (SEQ ID NO:20)).
  • the at least one domain comprises all four proline-rich domains (FPPPP (SEQ ID NO:21), FPPPP (SEQ ID NO:21), FPPPP (SEQ ID NO:21), FPPIP (SEQ ID NO:22)) of ActA.
  • the modified actA is actA-NIOO.
  • the polynucleotide is genomic. In some embodiments, the polynucleotide is not genomic.
  • the polynucleotide is operably linked with one or more of the following: (a) actA promoter; or (b) a bacterial (e.g., listerial) promoter that is not actA promoter.
  • the invention further provides a Listeria bacterium (e.g., Listeria monocytogenes) comprising the polynucleotide, as well as vaccines comprising the Listeria.
  • the Listeria comprises an attenuating mutation in actA and/or inlB.
  • the Listeria is is hMeso26 or hMeso38 (see Table 11 of Example VII, below).
  • the invention also provides methods for stimulating immune responses to an antigen from, or derived from, a cancer or infectious agent, comprising administering the Listeria to a mammal having the cancer or infectious agent, wherein the heterologous antigen shares at least one epitope with or is immunologically cross-reactive with the antigen from, or derived from, the cancer or infectious agent.
  • the stimulating is relative to immune response without administering the Listeria.
  • the cancer comprises a tumor or pre-cancerous cell.
  • the infectious agent comprises a virus, pathogenic bacterium, or parasitic organism.
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is immunologically cross-reactive with, or shares at least one epitope with, the cancer, tumor, or infectious agent.
  • the heterologous antigen is, or is derived from, mesothelin.
  • the heterologous antigen is, or is derived from, human mesothelin.
  • inclusion of the modified Act A sequence in the polynucleotide enhances expression and/or secretion of the heterologous antigen in Listeria.
  • inclusion of the modified Act A sequence in the polynucleotide enhances the immunogenicity of vaccine compositions comprising the Listeria.
  • the invention provides a plasmid comprising a first nucleic acid encoding a phage integrase, a second nucleic acid encoding a phage attachment site (attPP' site), and a third nucleic acid encoding a heterologous antigen or regulatory nucleic acid, wherein the plasmid is useful for mediating site-specific integration of the nucleic acid encoding the heterologous antigen at a bacterial attachment site (attBB' site) in a bacterial genome that is compatible with the attPP' site of the plasmid.
  • each of the nucleic acids is derivable from L.
  • each of the nucleic acids is derivable from L. innocua 1765, each of the nucleic acids is derivable from L. innocua 2601, or each of the nucleic acids is derivable from L. monocytogenes f6854_2703.
  • the first nucleic acid encodes a phiC31 integrase.
  • the plasmid is the polynucleotide sequence of pINT; or a polynucleotide hybridizable under stringent conditions to a polynucleotide encoding pINT, wherein the polynucleotide that is hybridizable is capable of mediating site specific integration at the same bacterial attachment site (attBB') in a bacterial genome as that used by pINT.
  • the bacterial genome is of a Listeria, Bacillus anthracis, or Francisella tularensis.
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the regulatory nucleic acid is a bacterial attachment site (attBB')-
  • the plasmid further comprises a fourth nucleic acid encoding a first lox site, a fifth nucleic acid encoding a second lox site, and a sixth nucleic acid encoding a selection marker, wherein the first lox site and second lox site are operably linked with the sixth nucleic acid, and wherein the operably linked lox sites are useful for mediating Cre recombinase catalyzed excision of the sixth nucleic acid.
  • the first lox site is a loxP site and the second lox site is a loxP site.
  • the plasmid further comprises a non compatible bacterial attachment site (attBB'), wherein the non compatible attBB' site is not compatible with the phage attachment site (attPP').
  • the plasmid further comprises a first promoter operably linked with the first nucleic acid, and a second promoter operably linked with the third nucleic acid.
  • the invention further provides a method of modifying a bacterial genome, comprising transfecting the bacterium with the plasmid, and allowing integrase-catalyzed integration of the third nucleic acid into the bacterial genome under conditions suitable for integration.
  • the bacterium is Listeria, Bacillus anthracis, or Francisella tularensis.
  • the invention further provides a plasmid comprising: (a) a first nucleic acid encoding a first region of homology to a bacterial genome, (b) a second nucleic acid encoding a second region of homology to the bacterial genome, and (c) a third nucleic acid comprising a bacterial attachment site (attBB'), wherein the third nucleic acid is flanked by the first and second nucleic acids, wherein the first nucleic acid and second nucleic acid are operably linked with each other and able to mediate homologous integration of the third nucleic acid into the bacterial genome.
  • a plasmid comprising: (a) a first nucleic acid encoding a first region of homology to a bacterial genome, (b) a second nucleic acid encoding a second region of homology to the bacterial genome, and (c) a third nucleic acid comprising a bacterial attachment site (attBB'), wherein the third nucleic
  • the bacterial attachment site comprises the attBB' of: Hsterial tRNAArg-attBB'; listerial comK attBB'; Listeria innocua 007 '1; Listeria innocua 1231 ; Listeria innocua 1765; Listeria innocua 2610; or Listeria monocytogenes f6854_2703; or phiC31.
  • the genome is of a Listeria, Bacillus anthracis, or Francisella tularensis.
  • the third nucleic acid encodes a selection marker flanked by a first lox site and a second lox site, wherein the lox sites are recognized as substrates by Cre recombinase and allow Cre recombinase catalyzed excision of the third nucleic acid, and wherein the selection marker is useful for detecting integration of the third nucleic acid into the bacterial genome.
  • the first lox site is a loxP site
  • the second lox site is a loxP site.
  • the third nucleic acid comprises an antibiotic resistance gene.
  • the first nucleic acid is homologous to a first region of a virulence factor gene and the second nucleic acid is homologous to a second region of the virulence factor gene, wherein the first and second regions of the virulence factor gene are distinct from each other and do not overlap each other.
  • the first region of the virulene factor gene covalently contacts or abuts the second region of the virulence factor gene.
  • the first region of the virulence factor gene is not in covalent contact with, and does not covalently about, the second region of the virulence factor gene.
  • the invention further provides bacteria modified by integration of the plasmid.
  • the integration is in a region of the genome that is necessary for mediating growth or spread. In other embodiments, the integration is in a region of the genome that is not necessary for mediating growth or spread.
  • the invention provides a bacterium wherein the genome comprises a polynucleotide containing two operably linked heterologous recombinase binding sites flanking a first nucleic acid, wherein the two sites are: (a) two lox sites; or (b) two Fit sites, and wherein the nucleic acid flanked by the two lox sites is excisable by Cre recombinase, and wherein the nucleic acid flanked by the two Frt sites is excisable by FLP recombinase.
  • the two lox sites are both loxP sites.
  • the first nucleic acid encodes a selection marker or a heterologous antigen.
  • the first nucleic acid encodes an antibiotic resistance gene.
  • the bacterium is Listeria, Bacillus anthracis, or Francisella tularensis.
  • the polynucleotide further comprises a second nucleic acid, wherein the second nucleic acid is not flanked by, and is not operably linked with, the first and second heterologous recombinase binding site.
  • the second nucleic acid encodes one or both of: heterologous antigen; or a bacterial attachment site (attBB').
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the invention further provides a method of excising the first nucleic acid from the bacterial genome, comprising contacting the genome with Cre recombinase or FLP recombinase, and allowing the recombinase to catalyze excision of the first nucleic acid, under conditions allowing or facilitating excision: (a) wherein the first nucleic acid is flanked by lox sites and the recombinase is Cre recombinase; or (b) wherein the first nucleic acid is flanked by Fit sites and the recombinase is FLP recombinase.
  • the recombinase is transiently expressed in the bacterium.
  • the invention provides Listeria (e.g., Listeria monocytogenes) in which the genome comprises a polynucleotide comprising a nucleic acid encoding a heterologous antigen.
  • the nucleic acid encoding the heterologous antigen has been integrated into the genome by site-specific recombination or homologous recombination.
  • the site of integration into the genome is the tRNA ⁇ 6 locus.
  • the presence of the nucleic acid in the genome attenuates the Listeria.
  • the nucleic acid encoding the heterologous antigen has been integrated into the locus of a virulence gene.
  • the nucleic acid encoding the heterologous antigen has been integrated into the actA locus. In some embodiments, the nucleic acid encoding the heterologous antigen has been integrated into the ⁇ nlB locus. In some embodiments, the genome of the Listeria comprises a first nucleic acid encoding a heterologous antigen that has been integrated into a first locus (e.g., the actA locus) and a second nucleic acid encoding a second heterologous antigen that has been integrated into a second locus (e.g., the inlB locus). The first and second heterologous antigens may be identical to each other or different.
  • the first and second heterologous antigens differ from each other, but are derived from the same tumor antigen or infectious agent antigen. In some embodiments, the first and second heterologous antigens are each a different fragment of an antigen derived from a cancer cell, tumor, or infectious agent.
  • the integrated nucleic acid encodes a fusion protein comprising a modified ActA and the heterologous antigen. In some embodiments, at least two, at least three, at least four, at least five, at least six, or at least seven nucleic acid sequences encoding heterologous antigens have been integrated into the Listerial genome.
  • the invention provides a Listeria bacterium comprising a genome, wherein the genome comprises a polynucleotide comprising a nucleic acid encoding a heterologous antigen, wherein the nucleic acid has been integrated into a virulence gene in the genome.
  • the Listeria is attenuated by disruption of expression of the virulence gene or disruption of a coding sequence of the virulence gene.
  • integration of the polynucleotide (a) disrupts expression of the virulence gene; or (b) disrupts a coding sequence of the virulence gene.
  • all or part of the virulence gene has been deleted.
  • the integration attenuates the Listeria.
  • the virulence gene is prfA-dependent. In other embodiments, the virulence gene is prfA-independent. In some embodiments, the virulence gene is necessary for mediated growth or spread of the bacterium. In some embodiments, the virulence gene is not necessary for growth and spread of the bacterium. In some embodiments, the virulence gene is actA or inlB.
  • the Listeria bacterium is Listeria monocytogenes.
  • the heterologous antigen is from, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is mesothelin (e.g., human mesothelin), or derived from mesothelin.
  • the nucleic acid encodes a fusion protein comprising a modified actA and the heterologous antigen.
  • the bacterium comprises a second nucleic acid encoding a second heterologous antigen that has been integrated into a second virulence gene. The invention provides vaccines comprising the Listeria bacterium.
  • the invention further provides a method for stimulating an immune response to the heterologous antigen in a mammal, comprising administering an effective amount of the Listeria bacterium, or an effective amount of a composition comprising the Listeria bacterium, to the mammal.
  • the invention provides a method of producing a Listeria bacterium (e.g., an attenuated bacterium), comprising integrating a polynucleotide into a virulence gene in the genome of the Listeria bacterium, wherein the polynucleotide comprises a nucleic acid encoding a heterologous antigen.
  • the Listeria is attenuated by disruption of expression of the virulence gene or disruption of a coding sequence of the virulence gene.
  • the integration of the polynucleotide (a) disrupts expression of the virulence gene or (b) disrupts a coding sequence of the virulence gene.
  • the integration of the polynucleotide results in both (a) and (b).
  • the method produces a Listeria bacterium for use in a vaccine.
  • the polynucleotide is integrated into the virulence gene by homologous recombination.
  • the polynucleotide is integrated via site- specific recombination.
  • all or part of the virulence gene is deleted during integration of the polynucleotide.
  • none of the virulence gene is deleted during the integration.
  • the virulence gene is actA or inlB.
  • the heterologous antigen is from, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is mesothelin (e.g., human mesothelin), or derived from mesothelin.
  • the nucleic acid encodes a fusion protein comprising a modified ActA and the heterologous antigen.
  • the invention further provides a Listeria bacterium produced by the method, and vaccine compositions comprising the bacterium.
  • the invention also provides a Listeria bacterium having the properties of a Listeria bacterium produced by the method, as well as vaccines comprising the bacterium. Methods for stimulating an immune response to the heterologous antigen in a mammal, comprising administering an effective amount of the Listeria bacterium, or an effective amount of a composition comprising the Listeria bacterium, are also provided.
  • the invention provides a Listeria bacterium comprising a genome, wherein the genome comprises a polynucleotide comprising a nucleic acid encoding a heterologous antigen, wherein the nucleic acid has been integrated into a gene necessary for mediating growth or spread.
  • integration of the polynucleotide attenuates the Listeria for growth or spread.
  • part or all of the gene has been deleted.
  • none of the gene has been deleted.
  • the gene is actA.
  • the Listeria bacterium is Listeria monocytogenes.
  • the heterologous antigen is from, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is mesothelin (e.g., human mesothelin), or derived from mesothelin.
  • the nucleic acid encodes a fusion protein comprising a modified ActA and the heterologous antigen.
  • the invention provides vaccines comprising the Listeria bacterium.
  • the invention further provides a method for stimulating an immune response to the heterologous antigen in a mammal, comprising administering an effective amount of the Listeria bacterium, or an effective amount of a composition comprising the Listeria bacterium, to the mammal.
  • the invention provides a method of producing a Listeria bacterium (e.g., an attenuated bacterium), comprising integrating a polynucleotide into a gene in the genome of the Listeria bacterium that is necessary for mediating growth or spread, wherein the polynucleotide comprises a nucleic acid encoding a heterologous antigen.
  • the integration of the polynucleotide attenuates the Listeria for growth or spread.
  • the method produces a Listeria bacterium for use in a vaccine.
  • the polynucleotide is integrated into the gene by homologous recombination.
  • the polynucleotide is integrated via site-specific recombination. In some embodiments, all or part of the gene necessary for mediating growth or spread is deleted during integration of the polynucleotide. In other embodiments, none of the gene is deleted during the integration. In some embodiments, the gene necessary for mediating growth or spread is actA.
  • the heterologous antigen is from, or is derived from, a cancer cell, tumor, or infectious agent. In some embodiments, the heterologous antigen is mesothelin (e.g., human mesothelin), or derived from mesothelin.
  • the nucleic acid encodes a fusion protein comprising the heterologous antigen and a modified ActA.
  • the invention further provides a Listeria bacterium produced by the method, and vaccine compositions comprising the bacterium.
  • the invention also provides a Listeria bacterium having the properties o ⁇ & Listeria bacterium produced by the method, as well as vaccines comprising the bacterium. Methods for stimulating an immune response to the heterologous antigen in a mammal, comprising administering an effective amount of the Listeria bacterium, or an effective amount of a composition comprising the Listeria bacterium, are also provided.
  • the invention provides a Listeria bacterium comprising a genome, wherein the genome comprises a polynucleotide comprising a nucleic acid encoding a heterologous antigen, wherein the nucleic acid has been integrated into a virulence gene in the genome and the bacterium is attenuated by disruption of expression of the virulence gene or disruption of a coding sequence of the virulence gene.
  • all or part of the virulence gene has been deleted.
  • none of the virulence gene has been deleted.
  • the virulence gene is actA or inlB.
  • the Listeria is Listeria monocytogenes.
  • the heterologous antigen is from, or is derived from, a cancer cell, tumor, or infectious agent.
  • bacterium further comprises a second nucleic acid encoding a second heterologous antigen that has been integrated into a second virulence gene.
  • the nucleic acid encodes a fusion protein comprising the heterologous antigen and a modified ActA.
  • Vaccines comprising the Listeria bacterium are further provided, as are methods for stimulating an immune response to the heterologous antigen in a mammal, comprising administering an effective amount of the Listeria bacterium or an effective amount of a composition comprising the Listeria bacterium, to the mammal.
  • the invention provides a method of producing a Listeria bacterium for use in a vaccine, comprising: integrating a polynucleotide into a virulence gene in the genome of the Listeria bacterium, wherein the polynucleotide comprises a nucleic acid encoding a heterologous antigen and wherein the bacterium is attenuated by disruption of the expression of the virulence gene or disruption of a coding sequence of the virulence gene.
  • the polynucleotide is integrated into the virulence gene by homologous recombination.
  • all or part of the virulence gene is deleted during integration of the polynucleotide into the virulence gene.
  • the virulence gene is actA or inlB.
  • the invention further provides a Listeria bacterium produced by the method.
  • the invention provides a method of producing a Listeria bacterium for use in a vaccine, comprising integrating a polynucleotide into a virulence gene in the genome of the Listeria bacterium, wherein the polynucleotide comprises a nucleic acid encoding a heterologous antigen and wherein the Listeria bacterium is or has been attenuated by mutation of the virulence gene.
  • the invention further provides a Listeria bacterium produced by this method.
  • the Listeria is attenuated with respect to cell-to-cell spread and/or entry into nonphagocytic cells.
  • the Listeria comprises an attenuating mutation in actA and/or inlB.
  • the polynucleotide and/or the nucleic acid encoding the fusion protein comprising the heterologous antigen has been integrated into a virulence gene in the genome.
  • the heterologous antigen is prostate stem cell antigen (PSCA) (e.g., human PSCA), or an antigen derived from PSCA.
  • PSCA prostate stem cell antigen
  • the heterologous antigen is mesothelin, or an antigen derived from mesothelin.
  • the polynucleotide comprises two nucleic acid sequences, each of which encodes the fusion protein comprising a heterologous antigen. In further embodiments, the polynucleotide comprises three nucleic acids, each of which encodes a fusion protein comprising a heterologous antigen. In some embodiments, the polynucleotide comprises four or more nucleic acids, each of which encodes a fusion protein comprising a heterologous antigen.
  • the invention provides a Listeria bacterium comprising a genome, wherein the genome comprises: (a) a first polynucleotide comprising a first nucleic acid encoding a first heterologous antigen, wherein the first polynucleotide has been integrated into a virulence gene in the genome and wherein the polynucleotide comprises a nucleic acid encoding a heterologous antigen; and (b) a second polynucleotide comprising a second nucleic acid encoding a second heterologous antigen, wherein the second polynucleotide has also been integrated into the genome.
  • the bacterium is attenuated by disruption of the expression of the virulence gene or by disruption of a coding sequence of the virulence gene.
  • the integration of the first polynucleotide disrupts expression of the virulence gene or disrupts a coding sequence of the virulence gene.
  • all or part of the virulence gene has been deleted.
  • none of the virulence gene has been deleted.
  • the virulence gene is actA or inlB.
  • the Listeria is Listeria monocytogenes.
  • the first and second heterologous antigens are from, or are derived from, a cancer cell, tumor, or infectious agent.
  • the first and/or second heterologous antigen is mesothelin, an antigen derived from mesothelin, PSCA, or an antigen derived from PSCA (e.g., the first heterologous antigen may be mesothelin, and the second heterologous antigen may be PSCA).
  • the second polynucleotide has been integrated into a virulence gene in the genome and the Listeria may be attenuated by disruption of the expression of the virulence gene or disruption of a coding sequence of the virulence gene.
  • the second polynucleotide has been integrated into actA or inlB. In some embodiments, the second polynucleotide has been integrated into a region of the genome which does not comprise a virulence gene (e.g., at the tRNA ⁇ 6 locus).
  • the first and/or second nucleic acid encodes a fusion protein comprising a modified ActA (e.g., ActA-NlOO) and the first or second heterologous antigen.
  • the first and/or second nucleic acid encodes a fusion protein comprising a signal sequence and the first or second heterologous antigen, wherein the signal sequence is an ActA signal sequence, p60 signal sequence, an LLO signal sequence, a BaPa signal sequence, a Llusp45 signal sequence, or a PhoD signal sequence.
  • Vaccines comprising the Listeria bacterium are further provided.
  • Methods of stimulating an immune response to the heterologous antigen in a mammal comprising administering an effective amount of the Listeria bacterium, or an effective amount of a composition comprising the Listeria bacterium, to the mammal are also provided.
  • the genome of the Listeria further comprises a third polynucleotide comprising a third nucleic acid encoding a third heterologous antigen, wherein the third polynucleotide has also been integrated into the genome.
  • the polynucleotides comprising the nucleic acid(s) encoding a heterologous antigen(s) or the fusion protein(s) comprising a heterologous antigen that are integrated into a region of the genome further comprise a promoter and/or other regulatory sequences necessary for expression of the nucleic acids once integrated.
  • the polynucleotides comprising the nucleic acids encoding the heterologous antigen or the fusion protein comprising the heterologous antigen are integrated into a region of the genome such that the nucleic acid is operably linked to a promoter and/or secretory signal already present in the Listeria genome.
  • the polynucleotides that are inserted in virulence genes are inserted in coding regions. In some other embodiments, the polynucleotides are inserted into non-coding regions of the virulence genes.
  • polynucleotides integrated into the Listeria genome are integrated via homologous recombination. In some alternative embodiments, the polynucleotides are integrated into the Listeria genome via site-specific integration.
  • the invention provides a Listeria bacterium containing a polynucleotide comprising a first nucleic acid encoding a fusion protein partner, operably linked and in frame with and a second nucleic acid encoding human mesothelin, or a derivative thereof.
  • the first nucleic acid can encode, e.g., LLO62 (non-codon optimized); LLO26 (codon optimized); LLO441 (non-codon optimized); LLO441 (codon optimized); full length LLO (non-codon optimized); full length LLO (codon optimized); BaPA secretory sequence; B.
  • subtilis phoD secretory sequence Bs phoD SS
  • p60 non-codon optimized
  • p60 codon optimized
  • actA non-codon optimized
  • actA codon optimized
  • actA-NlOO non-codon optimized
  • actA-NIOO codon optimized
  • actA A30R
  • the second nucleic acid can encode full length human mesothelin; human mesothelin deleted in its signal sequence; human mesothelin deleted in its GPI anchor; or human mesothelin deleted in both the signal sequence and the GPI anchor, where codon-optimized and non-codon optimized versions of mesothelin are provided.
  • the present invention provides the above polynucleotide integrated at the position of the inlB gene, actA gene, My gene, where integration can be mediated by homologous recombination, and where integration can optionally be with operable linking with the promoter of the inlB, actA, or My gene.
  • the invention provides listerial embodiments where the above polynucleotide is integrated into the listerial genome by way of site-specific integration, e.g., at the tRNA ⁇ 6 site.
  • Each of the individual embodiments disclosed herein optionally, encompasses a Listeria comprising a constitutively active pfrA gene (prfA*).
  • the listerial constructs are not limited to polynucleotides operably linked with an actA promoter or hly promoter. What is also encompassed is operable linkages with other bacterial promoters, synthetic promoters, bacteriovirus promoters, and combinations of two or more promoters.
  • the heterologous antigen encoded by a nucleic acid in the polynucleotides, Listeria bacteria, and/or vaccines described above, or elsewhere herein comprises an EphA2 antigenic peptide.
  • the heterologous antigen encoded by a nucleic acid in the polynucleotides, Listeria bacteria, and/or vaccines comprises full-length EphA2 or an antigenic fragment, analog or derivative thereof.
  • the heterologous antigen encoded by a nucleic acid in the polynucleotides, Listeria bacteria, and/or vaccines described above, or elsewhere herein does not comprise an EphA2 antigenic peptide.
  • the heterologous antigen encoded by a nucleic acid in the polynucleotides, Listeria bacteria, and/or vaccines does not comprise full- length EphA2 or an antigenic fragment, analog or derivative thereof.
  • Figure 1 discloses pINT, a 6055 bp plasmid. Once pINT is integrated in a listerial genome, the Listeria can be isolated by erythromycin resistance (ErmC), followed by treatment with Cre recombinase to remove a region of the plasmid encoding the antibiotic resistance genes (CAT and ErmC).
  • ErmC erythromycin resistance
  • CAT and ErmC Cre recombinase
  • Figure 2 shows pKSV7, a 7096 plasmid that mediates homologous recombination.
  • Figure 3 shows steps, or intermediates, occurring with pKSV7-mediated homologous recombination into a bacterial genome.
  • Figure 4 discloses a method for preparing an insert bearing homologous arms, where the insert bearing the homologous arms is placed into pKSV7. The loxP-flanked region is bracketed by the homologous arms. After integration into a bacterial genome, transient exposure to Cre recombinase catalyzes removal of the antibiotic resistance gene.
  • Integration occurs with deletion of part of the genome, corresponding to the region between areas matching the homologous arms.
  • Figure 5 shows an alternate method for preparing an insert bearing homologous arms, where the insert bearing homologous arms is placed into pKSV7.
  • the loxP-flanked region resides outside the homologous arms.
  • transient exposure to Cre recombinase catalyzes removal of the antibiotic resistance gene (or other selection marker). Integration occurs with deletion of part of the genome, corresponding to the region between areas matching the homologous arms.
  • Figure 6 discloses the preparation of an insert bearing homologous arms, where the insert bearing homologous arms is placed into pKSV7.
  • the loxP-flanked region resides in between the homologous arms.
  • integration is not followed by deletion of any corresponding region of the genome.
  • Figure 7 is a schematic disclosing some of the mesothelin constructs of the present invention, including, e.g., any promoters, secretory sequences, fusion protein partners, and so on.
  • Figure 8 is a gel showing expression of mesothelin from various listerial constructs.
  • Figure 9 is a gel showing expression of mesothelin from a number of listerial constructs.
  • Figures 10-12 show expression of interferon-gamma (IFN gamma) from spot forming cell (SFC) assays, and compare immune responses where mice had been vaccinated with various numbers (colony forming units; c.f.u.) of engineered L. monocytogenes.
  • IFN gamma interferon-gamma
  • SFC spot forming cell
  • Figures 13 disclose numbers of tumor metastases on the surfaces of livers, after treating tumor-bearing mice with various preparations of recombinant L. monocytogenes.
  • Figure 13 reveals the raw data (photographs of fixed livers).
  • Figure 14 also disclose numbers of tumor metastases on the surfaces of livers, after treatment of tumor-bearing mice with various preparations of recombinant L. monocytogenes.
  • Figure 15A-G further disclose numbers of tumor metastases on the surfaces of livers, after treating tumor-bearing mice with recombinant L. monocytogenes.
  • Figure 16 demonstrates increased survival to tumors by tumor-bearing mice with treatment with various preparations of recombinant L. monocytogenes.
  • Figure 17 illustrates mesothelin constructs and secretion of mesothelin by various preparations of recombinant L. monocytogenes.
  • Figure 18 discloses secretion of mesothelin and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 19 shows secretion of mesothelin and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 20 further reveals mesothelin expression and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 21 additionally illustrates secretion of mesothelin and immune responses . stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 22 demonstrates mesothelin expression and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 23 discloses immune responses stimulated by vaccination with various preparations of recombinant Listeria.
  • Figure 24 further discloses secretion of mesothelin and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 25 reveals immune responses stimulated after vaccination with a number of preparations of recombinant Listeria.
  • Figure 26 additionally discloses secretion of mesothelin and immune responses stimulated by various preparations of recombinant Z. monocytogenes.
  • hMeso ⁇ L. monocytogenes ⁇ actA ⁇ inlB encoding actA promoter; actA-NIOO-hMeso ⁇ SS ⁇ GP1; integrated at actA locus.
  • hMeso25 L. monocytogenes ⁇ actA ⁇ inlB encoding actA promoter; actA-NIOO-hMeso ⁇ SS ⁇ GPI; integrated at inlB locus.
  • Figure 27 further demonstrates secretion of mesothelin and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 28 shows photographs of fixed lungs.
  • Figure 29 shows a histogram of data from the photographs of fixed lung.
  • Figure 30 reveals the effectiveness of various preparations of recombinant Listeria in improving survival of tumor-bearing mice.
  • Figure 31 discloses secretion of mesothelin and immune responses stimulated by various preparations of recombinant L. monocytogenes.
  • Figure 32 compares mesothelin expression from various preparations of recombinant Listeria.
  • Figure 33 depicts mesotheiin secretion and immune responses stimulated after vaccination with recombinant L. monocytogenes.
  • Figure 34 demonstrates immune response stimulated after vaccination with the preparations and doses of recombinant Listeria.
  • Figures 35A and 35B disclose numbers of tumor metastases on livers, after treatment of tumor-bearing mice with various preparations of recombinant L. monocytogenes.
  • Figure 35 A illustrates raw data (photographs of fixed livers).
  • Figure 36 demonstrates the effectiveness of various preparations of recombinant
  • Figure 37 discloses immune response after vaccination with various preparations of recombinant Listeria, and compares CD4 + T cell and CD8 + T cell responses.
  • Figure 38 reveals survival of tumor-bearing mice to the tumors after vaccination with various preparations of recombinant Listeria.
  • Figure 39 further illustrates survival of tumor-bearing mice to the tumors after vaccination with various preparations of recombinant Listeria.
  • Figure 40 discloses alignment of a phage integrase of the present invention with a another phage integrase (U 153 inf. SEQ ID NO: 1; Hn 1231 : SEQ ID NO:2).
  • Figure 41 discloses alignment of yet another phage integrase of the present invention another phage integrase (PSA int: SEQ ID NO:3; Hn 0071: SEQ ID NO:4).
  • Figure 42 shows alignment of still another phage integrase of the present invention with a different phage integrase (PSA int: SEQ ID NO:5; Hn 1765: SEQ ID NO:6).
  • Figure 43 discloses alignment of a further phage integrase of the present invention with another phage integrase (PSA int: SEQ ID NO:7; Hn 2601 : SEQ ID NO: 8).
  • Figure 44 provides an alignment of an additional phage integrase of the present invention with a nucleic acid encoding another phage integrase (PSA int: SEQ ED NO: 119;
  • Imof6854_2703 SEQ BD NO: 120).
  • Figure 45A-B provides the human EphA2 cDNA sequence (CDS: nt 138 to 3068)
  • Figure 46 A-B provides the human EphA2 polypeptide sequence (SEQ ID NO: 153) published as SEQ ID NO:2 in U.S. Patent Publication No. 2005/0281783 Al, incorporated by reference herein in its entirety.
  • Figure 47A and 47B discloses pINT-ActANlOO-BamHI-Spel-Mfel-SIINFEKL, a
  • Figure 47B shows the cloning region of pINT-ActAN 100-BamHI- Spel-Mfel-SirNFEKL.
  • Nucleic acid sequence is SEQ ID NO: 150
  • Peptide sequence is SEQ ID NO: 1
  • Figure 48 discloses the schematic configuration of PSCA molecular constructs with
  • Figure 49A shows the results of dendritic cell presentation of peptides to the reporter cell line B3Z.
  • Figure 49B is a Western blot analysis of expression and secretion of
  • Figure 50 demonstrates immune response stimulated after vaccination with recombinant Listeria monocytogenes expressing ActA-NIOO-PSCA fusion proteins.
  • Figure 5 IA and 5 IB disclose bivalent vaccine strains expressing two different human tumor antigens.
  • Figure 5 IA discloses fusion molecules encoded by integrated constructs.
  • Figure 5 IB discloses the expression and secretion of ActA fusion proteins following infection of J774 cells with monovalent or bivalent Listeria monocytogenes vaccines.
  • Figure 52 demonstrates immune response stimulated after vaccination with monovalent or divalent recombinant Listeria monocytogenes vaccines.
  • Abbreviations used to indicate a mutation in a gene, or a mutation in a bacterium comprising the gene are as follows.
  • the abbreviation "L. monocytogenes ⁇ ActA” means that part, or all, of the ActA gene was deleted.
  • the delta symbol ( ⁇ ) means deletion.
  • An abbreviation including a superscripted minus sign ⁇ Listeria ActA ' ) means that the ActA gene was mutated, e.g., by way of a deletion, point mutation, or frameshift mutation, but not limited to these types of mutations.
  • Exponentials are abbreviated, where, for example, "3e7" means 3 x 10 7 .
  • administering refers without limitation to contact of an exogenous ligand, reagent, placebo, small molecule, pharmaceutical agent, therapeutic agent, diagnostic agent, or composition to the subject, cell, tissue, organ, or biological fluid, and the like.
  • administering can refer, e.g., to therapeutic, pharmacokinetic, diagnostic, research, placebo, and experimental methods. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
  • administering also encompasses in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding composition, or by another cell.
  • An "agonist,” as it relates to a ligand and receptor, comprises a molecule, combination of molecules, a complex, or a combination of reagents, that stimulates the receptor.
  • an agonist of granulocyte-macrophage colony stimulating factor can encompass GM-CSF, a mutein or derivative of GM-CSF, a peptide mimetic of GM-CSF, a small molecule that mimics the biological function of GM-CSF, or an antibody that stimulates GM-CSF receptor.
  • An antagonist as it relates to a ligand and receptor, comprises a molecule, combination of molecules, or a complex, that inhibits, counteracts, downregulates, and/or desensitizes the receptor.
  • "Antagonist” encompasses any reagent that inhibits a constitutive activity of the receptor.
  • a constitutive activity is one that is manifest in the absence of a ligand/receptor interaction.
  • "Antagonist” also encompasses any reagent that inhibits or prevents a stimulated (or regulated) activity of a receptor.
  • an antagonist of GM-CSF receptor includes, without implying any limitation, an antibody that binds to the ligand (GM-CSF) and prevents it from binding to the receptor, or an antibody that binds to the receptor and prevents the ⁇ gand from binding to the receptor, or where the antibody locks the receptor in an inactive conformation.
  • an "analog" in the context of an EphA2 polypeptide refers to a proteinaceous agent (e.g., a peptide, polypeptide or protein) that possesses a similar or identical function as the EphA2 polypeptide (or fragment of an EphA2 polypeptide), but does not necessarily comprise a similar or identical amino acid sequence or structure of the EphA2 polypeptide (or fragment).
  • a proteinaceous agent e.g., a peptide, polypeptide or protein
  • An analog of an EphA2 polypeptide that has a similar amino acid sequence to an EphA2 polypeptide refers to a proteinaceous agent that satisfies at least one of the following: (a) a proteinaceous agent having an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the amino acid sequence of an EphA2 polypeptide; (b) a proteinaceous agent encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding an EphA2 polypeptide of at least 20 amino acid residues, at least 30 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues,
  • a proteinaceous agent with similar structure to an EphA2 polypeptide refers to a proteinaceous agent that has a similar secondary, tertiary or quaternary structure of the EphA2 polypeptide.
  • the structure of a proteinaceous agent can be determined by methods known to those skilled in the art, including but not limited to, X-ray crystallography, nuclear magnetic resonance, and crystallographic electron microscopy.
  • the proteinaceous agent has EphA2 activity.
  • APCs Antigen presenting cells
  • APCs include dendritic cells, monocytes, macrophages, marginal zone Kupffer cells, microglia, Langerhans cells, T cells, and B cells (see, e.g., Rodriguez-Pinto and Moreno (2005) Eur. J. Immunol. 35: 1097-1 105).
  • Dendritic cells occur in at least two lineages. The first lineage encompasses pre-DCl, myeloid DCl, and mature
  • the second lineage encompasses CD34 ++ CD45RA " early progenitor multipotent cells, rni d ⁇ rn/i cD A + «» ⁇ r ⁇ r ⁇ i A ++ r ⁇ r ⁇ ⁇ t> A 4+ ZTAj + IT ID ⁇ I-U- 44ön ⁇ nr> ⁇ .-n- /-T ⁇ /t+r-TM i favor- plasmacytoid pre-DC2 cells, lymphoid human DC2 plasmacytoid-derived DC2s, and mature DC2s (see, e.g., Gilliet and Liu (2002) J. Exp. Med. 195:695-704; Bauer, et al. (2001) J. Immunol.
  • Attenuation and “attenuated” encompasses a bacterium, virus, parasite, infectious organism, prion, tumor cell, gene in the infectious organism, and the like, that is modified to reduce toxicity to a host.
  • the host can be a human or animal host, or an organ, tissue, or cell.
  • the bacterium to give a non-limiting example, can be attenuated to reduce binding to a host cell, to reduce spread from one host cell to another host cell, to reduce extracellular growth, or to reduce intracellular growth in a host cell.
  • Attenuation can be assessed by measuring, e.g., an indicum or indicia of toxicity, the LD50, the rate of clearance from an organ, or the competitive index (see, e.g., Auerbuch, el al. (2001) Infect. Immunity 69:5953-5957).
  • an attenuation results an increase in the LD50 and/or an increase in the rate of clearance by at least 25%; more generally by at least 50%; most generally by at least 100% (2-fold); normally by at least 5-fold; more normally by at least 10-fold; most normally by at least 50-fold; often by at least 100-fold; more often by at least 500-fold; and most often by at least 1000-fold; usually by at least 5000-fold; more usually by at least 10,000-fold; and most usually by at least 50,000-fold; and most often by at least 100,000-fold.
  • Attenuated gene encompasses a gene that mediates toxicity, pathology, or virulence, to a host, growth within the host, or survival within the host, where the gene is mutated in a way that mitigates, reduces, or eliminates the toxicity, pathology, or virulence. The reduction or elimination can be assessed by comparing the virulence or toxicity mediated by the mutated gene with that mediated by the non-mutated (or parent) gene.
  • “Mutated gene” encompasses deletions, point mutations, and frameshift mutations in regulatory regions of the gene, coding regions of the gene, non-coding regions of the gene, or any combination thereof.
  • "Cancerous condition” and “cancerous disorder” encompass, without implying any limitation, a cancer, a tumor, metastasis, angiogenesis of a tumor, and precancerous disorders such as dysplasias.
  • Constantly modified variants applies to both amino acid and nucleic acid sequences.
  • a conservatively modified variant refers to nucleic acids encoding identical amino acid sequences, or amino acid sequences that have one or more conservative substitutions.
  • An example of a conservative substitution is the exchange of an amino acid in one of the following groups for another amino acid of the same group (U.S. Pat. No. 5,767,063 issued to Lee, et al.; Kyte and Doolittle (1982) J. MoI. Biol. 157:105-132).
  • Hydrophobic Norleucine, He, VaI, Leu, Phe, Cys, Met
  • Neutral hydrophilic Cys, Ser, Thr;
  • a "derivative" in the context of an EphA2 polypeptide or a fragment of an EphA2 polypeptide refers to a proteinaceous agent that comprises an amino acid sequence of an EphA2 polypeptide or a fragment of an EphA2 polypeptide that has been altered by the introduction of amino acid residue substitutions, deletions or additions (i.e., mutations).
  • the term "derivative" in the context of EphA2 proteinaceous agents also refers to an EphA2 polypeptide or a fragment of an EphA2 polypeptide which has been modified, i.e, by the covalent attachment of any type of molecule to the polypeptide.
  • an EphA2 polypeptide or a fragment of an EphA2 polypeptide may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc.
  • a derivative of an EphA2 polypeptide or a fragment of an EphA2 polypeptide may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc.
  • a derivative of an EphA2 polypeptide or a fragment of an EphA2 polypeptide may contain one or more non- classical amino acids.
  • a polypeptide derivative possesses a similar or identical function as an EphA2 polypeptide or a fragment of an EphA2 polypeptide described herein.
  • a derivative of EphA2 polypeptide or a fragment of an EphA2 polypeptide has an altered activity when compared to an unaltered polypeptide.
  • a derivative of an EphA2 polypeptide or fragment thereof can differ in phosphorylation relative to an EphA2 polypeptide or fragment thereof.
  • Effective amount encompasses, without limitation, an amount that can ameliorate, reverse, mitigate, prevent, or diagnose a symptom or sign of a medical condition or disorder. Unless dictated otherwise, explicitly or by context, an "effective amount” is not limited to a minimal amount sufficient to ameliorate a condition.
  • EphA2 antigenic peptides (sometimes referred to as “EphA2 antigenic polypeptides"), are defined and described in U.S. Patent Publication No. 2005/0281783 Al, which is hereby incorporated by reference herein in its entirety, including all sequences contained therein.
  • EphA2 is a 130 kDa receptor tyrosine kinase expressed in adult epithelia (Zantek et al. (1999) Cell Growth & Differentiation 10:629; Lindberg et al. (1990) Molecular & Cellular Biology 10:6316).
  • EphA2 antigenic peptide or an “EphA2 antigenic polypeptide” refers to an EphA2 polypeptide, or a fragment, analog or derivative thereof comprising one or more B cell epitopes or T cell epitopes of EphA2.
  • the EphA2 polypeptide may be from any species.
  • the EphA2 polypeptide may be a human EphA2 polypeptide.
  • EphA2 polypeptide includes the mature, processed form of EphA2, as well as immature forms of EphA2.
  • the EphA2 polypeptide is the sequence shown in Figure 46A-B (SEQ ID NO:2 of U.S. Patent Publication No. 2005/0281783 Al).
  • Examples of the nucleotide sequence of human EphA2 can be found in the GenBank database (see, e.g., Accession Nos. BC037166, M59371 and M36395). Examples of the amino acid sequence of human EphA2 can also be found in the GenBank database (see, e.g., Accession Nos. NP_004422, AAH37166, and AAA53375). Additional examples of amino acid sequences of EphA2 include those listed as GenBank Accession Nos. NP 034269 (mouse), AAH06954 (mouse), XP_345597 (rat), and BAB63910 (chicken).
  • an "extracellular fluid” encompasses, e.g., serum, plasma, blood, interstitial fluid, cerebrospinal fluid, secreted fluids, lymph, bile, sweat, fecal matter, and urine.
  • An "extracelluar fluid” can comprise a colloid or a suspension, e.g., whole blood or coagulated blood.
  • fragments in the context of EphA2 polypeptides include an EphA2 antigenic peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least IS contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least !75 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues of the amino acid sequence of an EphA2 polypeptide.
  • Gene refers to a nucleic acid sequence encoding an oligopeptide or polypeptide.
  • the oligopeptide or polypeptide can be biologically active, antigenically active, biologically inactive, or antigenically inactive, and the like.
  • gene encompasses, e.g., the sum of the open reading frames (ORFs) encoding a specific oligopeptide or polypeptide; the sum of the ORFs plus the nucleic acids encoding introns; the sum of the ORFs and the operably linked promoter(s); the sum of the ORFS and the operably linked promoter(s) and any introns; the sum of the ORFS and the operably linked promoter(s), intron(s), and promoter(s), and other regulatory elements, such as enhancer(s).
  • ORFs open reading frames
  • gene can also refer to a nucleic acid that encodes a peptide encompassing an antigen or an antigenically active fragment of a peptide, oligopeptide, polypeptide, or protein.
  • the term gene does not necessarily imply that the encoded peptide or protein has any biological activity, or even that the peptide or protein is antigenically active.
  • a nucleic acid sequence encoding a non-expressable sequence is generally considered a pseudogene.
  • gene also encompasses nucleic acid sequences encoding a ribonucleic acid such as rRNA, tRNA, or a ribozyme.
  • “Growth" of a Listeria bacterium encompasses, without limitation, functions of bacterial physiology and genes relating to colonization, replication, increase in listerial protein content, increase in listerial lipid content.
  • growth of a Listeria encompasses growth of the bacterium outside a host cell, and also growth inside a host cell.
  • Growth related genes include, without implying any limitation, those that mediate energy production (e.g., glycolysis, Krebs cycle, cytochromes), anabolism and/or catabolism of amino acids, sugars, lipids, minerals, purines, and pyrimidines, nutrient transport, transcription, translation, and/or replication.
  • "growth" of a Listeria bacterium refers to intracellular growth of the Listeria bacterium, that is, growth inside a host cell such as a mammalian cell. While intracellular growth of a Listeria bacterium can be measured by light microscopy or colony forming unit (CFU) assays, growth is not to be limited by any technique of measurement. Biochemical parameters such as the quantity of a listerial antigen, listerial nucleic acid sequence, or lipid specific to the Listeria bacterium, can be used to assess growth. In some embodiments, a gene that mediates growth is one that specifically mediates intracellular growth.
  • a gene that specifically mediates intracellular growth encompasses, but is not limited to, a gene where inactivation of the gene reduces the rate of intracellular growth but does not detectably, substantially, or appreciably, reduce the rate of extracellular growth (e.g., growth in broth), or a gene where inactivation of the gene reduces the rate of intracellular growth to a greater extent than it reduces the rate of extracellular growth.
  • a gene where inactivation reduces the rate of intracellular growth to a greater extent than extracellular growth encompasses the situation where inactivation reduces intracellular growth to less than 50% the normal or maximal value, but reduces extracellular growth to only 1-5%, 5-10%, or 10-15% the maximal value.
  • the invention in certain aspects, encompasses a Listeria attenuated in intracellular growth but not attenuated in extracellular growth, a Listeria not attenuated in intracellular growth and not attenuated in extracellular growth, as well as a Listeria not attenuated in intracellular growth but attenuated in extracellular growth.
  • Immuno condition or “immune disorder” encompasses a disorder, condition, syndrome, or disease resulting from ineffective, inappropriate, or pathological response of the immune system, e.g., to a persistent infection or to a persistent cancer (see, e.g., Jacobson, et al. (1997) Clin. Immunol. Immunopathol. 84:223-243).
  • Immunune condition or “immune disorder” encompasses, e.g., pathological inflammation, an inflammatory disorder, and an autoimmune disorder or disease.
  • Immuno condition also can refer to infections, persistent infections, cancer, tumors, precancerous disorders, cancers that resist irradication by the immune system, and angiogenesis of tumors.
  • "Immune condition” or “immune disorder” also encompasses cancers induced by an infective agent, including the non-limiting examples of cancers induced by hepatitis B virus, hepatitis C virus, simian virus 40 (SV40), Epstein-Barr virus, papillomaviruses, polyomaviruses, Kaposi's sarcoma herpesvirus, human T-cell leukemia virus, and Helicobacter pylori (see, e.g., Young and Rickinson (2004) Nat. Rev. Cancer 4:757-768; Pagano, et al. (2004) Semin. Cancer Biol. 14:453-471 ; Li, et al. (2005) Cell Res. 15:262-271).
  • a composition that is "labeled” is detectable, either directly or indirectly, by spectroscopic, photochemical, biochemical, immunochemical, isotopic, or chemical methods.
  • useful labels include 32 P, 33 P, 35 S, 14 C, 3 H, 125 I, stable isotopes, epitope tags, fluorescent dyes, electron-dense reagents, substrates, or enzymes, e.g., as used in enzyme- linked immunoassays, or fluorettes (see, e.g., Rozinov and Nolan (1998) Chem. Biol. 5:713- 728).
  • Ligand refers to a small molecule, peptide, polypeptide, or membrane associated or membrane-bound molecule, that is an agonist or a ⁇ iagunisl of a receptor. "Ligand” also encompasses a binding agent that is not an agonist or antagonist, and has no agonist or antagonist properties. By convention, where a ligand is membrane-bound on a first cell, the receptor usually occurs on a second cell. The second cell may have the same identity (the same name), or it may have a different identity (a different name), as the first cell. A ligand or receptor may be entirely intracellular, that is, it may reside in the cytosol, nucleus, or in some other intracellular compartment.
  • the ligand or receptor may change its location, e.g., from an intracellular compartment to the outer face of the plasma membrane.
  • the complex of a ligand and receptor is termed a "ligand receptor complex.” Where a ligand and receptor are involved in a signaling pathway, the ligand occurs at an upstream position and the receptor occurs at a downstream position of the signaling pathway.
  • "Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single stranded, double-stranded form, or multi-stranded form.
  • Non-limiting examples of a nucleic acid are a, e.g., cDNA, mRNA, oligonucleotide, and polynucleotide.
  • a particular nucleic acid sequence can also implicitly encompasses "allelic variants” and "splice variants.”
  • “Operably linked” in the context of a promoter and a nucleic acid encoding a mRNA means that the promoter can be used to initiate transcription of that nucleic acid.
  • the terms "percent sequence identity” and “% sequence identity” refer to the percentage of sequence similarity found by a comparison or alignment of two or more amino acid or nucleic acid sequences. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100.
  • Precancerous condition encompasses, without limitation, dysplasias, preneoplastic nodules; macroregenerative nodules (MRN); low-grade dysplastic nodules (LG-DN); high-grade dysplastic nodules (HG-DN); biliary epithelial dysplasia; foci of altered hepatocytes (FAH); nodules of altered hepatocytes (NAH); chromosomal imbalances; aberrant activation of telomerase; re-expression of the catalytic subunit of telomerase; expression of endothelial cell markers such as CD31, CD34, and BNH9 (see, e.g., Terracciano and Tornillo (2003) Pathologica 95:71-82; Su and Bannasch (2003) Toxicol.
  • purified and isolated is meant, when referring to a polypeptide, that the polypeptide is present in the substantial absence of the other biological macromolecules with which it is associated in nature.
  • purified means that an identified polypeptide often accounts for at least 50%, more often accounts for at least 60%, typically accounts for at least 70%, more typically accounts for at least 75%, most typically accounts for at least 80%, usually accounts for at least 85%, more usually accounts for at least 90%, most usually accounts for at least 95%, and conventionally accounts for at least 98% by weight, or greater, of the polypeptides present.
  • the weights of water, buffers, salts, detergents, reductants, protease inhibitors, stabilizers (including an added protein such as albumin), and excipients, and molecules having a molecular weight of less than 1000, are generally not used in the determination of polypeptide purity. See, e.g., discussion of purity in U.S. Pat. No. 6,090,611 issued to Covacci, et al.
  • Peptide refers to a short sequence of amino acids, where the amino acids are connected to each other by peptide bonds.
  • a peptide may occur free or bound to another moiety, such as a macromolecule, lipid, oligo- or polysaccharide, and/or a polypeptide. Where a peptide is incorporated into a polypeptide chain, the term “peptide” may still be used to refer specifically to the short sequence of amino acids.
  • a “peptide” may be connected to another moiety by way of a peptide bond or some other type of linkage.
  • a peptide is at least two amino acids in length and generally less than about 25 amino acids in length, where the maximal length is a function of custom or context.
  • the terms “peptide” and “oligopeptide” may be used interchangeably.
  • Protein generally refers to the sequence of amino acids comprising a polypeptide chain. Protein may also refer to a three dimensional structure of the polypeptide. “Denatured protein” refers to a partially denatured polypeptide, having some residual three dimensional structure or, alternatively, to an essentially random three dimensional structure, i.e., totally denatured.
  • the invention encompasses reagents of, and methods using, polypeptide variants, e.g., involving glycosylation, phosphorylation, sulfation, disulfide bond formation, dearnidation, isonierization, cleavage points in signal or leader sequence processing, c ⁇ vaieni and non-covalently bound cofactors, oxidized variants, and the like.
  • polypeptide variants e.g., involving glycosylation, phosphorylation, sulfation, disulfide bond formation, dearnidation, isonierization, cleavage points in signal or leader sequence processing, c ⁇ vaieni and non-covalently bound cofactors, oxidized variants, and the like.
  • disulfide linked proteins is described (see, e.g., Woycechowsky and Raines (2000) Curr. Opin. Chem. Biol. 4:533-539; Creighton, et al. (1995) Trends Biotechnol
  • Recombinant when used with reference, e.g., to a nucleic acid, cell, animal, virus, plasmid, vector, or the like, indicates modification by the introduction of an exogenous, non- native nucleic acid, alteration of a native nucleic acid, or by derivation in whole or in part from a recombinant nucleic acid, cell, virus, plasm id, or vector.
  • Recombinant protein refers to a protein derived, e.g., from a recombinant nucleic acid, virus, plasmid, vector, or the like.
  • Recombinant bacterium encompasses a bacterium where the genome is engineered by recombinant methods, e.g., by way of a mutation, deletion, insertion, and/or a rearrangement.
  • Recombinant bacterium also encompasses a bacterium modified to include a recombinant extra-genomic nucleic acid, e.g., a plasmid or a second chromosome, or a bacterium where an existing extra-genomic nucleic acid is altered.
  • sample refers to a sample from a human, animal, placebo, or research sample, e.g., a cell, tissue, organ, fluid, gas, aerosol, slurry, colloid, or coagulated material.
  • the “sample” may be tested in vivo, e.g.,. without removal from the human or animal, or it may be tested in vitro.
  • the sample may be tested after processing, e.g., by histological methods.
  • Sample also refers, e.g., to a cell comprising a fluid or tissue sample or a cell separated from a fluid or tissue sample.
  • sample may also refer to a cell, tissue, organ, or fluid that is freshly taken from a human or animal, or to a cell, tissue, organ, or fluid that is processed or stored.
  • a "selectable marker” encompasses a nucleic acid that allows one to select for or against a cell that contains the selectable marker.
  • selectable markers include, without limitation, e.g.: (1) A nucleic acid encoding a product providing resistance to an otherwise toxic compound (e.g., an antibiotic), or encoding susceptibility to an otherwise harmless compound (e.g., sucrose); (2) A nucleic acid encoding a product that is otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers); (3) A nucleic acid encoding a product that suppresses an activity of a gene product; (4) A nucleic acid that encodes a product that can be readily identified (e.g., phenotypic markers such as beta- galactosidase, green fluorescent protein (GFP), cell surface proteins, an epitope tag, a FLAG tag); (5) A nucleic acid that can be identified by hybridization techniques, for example, PCR or molecular beacons.
  • an otherwise toxic compound e.g., an antibiotic
  • an otherwise harmless compound e.g., sucrose
  • nucleic acid/complementary nucleic acid, antibody/antigen, or other binding pair indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologies.
  • a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample.
  • Specific binding can also mean, e.g., that the binding compound, nucleic acid ligand, antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its target with an affinity that is often at least 25% greater, more often at least 50% greater, most often at least 100% (2 -fold) greater, normally at least ten times greater, more normally at least 20-times greater, and most normally at least 100-times greater than the affinity with any other binding compound.
  • an antibody will have an affinity that is greater than about 10 9 liters/mol, as determined, e.g., by Scatchard analysis (Munsen, et al. (1980) Analyt. Biochem. 107:220-239). It is recognized by the skilled artisan that some binding compounds can specifically bind to more than one target, e.g., an antibody specifically binds to its antigen, to lectins by way of the antibody's oligosaccharide, and/or to an Fc receptor by way of the antibody's Fc region.
  • "Spread" of a bacterium encompasses "cell to cell spread,” that is, transmission of * ⁇ the bacterium from a first host cell to a second host cell, as mediated, for example, by a vesicle.
  • Functions relating to spread include, but are not limited to, e.g., formation of an actin tail, formation of a pseudopod-like extension, and formation of a double-membraned vacuole.
  • the "target site" of a recombinase is the nucleic acid sequence or region that is recognized, bound, and/or acted upon by the recombinase (see, e.g., U.S. Pat. No.
  • Therapeutically effective amount is defined as an amount of a reagent or pharmaceutical composition that is sufficient to show a patient benefit, i.e., to cause a decrease, prevention, or amelioration of the symptoms of the condition being treated.
  • agent or pharmaceutical composition comprises a diagnostic agent
  • a "diagnostically effective amount” is defined as an amount that is sufficient to produce a signal, image, or other diagnostic parameter. Effective amounts of the pharmaceutical formulation will vary according to factors such as the degree of susceptibility of the individual, the age, gender, and weight of the individual, and idiosyncratic responses of the individual (see, e.g., U.S. Pat. No. 5,888,530 issued to Netti, et al.).
  • Treatment or “treating” (with respect to a condition or a disease) is an approach for obtaining beneficial or desired results including and preferably clinical results.
  • beneficial or desired results with respect to a disease include, but are not limited to, one or more of the following: improving a condition associated with a disease, curing a disease, lessening severity of a disease, delaying progression of a disease, alleviating one or more symptoms associated with a disease, increasing the quality of life of one suffering from a disease, and/or prolonging survival.
  • beneficial or desired results with respect to a condition include, but are not limited to, one or more of the following: improving a condition, curing a condition, lessening severity of a condition, delaying progression of a condition, alleviating one or more symptoms associated with a condition, increasing the quality of life of one suffering .from a condition, and/or prolonging survival.
  • the beneficial or desired results include, but are not limited to, one or more of the following: reducing the proliferation of (or destroying) neoplastic or cancerous cells, reducing metastasis of neoplastic cells found in cancers, shrinking the size of a tumor, decreasing symptoms resulting from the cancer, increasing the quality of life of those suffering from the cancer, decreasing the dose of other medications required to treat the disease, delaying the progression of the cancer, and/or prolonging survival of patients having cancer.
  • "treatment" of a subject can imply that the subject is in need of treatment, e.g., in the situation where the subject comprises a disorder expected to be ameliorated by administration of a reagent.
  • Vaccine encompasses preventative vaccines. Vaccine also encompasses therapeutic vaccines, e.g., a vaccine administered to a mammal that comprises a condition or disorder associated with the antigen or epitope provided by the vaccine.
  • the present invention provides reagents and methods useful for the treatment and diagnosis of cancer, tumors, precancerous disorders, and infections.
  • nucleic acids Listeria bacteria, and vaccines comprising a Listeria bacterium.
  • the invention encompasses listerial cells that have been modified in vitro, including during storage, or in vivo, including products of bacterial cell division and products of bacterial deterioration.
  • nucleic acids encoding at least one heterologous antigen (heterologous to the Listeria bacterium).
  • the heterologous antigen can be derived from a tumor, cancer cell, or and/or infective agent, e.g., a virus, bacterium, or protozoan.
  • the heterologous antigen can also be a listerial antigen, for example, where the antigen is expressed in greater amounts than that which naturally occurs within the Listeria bacterium, where the listerial antigen is operably linked with a non-native regulatory sequence, or where the listerial antigen is modified to be attenuated or to increase its antigenicity.
  • heterologous antigen encompasses, but is not necessarily limited to, an antigen from, or derived from: (1) A non-listerial organism; (2) An antigen of synthetic origin; (3) An antigen of listeria! origin where the nucleic acid is integrated at a position in the listeria! genome that is different from that found in the wild type; and (4) An antigen of listeria! origin, but where the nucleic acid is operably linked with a regulatory sequence not normally used in a wild type Listeria.
  • heterologous antigen encompasses antigens that are not from, and not derived from, that viral vector, as well as, for example, antigens from the viral vector that are controlled by a non-native nucleic acid regulatory sequence.
  • reagents and methods for stimulating the mammalian immune system for reducing the number and/or size of tumors, for reducing metastasis, and for reducing titer of an infectious organism.
  • the present invention also provides reagents and methods for improving survival of a cell, tissue, organ, or mammal, to a cancer or infection.
  • the present invention also provides reagents and methods for improving survival of a cell (in vivo or in vitro), a tissue (in vivo or in vitro), an organ (in vivo or in vitro), an organism, a mammal, a veterinary subject, a research subject, or a human subject, to a cancer, tumor, or infection.
  • administration that is in vivo or in vitro, survival of the cell, tissue, or organ in vitro or in vivo, or any combination thereof. Any combination includes, e.g., administration that is in vivo where subsequent survival is in vitro, or administration that is in vitro and where subsequent survival is in vivo.
  • a Listeria comprising a polynucleotide encoding at least one heterologous antigen wherein the one polynucleotide is genomic. Also encompassed is a Listeria comprising a polynucleotide encoding at least one heterologous antigen, wherein the polynucleotide is genomic and not residing on a plasmid within the Listeria. Moreover, encompassed is a Listeria comprising a polynucleotide encoding at least one heterologous antigen, wherein the polynucleotide resides on a plasmid within the Listeria.
  • a Listeria comprising a polynucleotide encoding at least one heterologous antigen, where the polynucleotide resides on a plasmid and does noi occur integrated in lhe genome.
  • the present invention provides a Listeria comprising a polynucleotide encoding at least one heterologous antigen, where the polynucleotide is integrated in the genome and also separately resides in a plasmid. [0125] The mouse is an accepted model for human immune response.
  • mouse T cells are a model for human T cells
  • mouse dendritic cells DCs
  • mouse NK cells are a model for human NK cells
  • mouse NKT cells are a model for human NKT cells
  • mouse innate response is an accepted model for human innate response, and so on.
  • Model studies are disclosed, for example, for CD8 + T cells, central memory T cells, and effector memory T cells (see, e.g., Walzer, et al. (2002) J. Immunol. 168:2704- 271 1); the two subsets of NK cells (see, e.g., Chakir, et al. (2000) J. Immunol. 165:4985- 4993; Smith, et al.
  • Mouse innate response including the Toll-Like Receptors (TLRs) is a model for human innate immune response, as disclosed (see, e.g., Janssens and Beyaert (2003) Clinical Microb. Revs. 16:637-646).
  • Mouse neutrophils are an accepted model for human neutrophils (see, e.g., Kobayashi, et al. (2003) Proc. Natl. Acad. Sci. USA 100: 10948-10953; Torres, et al. (2004) 72:2131-2139; Sibelius, et al. (1999) Infection Immunity 67:1125-1 130; Tvinnereim, et al. (2004) J. Immunol.
  • Murine immune response to Listeria is an accepted model for human response to Listeria (see, e.g., Kolb-Maurer, et al. (2000) Infection Immunity 68:3680-3688; Brzoza, et al. (2004) J. Immunol. 173:2641-2651 ; Esplugues, et al. (2005) Blood Feb. 3 (epub ahead of print); Paschen, et al. (2000) Eur. J. Immunol. 30:3447-3456; Way and Wilson (2004) J. Immunol. 173:5918-5922; Ouadrhiri, et al. (1999) J.
  • the present invention embraces a nucleic acid encoding a secretory sequence, or encoding a listerial protein, or a fragment thereof, suitable for use as a fusion protein partner.
  • a nucleic acid encoding: i. a secretory sequence, ii. a signal sequence, iii. a listerial polypeptide containing its native secretory sequence, iv. a listerial protein with its native secretory sequence replaced with that of another listerial protein, v. a listerial protein with its native secretory sequence replaced with the secretory sequence of a non-listerial bacterial protein, vi. a non-secreted listerial protein, or fragment thereof, not containing any secretory sequence; and vii. a non-listerial bacterial secretory sequence fused with, and in frame with, a non-secreted listerial protein, or fragment thereof.
  • listeriolysin The secretory signal sequence of listeriolysin O (hly gene) has been identified (see, e.g., Lety, et al. (2003) Microbiol. 149:1249-1255).
  • ActA The ribosomal binding site, promoter, and signal sequence have been identified for listerial ActA. The ribosomal binding site occurs 6 bp upstream of the start codo ⁇ of the ActA gene (Vazquez-Boland, et al. (1992) Infect. Immunity 60:219-230).
  • Table 1 discloses a number of non-limiting examples of signal peptides for use in fusing with a fusion protein partner sequence such as a heterologous antigen.
  • the SignalP algorithm can be used to determine signal sequences in Gram positive bacteria. This program is available on the world wide web at: cbs.dtu.dk/services/SignalP/. Signal peptides tend to contain three domains: a positively charged N-terminus (1-5 residues long); a central hydrophobic comain (7-15 residues long); and a neutral but polar C-terminal domain (see, e.g., Lety, et al. (2003) Microbiology 149:1249-1255; Paetzel, et al. (2000) Pharmacol.
  • the present invention also provides nucleic acids originating from the Listeria genome, or from a genome or plasm id of another bacterium, that are altered by codon optimized for expressing by a L. monocytogenes.
  • the present invention is not to be limited to polypeptide and peptide antigens that are secreted, but also embraces polypeptides and peptides that are not secreted or cannot be secreted from a Listeria or other bacterium.
  • the polypeptide comprising the heterologous antigen that is expressed by the Listeria comprises a signal sequence which is a non-listerial signal sequence.
  • the signal sequence is a secAl signal peptide.
  • the signal sequence is a secA2 or Tat signal peptide.
  • the signal peptide is an actA signal peptide.
  • the signal peptide used to effect secretion of the heterologous antigen is selected from p60 signal sequence, a Listeria monocytogenes LLO signal sequence, a Bacillus anthracis Protective Antigen (BaPa) signal sequence, a Lactococcus lactis usp45 signal sequence, and a Bacillus subtilis PhoD signal sequence.
  • Signal peptides that can be used for the expression and secretion of heterologous antigens are described in, e.g., U.S. Patent Publication No. 2005/0249748, incorporated by reference herein in its entirety.
  • the present invention provides codon optimization of a nucleic acid heterologous to Listeria, or of a nucleic acid endogenous to Listeria.
  • the optimal codons utilized by L. monocytogenes for each amino acid are shown (Table 2).
  • a nucleic acid is codon-optimized if at least one codon in the nucleic acid is replaced with a codon that is more frequently used by L. monocytogenes for that amino acid than the codon in the original sequence.
  • any non-optimal codons are changed to provide optimal codons, more normally at least five percent are changed, most normally at least ten percent are changed, often at least 20% are changed, more often at least 30% are changed, most often at least 40%, usually at least 50 % are changed, more usually at least 60% are changed, most usually at least 70% are changed, optimally at least 80% are changed, more optimally at least 90% are changed, most optimally at least 95% are changed, and c —o —nv , e ⁇ —n it ⁇ onally 100% of any non-optimal codons are codon-optimized for Listeria expression (Table 2).
  • the nucleic acid encoding the heterologous antigen is codon- optimized for expression in Listeria monocytogenes.
  • the polynucleotide encoding the fusion protein comprising the modified ActA or an alternative signal peptide sequence and the heterologous antigen is codon-optimized.
  • L. monocytogenes expresses various genes and gene products that contribute to invasion, growth, or colonization of the host (Table 3). Some of these are classed as "virulence factors.” These virulence factors include ActA, listeriolysin (LLO), protein 60 (p60), internal in A (inlA), internalin B (inlB), phosphatidylcholine phospholipase C (PC- PLC), phosphatidylinositol-specific phospholipase C (PI-PLC; plcA gene). A number of other internal ins have been characterized, e.g., InlC2, InID, InIE, and InIF (Dramsi, et al. (1997) Infect.
  • LLO listeriolysin
  • p60 protein 60
  • inlA internal in A
  • inlB internalin B
  • PC- PLC phosphatidylcholine phospholipase C
  • PI-PLC phosphatidylinos
  • a virulence gene is a gene that encodes a virulence factor. Without limiting the present invention to the attenuated genes disclosed herein, the present invention supplies a Listeria that is altered, mutated, or attenuated in one or more of the sequences of Table 3. [0137] In some embodiments, the virulence gene is a prf-A dependent gene. In other embodiments, the virulence gene is a prf-A independent gene.
  • the Listeria comprises an attenuating mutation in actA and/or inlB.
  • a polynucleotide encoding a heterologous antigen has been integrated into the aclA and/or inlB gene.
  • DNA repair genes can also be the target of an attenuating mutation. Mutating or deleting a DNA repair gene can result in an attenuated bacterium (see, e.g., Darwin and Nathan (2005) Infection Immunity 73:4581-4587).
  • Listeriolysin (LLO) biology is described (see, e.g., Glomski, et al. (2003) Infect. Immun. 71 :6754-6765; Gedde, et al. (2000) Infect. Immun. 68:999-1003; Glomski, et al. (2002) J. Cell Biol. 156:1029-1038; Dubail, et al. (2001) Microbiol. 147:2679-2688; Dramsi and Cosssart (2002) J. Cell Biol. 156:943-946). ActA biochemistry and physiology is disclosed (see, e.g., Machner, et al. (2001) J. Biol. Chem. 276:40096-40103; Lauer, et al.
  • the invention also contemplates a Listeria attenuated in at least one regulatory factor, e.g., a promoter or a transcription factor.
  • a regulatory factor e.g., a promoter or a transcription factor.
  • the transcription factor prfA is required for transcription of a number of L. monocytogenes genes, e.g., hly, plcA, ActA, mpl, prfA, and iap.
  • PrfA's regulatory properties are mediated by, e.g., the PrfA-dependent promoter (PinlC) and the PrfA-box.
  • the present invention provides a nucleic acid encoding inactivated, mutated, or deleted in at least one of ActA promoter, inlB promoter, PrfA, PinlC, PrfA-box, and the like (see, e.g., Lalic-Mullthaler, et al. (2001 ) MoI. Microbiol. 42:11 1-120; Shetron-Rama, et al. (2003) MoI. Microbiol. 48:1537-1551; Luo, et al. (2004) MoI. Microbiol. 52:39-52).
  • PrfA can be made constitutively active by a Glyl45Ser mutation, Glyl55Ser mutation, or Glu77Lys mutation (see, e.g., Mueller and Freitag (2005) Infect. Immun. 73:1917-1926; Wong and Freitag (2004) J. Bacteriol. 186:6265-6276; Ripio, et al. (1997) J. Bacterio!. 179:1533-1540).
  • Attenuation can be effected by, e.g., heat-treatment or chemical modification. Attenuation can also be effected by genetic modification of a nucleic acid that modulates; e.g., metabolism, extracellular growth, or intracellular growth, genetic modification of a nucleic acid encoding a virulence factor, such as listeria] prfA, ActA, listeriolysin (LLO), an adhesion mediating factor (e.g., an internal in such as inlA or inlB), mpl, phosphatidylcholine phospholipase C (PC-PLC), phosphatidylinositol-specific phospholipase C (PI-PLC; plcA gene), any combination of the above, and the like. Attenuation can be assessed by comparing a biological function of an attenuated Listeria with the corresponding biological function shown by an appropriate parent Listeria.
  • a virulence factor such as listeria
  • the present invention in other embodiments, provides a Listeria that is attenuated by treating with a nucleic acid targeting agent, such as a cross-linking agent, a psoralen, a nitrogen mustard, cis-platin, a bulky adduct, ultraviolet light, gamma irradiation, any combination thereof, and the like.
  • a nucleic acid targeting agent such as a cross-linking agent, a psoralen, a nitrogen mustard, cis-platin, a bulky adduct, ultraviolet light, gamma irradiation, any combination thereof, and the like.
  • a nucleic acid targeting agent such as a cross-linking agent, a psoralen, a nitrogen mustard, cis-platin, a bulky adduct, ultraviolet light, gamma irradiation, any combination thereof, and the like.
  • the lesion produced by one molecule of cross-linking agent involves cross-linking of both
  • the Listeria of the invention can also be attenuated by mutating at least one nucleic acid repair gene, e.g., uvrA, uvrB, uvrAB, uvrC, uvrD, uvrAB, phrA, and/or a gene mediating recombinational repair, e.g., recA.
  • the invention provides a Listeria attenuated by both a nucleic acid targeting agent and by mutating a nucleic acid repair gene.
  • the invention encompasses treating with a light sensitive nucleic acid targeting agent, such as a psoralen, and/or a light sensitive nucleic acid cross-linking agent, such as psoralen, followed by exposure to ultraviolet light.
  • a light sensitive nucleic acid targeting agent such as a psoralen
  • a light sensitive nucleic acid cross-linking agent such as psoralen
  • the Listeria of the invention is attenuated.
  • Attenuated Listeria useful in the present invention are described in, e.g., in U.S. Pat. Publ. Nos. 2004/0228877 and 2004/0197343, each of which is incorporated by reference herein in its entirety.
  • Various assays for assessing whether a particular strain of Listeria has the desired attenuation are provided, e.g., in U.S. Pat. Publ. Nos. 2004/0228877, 2004/0197343, and 2005/0249748, each of which is incorporated by reference here
  • the invention supplies a number of listerial species and strains for making or engineering an attenuated Listeria of the present invention (Table 4). Each of the references listed in Table 4 is incorporated by reference herein in its entirety. The Listeria of the present invention is not to be limited by the species and strains disclosed in this table.
  • the present invention provides a nucleic acid encoding at least one antigen, an antigen with one or more conservative changes, one or more epitopes from a specified antigen, or a peptide or polypeptide that is immunologically cross-reactive with an antigen (Table 5).
  • the nucleic acids and antigens of the invention are not to be limited to those disclosed in the table.
  • the antigen is non-Listerial. In some embodiments, the antigen is from a cancer cell, tumor, or infectious agent. In some embodiments, the antigen is derived from an antigen from a cancer cell, tumor, or infectious agent. In some embodiments, an antigen that is "derived from" another antigen is a fragment or other derivative of the antigen. In some embodiments, the derived antigen comprises a fragment of at least 8 amino acids, at least 12 amino acids, at least 20 amino acids, at least 50 amino acids, at least 75 amino acids, at least 100 amino acids, or at least 200 amino acids.
  • the derivative of the antigen has at least about 80 % sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, at least about 95% sequence identity, or at least about 98% sequence identity to the antigen from which it is derived, or a fragment thereof.
  • a derived antigen comprises an antigen deleted of its signal sequence and/or membrane anchor.
  • an antigen derived from another antigen comprises at least one MHC class I epitope and/or at least one MHC class II epitope from the original (full-length) antigen.
  • the antigen is a tumor antigen. Assays for testing the immunogenicity of antigens are described herein and are well known in the art.
  • the heterologous antigen is a human tumor antigen or an antigen derived from a human tumor antigen.
  • the antigen derived from a tumor antigen consists of an amino acid sequence that exhibits at least about 65% sequence identity to the tumor antigen, at least 70% sequence identity to the tumor antigen, or at least about 75% sequence identity to the tumor antigen.
  • the derived antigen consists of an amino acid sequence that exhibits at least 85% sequence identity to the tumor antigen, at least 90% sequence identity to the tumor antigen, or at least about 95% sequence identity to the tumor antigen.
  • the antigen derived from the tumor antigen comprises at least 10, 20, 30, 40, 50, 75, 100, or 200 amino acids of the tumor antigen. In some embodiments, the antigen derived from the tumor antigen consists of at least 10, 20, 30, 40, 50, 75, 100, or 200 continguous amino acids of the tumor antigen.
  • the antigen is mesothelin, or derived from mesothelin. In some embodiments, the mesothelin is human. In some embodiments, the mesothelin is full- length (e.g., full length human mesothelin).
  • the antigen derived from mesothelin comprises mesothelin (e.g., human mesothelin) deleted in its signal sequence, deleted in its GPI anchor, or deleted in both the signal sequence and the GPI anchor.
  • the polynucleotide encoding the mesothelin may be codon-optimized or non-codon optimized for expression in Listeria.
  • the antigen derived from mesothelin consists of an amino acid sequence that exhibits at least about 65% sequence identity to human mesothelin , at least 70% sequence identity to human mesothelin, or at least about 75% sequence identity to human mesothelin.
  • the mesothelin polypeptide sequence consists of an amino acid sequence that exhibits at least 85% sequence identity to human mesothelin , at least 90% sequence identity to human mesothelin, or at least about 95% sequence identity to human mesothelin.
  • the antigen derived from mesothelin comprises at least 10, 20, 30, 40, 50, 75, 100, or 200 amino acids of a mesothelin polypeptide, such as human mesothelin or human mesothelin deleted of its signal peptide sequence and/or GPI anchor.
  • the antigen derived from mesothelin consists of at least 10, 20, 30, 40, 50, 75, 100, or 200 continguous amino acids of a mesothelin polypeptide, such as human mesothelin or human mesothelin deleted of its signal peptide sequence and/or GPI anchor.
  • the antigen is prostate stem cell antigen (PSCA), or is an antigen derived from PSCA.
  • PSCA is human PSCA.
  • the PSCA is full-length (e.g., full length human PSCA).
  • the antigen derived from PSCA comprises PSCA (e.g., human PSCA) deleted of (a) part or all its signal peptide region, (b) its GPI anchor region, or (c) its GPI anchor region and part or all of its signal peptide region.
  • the polynucleotide encoding the PSCA may be codon-optimized or non-codon optimized for expression in Listeria.
  • the antigen derived from PSCA consists of an amino acid sequence that exhibits at least about 65% sequence similarity to human PSCA, at least 70% sequence similarity to human PSCA, or at least about 75% sequence similarity to human PSCA.
  • the PSCA polypeptide sequence consists of an amino acid sequence that exhibits at least 85% sequence similarity to human PSCA, at least 90% sequence similarity to human PSCA, or at least about 95% sequence similarity to human PSCA.
  • the antigen derived from PSCA comprises at least 10, 20, 30, 40, 50, 75, 100, or 200 amino acids of a PSCA polypeptide, such as human PSCA or human PSCA deleted of its signal peptide sequence and/or GPI anchor.
  • the antigen derived from PSCA consists of at least 10, 20, 30, 40, 50, 75, 100, or 200 continguous amino acids of a PSCA polypeptide, such as human PSCA or human PSCA deleted of its signal peptide sequence and/or GPI anchor.
  • the antigen (e.g., heterologous antigen) comprises an EphA2 antigenic peptide (sometimes referred to as an "EphA2 antigenic polypeptide"), as defined and described in U.S. Patent Publication No. 2005/0281783 Al 3 which is hereby incorporated by reference herein in its entirety, including all sequences contained therein.
  • the antigen does not comprise an EphA2 antigenic peptide.
  • the EphA2 antigenic peptide that is used (or excluded from use) in the methods and compositions described herein can be any EphA2 antigenic peptide that is capable of eliciting an immune response against EphA2-expressing cells involved in a hyperproliferative disorder.
  • the EphA2 antigenic peptide can be an EphA2 polypeptide (e.g., the EphA2 polypeptide of SEQ ID NO:2 in U.S. Patent Publication No.
  • an EphA2 polypeptide that (1) displays ability to bind or compete with EphA2 for binding to an anti-EphA2 antibody, (2) displays ability to generate antibody which binds to EphA2, (3) contains one or more T cell epitopes of EphA2, and/or (4) displays ability to generate a T cell response against an EphA2 peptide.
  • the EphA2 antigenic peptide is a sequence encoded by one of the following nucleotide sequences, or a fragment or derivative thereof: Genbank Accession No. NM_004431 (Human); Genbank Accession No. NM_010139 (Mouse); or Genbank Accession No. AB038986 (Chicken, partial sequence).
  • the EphA2 antigenic peptide is full-length human EphA2 (e.g., SEQ ID NO:2 of U.S. Patent Publication No. 2005/0281783 Al, the polypeptide sequence shown in Figure 46A-B of the present application).
  • the EphA2 antigenic peptide comprises the extracellular domain of EphA2 (residue 22 to 554 of SEQ ID NO:2 of U.S. Patent Publication No. 2005/0281783 Al). In some other embodiments, the EphA2 antigenic peptide comprises the intracellular domain EphA2 (residue 558 to 976 of SEQ ID NO:2 of U.S. Patent Publication No. 2005/0281783 Al).
  • the EphA2 antigenic peptide comprises the extracellular domain of EphA2 or the intracellular domain of EphA2. In some embodiments, the EphA2 antigenic peptide comprises more than one domain of the full length human EphA2. In some embodiments, the EphA2 antigenic peptides comprise the extracellular domain and the intracellular cytoplasmic domain, joined together. In some embodiments, the EphA2 antigenic peptide lacks the EphA2 transmembrane domain. In some embodiments, the EphA2 antigenic peptide comprises the EphA2 extracellular and intracellular domains and lacks the transmembrane domain of EphA2.
  • the tyrosine kinase activity of EphA2 is ablated.
  • EphA2 may contain deletions, additions or substitutions of amino acid residues that result in the elimination of tyrosine kinase activity.
  • a lysine to methione substitution at position 646 is present.
  • the EphA2 antigenic peptide comprises full length EphA2 or a fragment thereof with a substitution of lysine to methionine at amino acid residue 646 of EphA2.
  • the EphA2 antigenic peptide comprises the extracellular and intracellular domains of EphA2, lacks the transmembrane domain of EphA2 and has a substitution of lysine to methionine at amino acid residue 646 of EphA2.
  • the EphA2 antigenic peptide is a chimeric polypeptide comprising at least an antigenic portion of EphA2 and a second polypeptide.
  • the fragments of EphA2 used in the methods and compositions of the invention may contain deletions, additions or substitutions of amino acid residues within the amino acid sequence encoded by an EphA2 gene.
  • mutations result in a silent change, thus producing a functionally equivalent EphA2 gene product.
  • functionally equivalent it is meant that the mutated EphA2 gene product has the same function as the wild-type EphA2 gene product, e.g., contains one or more epitopes ofEphA2.
  • the EphA2 antigenic peptide sequence comprises an amino acid sequence that exhibits at least about 65% sequence similarity to human EphA2, at least 70% sequence similarity to human EphA2, or at least about 75% sequence similarity to human EphA2.
  • the EphA2 polypeptide sequence comprises an amino acid sequence that exhibits at least 85% sequence similarity to human EphA2, at least 90% sequence similarity to human EphA2, or at least about 95% sequence similarity to human EphA2.
  • the EphA2 antigenic peptide comprises at least 10, 20, 30, 40, 50, 75, 100, or 200 amino acids of an EphA2 polypeptide (e.g., SEQ ID NO:2 of U.S. Patent Publication No. 2005/0281783 Al). In some embodiments, the EphA2 antigenic peptide comprises at least 10, 20, 30, 40, 50, 75, 100, or 200 continguous amino acids of an EphA2 polypeptide (e.g., SEQ ID NO:2 of U.S. Patent Publication No. 2005/0281783 Al). In some embodiments, the polypeptide comprises all or a portion of the extracellular domain of an EphA2 polypeptide of SEQ ID NO:2 of U.S.
  • EphA2 antigenic peptide e.g., 2, 3, 4, 5, 6, or more EphA2 antigenic peptides
  • a polycistronic expression cassette e.g., a bicistronic expression cassette
  • the invention supplies methods and reagents for stimulating immune response to infections, e.g., infections of the liver.
  • hepatotropic viruses include infections from hepatotropic viruses and viruses that mediate hepatitis, e.g., hepatitis B virus, hepatitis C virus, and cytomegalovirus.
  • the invention contemplates methods to treat other hepatotropic viruses, such as herpes simplex virus, Epstein-Barr virus, and dengue virus (see, e.g., Ahlenstiel and Rehermann (2005) Hepatology 41:675-677; Chen, et al. (2005) J. Viral Hepat. 12:38-45; Sun and Gao (2004) Gasteroenterol. 127:1525-1539; Li, et al. (2004) J. Leukoc. Biol.
  • the present invention provides methods and reagents for the treatment and/or prevention of parasitic infections, e.g., parasitic infections of the liver.
  • parasitic infections e.g., parasitic infections of the liver.
  • liver flukes e.g., Clonorchis, Fasciola hepatica, Opistorchis
  • Leishmania Ascaris lumbricoides
  • Schistosoma and helminths.
  • Helminths include, e.g., nematodes (roundworms), cestodes (tapeworms), and trematodes (fiatworms or flukes) (see, e.g., Tliba, et al. (2002) Vet. Res.
  • Yet another aspect of the present invention provides methods and reagents for the treatment and/or prevention of bacterial infections, e.g., by hepatotropic bacteria.
  • the heterologous of the present invention is derived from Human Immunodeficiency Virus (HIV), e.g., gpl20; gpl60; gp41; gag antigens such as p24gag or p55 gag, as well as protein derived from the pol, env, tat, vir, rev, nef, vpr, vpu, and LTR regions of HIV.
  • HIV Human Immunodeficiency Virus
  • the heterologous antigens contemplated include those from herpes simplex virus (HSV) types 1 and 2, from cytomegalovirus, from Epstein-Barr virus, or Varicella Zoster Virus.
  • antigens derived from a heptatis virus e.g., hepatitis A, B, C, delta, E, or G.
  • the antigens also encompass antigens from Picornaviridae (poliovirus; rhinovirus); Caliciviridae; Togaviridae (rubella; dengue); Flaviviridiae; Coronaviridae; Reoviridae; Birnaviridae; Rhabdoviridae; Orthomyxoviridae; Filoviridae; Paramyxoviridae (mumps; measle); Bunyviridae; Arenaviridae; Retroviradae (HTLV-I; HIV-I); Papillovirus, tick-borne encephalitis viruses, and the like.
  • Picornaviridae poliovirus; rhinovirus
  • Caliciviridae Togaviridae (rubella; dengue); Flaviviridiae; Coronaviridae; Reoviridae; Birnaviridae;
  • the present invention provides reagents and methods for the prevention and treatment of bacterial and parasitic infections, e.g., Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium, Toxoplasma, Mycobacterium tuberculosis, Bacillus anthracis, Yersinia pestis, Diphtheria, Pertussis, Tetanus, bacterial or fungal pneumonia, Otitis Media, Gonorrhea, Cholera, Typhoid, Meningitis, Mononucleosis, Plague, Shigellosis, Salmonellosis, Legionaire's Disease, Lyme disease, Leprosy, Malaria, Hookworm, Onchocerciasis, Schistosomiasis, Trypanasomes, Leshmania, Giardia, Amoebiasis, Filariasis, Borelia, and Trichinosis (see, e.g., Despommier,
  • the present invention provides reagents and methods for treating a disorder or condition, or stimulating an immune response to a disorder or condition, that comprises both a cancer and infection.
  • an antigen can be both a tumor antigen and a viral antigen (see, e.g., Montesano, et al. (1990)
  • the heterologous antigen shares at least one epitope with, or is immunologically cross-reactive with, an antigen from, or derived from, a cancer or infectious agent.
  • the present invention provides Listeria mutants, where the mutant is defective in repair of DNA damage, including, e.g., the repair of UV-light induced DNA damage, radiation induced damage, interstrand cross-links, intrastrand cross-links, covalent adducts, bulky adduct-modified DNA, deamidated bases, depurinated bases, depyrimidinated bases, oxidative damage, psoralen adducts, cis-platin adducts, combinations of the above, and the like (Mu and Sancar (1997) Prog. Nucl. Acid Res. MoI. Biol.
  • a Listeria that comprises at least one interstrand cross-link in its genomic DNA, or at least two, at least three, at least four, at least five, at least ten, at least 20, at least 30, at least 40, at least 50, at least 100, or more, cross-links in its genomic DNA.
  • One embodiment of the present invention comprises Listeria uvrAB engineered to express a heterologous antigen, where the engineered bacterium is treated with a nucleic acid cross-linking agent, a psoralen compound, a nitrogen mustard compound, 4'-(4-amino-2- oxa)butyl-4,5',8-trimethylpsoralen, or beta-aIanine,N-(acridine-9-yl),2-[bis(2- chloroethyl)amino]ethyl ester (see, e.g., U.S. Publ. Pat. Appl. No. US 2004/0197343 of Dubensky; Brockstedt, et al (2005) Nat. Med. 11 :853-860).
  • Hybridization of a polynucleotide such as a plasmid to a variant of that polynucleotide, bearing at least one mutation can be accomplished under the following stringent conditions.
  • the plasmid can be between 2-3 kb, 3-4 kb, 4-5 kb, 5-6 kb, 6-7 kb, and so on.
  • the mutation can consist of 1-10 nucleotides (nt), 10-20 nt, 20-30 nt, 30-40 nt, 40-50 nt, 50-60 nt, 60-70 kb, 70-80 kb, 80-90 kb, 90-100 kb, and the like.
  • Stringent conditions for hybridization in formamide can use the following hybridization solution: 48 ml formamide; 24 ml 20 times SSC; 1.0 ml 2 M Tris Cl, pH 7.6; 1.0 ml 100 times Denhardt's solution; 5.0 ml water; 20 ml 50% dextran sulfate, 1.0 ml 10% sodium dodecylsulfate (total volume 100 ml).
  • Hybridization can be for overnight at 42° C (see, e.g., (1993) Current Protocols in Molecular Biology, Suppl. 23, pages 6.3.3-6.3.4).
  • More stringent hybridization conditions comprise use of the above buffer but at the temperature of 43°, 44°, 45°, 46°, 47°, 48°, 49°, 50°, 51°, 52°, 53°, 54°, and the like.
  • Stringent hybridization under aqueous conditions are 1% bovine serum albumin; 1 mM EDTA; 0.5 M NaHPO/j, pH 7.2, 7% sodium dodecyl sulfate, with overnight incubation at 65° C.
  • More stringent aqueous hybridization conditions comprise the use of the above buffer, but at a temperature of 66°, 67°, 68°, 69°, 70°, 71°, 72°, 73°, 74°, 75°, and so on (see, e.g., (1993) Current Protocols in Molecular Biology, Suppl. 23, pages 6.3.3-6.3.4).
  • Increasing formamide concentration increases the stringency of hybridization. Mismatches between probe DNA and target DNA slows down the rate of hybridization by about 2-fold, for every 10% mismatching.
  • the melting temperature of mismatched DNA duplex decreases by about one degree centigrade for every 1.7% mismatching (Anderson (1999) Nucleic Acid Hybridization, Springer-Verlag, New York, N.Y., pp. 70-72; Tijssen (1993) Hybridization with Nucleic Acid Probes, Elsevier Publ. Co., Burlington, MA; Ross (ed.) (1998) Nucleic Acid Hybridization:Essential Techniques, John Wiley and Sons, Hoboken, NJ; U.S. Pat. No. 6,551,784 issued to Fodor, et al.).
  • the invention encompasses a variant first plasmid that hybridizes under stringent conditions to a second plasmid of the present invention, where both plasmids are functionally equivalent, and where hybridization is determinable by hybridizing the first plasmid directly to the second plasmid, or by hybridizing oligonucleotide probes spanning the entire length (individually or as a collection of probes) of the first variant plasmid to the second plasmid, and so on.
  • nucleotides 20-25 nucleotides, 25-30 nucleotides, 30-35 nucleotides, 35-40 nucleotides, 40-45 nucleotides, 45-50 nucleotides, 50-55 nucleotides, 55-60 nucleotides, 60-65 nucleotides,
  • the invention provides polynucleotides that hybridize under stringent conditions to each of the polynucleotides described herein or their complements.
  • nucleic acids, polynucleotides, bacterial genomes including listeria! genomes, and bacteria including Listeria and Bacillus anthracis, of the present invention are modified by site-specific recombination and/or by homologous recombination.
  • Site specific recombinases are described (see, e.g., Landy (1993) Curr. Op. Biotechnol. 3:699-707; Smith and Thorpe (2002) MoI. Microbiol. 44:299-307; Groth and Calos (2004) J. MoI. Biol.
  • Transposition is distinguished from site-specific recombination (see, e.g., Hallett and Sherratt (1997) FEMS Microbiol. Rev. 21:157-178; Grindley (1997) Curr. Biol. 7:R608-R612).
  • the present invention provides systems for mediating site-specific integration into a nucleic acid, vector, or genome.
  • system is meant, a first nucleic acid encoding an integrase, as well as the expressed integrase polypeptide, a second nucleic acid encoding a phage attachment site (attPP'), and a third nucleic acid encoding a corresponding bacterial attachment site (attBB').
  • attPP' a phage attachment site
  • attBB' a corresponding bacterial attachment site
  • any given attPP' site corresponds to, or is compatible with, a particular attBB' site.
  • the availability of the integration systems of the present invention allow for the integration of one or more nucleic acids into any given polynucleotide or genome.
  • the integration site of the present invention can be implanted at a pre-determined position in a listerial genome by way of site-specific integration at an existing site (e.g., at the tRNA 1 ⁇ 6 integration site or the comK integration site).
  • the integration system site can be implanted at a pre-determined location by way of homologous integration.
  • Homologous recombination can result in deletion of material from the integration site, or no deletion of material, depending on the design of the regions of homology (the "homologous arms"). Any deletion that occurs, during homologous recombination corresponds to the region of the target DNA that resides in between regions of the target DNA that can hybridize with the "homologous arms.” Homologous recombination can be used to implant an integration site (attBB 5 ) within a bacterial genome, for future use in site-specific recombination.
  • integration site attBB 5
  • Figure 1 discloses a strategy for preparing the plasm id, pINT, for use in site-directed integration into a bacterial genome.
  • pENT contains a chloramphenicol resistance gene and an erythromycin resistance gene (see, e.g., Roberts, et al. (1996) Appl. Environ. Microbiol. 62:269-270).
  • the antibiotic resistance genes can be subsequently eliminated by transient exposure to Cre recombinase. As shown in Figure 1, the antibiotic resistance genes reside in between a first loxP site and a second loxP site.
  • Cre recombinase can catalyze removal of material residing in between the two loxP sites.
  • Transient expression of Cre recombinase can be effected by electroporation by a plasmid encoding Cre recombinase, or by any number of other techniques.
  • the Listeria genome or chromosome of the present invention is modified using the plasmids pPLl, pPL2, and/or pINTl (Lauer, et al. (2002) J. Bact. 184:4177-4186).
  • the plasmid pPLl (GenBank Ace. No. AJ417488) comprises a nucleic acid encoding U 153 integrase, where this integrase catalyzes integration at the comK-attBB' location of the listerial genome (Lauer, et al. (2002) J. Bact. 184:4177-4186).
  • the structure of comK is available (nucleotides 542-1 1 14 of GenBank Ace. No. AF 174588).
  • pPLl contains a number of restriction sites suitable for inserting a cassette.
  • a cassette of the present invention encodes at least one heterologous antigen and a loxP-flanked region, where the loxP-flanked region comprises: a first nucleic acid encoding an integrase and a second nucleic acid encoding an antibiotic resistance factor.
  • Some of the restriction sites are disclosed in Table 6. Restriction sites can also be introduced de novo by standard methods. Table 6. Restriction sites in pPLl and pPL2.
  • pPL2 (GenBank Ace. No. AJ417499) comprises a nucleic acid encoding
  • PSA integrase where this integrase catalyzes integration at the tRNA ⁇ 6 gene of the
  • L. monocytogenes genome L. monocytogenes genome (Lauer, et al. (2002) J. Bact. 184:4177-4186).
  • the 74 nucleotide tRNA ⁇ 8 gene is found at nucleotide 1, ,266,675 to 1,266,748 of L. monocytogenes strain EGD genome (see, e.g., GenBank Ace. No. NC_003210), and at nucleotides 1,243,907 to
  • pPL2 contains a number of restriction sites suitable for inserting a cassette.
  • the present invention provides a cassette encoding, e.g., a heterologous antigen and loxP-flanked region, where the loxP-flanked region comprises: a first nucleic acid encoding an integrase and a second nucleic acid encoding an antibiotic-resistance factor.
  • Some of the restriction sites are disclosed in Table 6. Standard methods can be used to introduce other restriction sites de novo.
  • a first embodiment of site-specific recombination involves integrase-catalyzed site-specific integration of a nucleic acid at an integration site located at a specific tRNA Are region of the Listeria genome.
  • a second embodiment uses integration of a nucleic acid at the ComK region of the
  • Additional embodiments comprise prophage attachment sites where the target is found at, e.g., tRNA-Thr4 of L. monocytogenes F6854 ⁇ F6854.3 (nucleotides 277,661-
  • a further embodiment of site-specific recombination comprises insertion of a loxP sites (or Fit site) by site-specific integration at the tRNA ⁇ 6 region or ComK region, where insertion of the loxP sites is followed by Cre recombinase-mediated insertion of a nucleic acid into the Listeria genome.
  • pPLl integrates at the comK-attBB' chromosomal location (6,101 bp; GenBank Ace. No. AJ417488). This integration is catalyzed by U153 integrase.
  • the L. monocytogenes comK gene is disclosed (nucleotides 542-11 14 of GenBank Ace. No. AFl 74588).
  • the pPLl integration site comprises nucleotides 2694-2696 of the plasmid sequence AJ417488.
  • Primer PL60 is 5'-TGA AGT AAA CCC GCA CAC GATC-3' (SEQ ID NO:9); Primer PL61 is 5'-TGT AAC ATG GAG GTT CTG GCA ATC-3' (SEQ ID NO: 10).
  • the primer pair PL60 and PL61 amplifies comK-attBB' resulting in a 417 bp product in non-lysogenic strains, e.g., DP-L4056.
  • pPL2 integrates at the tRNA Arg -attBB' chromosomal location (6,123 bp; GenBank Ace. No. AJ417449). This integration is catalyzed by PSA integrase.
  • pPL2 is similar to pPLl, except that the PSA phage attachment site and U 153 integrase of pPLl were deleted and replaced with PSA integrase and the PSA phage attachment site.
  • the pPL2 integration site comprises a 17 bp region that resides at at nucleotides 2852-2868 of the plasmid pPL2 (AJ417449), with the corresponding bacterial region residing at nucleotides 1,266,733- 1,266,749 of L. monocytogenes strain EGD genome (GenBank Ace. No. NC 003210).
  • the attB position resides at nucleotides 187-189 of the 573 bp comK ORF (Loessner, et a (2000) MoI. Microbiol. 35:324-340).
  • This 573 bp ORG (nucleotide 542-11 14 of GenBank Ace. No. AFl 74588) and the attB site (nucleotide 701-757 of GenBank Ace. No. AFl 74588) are both disclosed in GenBank Ace. No. AF174588.
  • the attP site resides in the listeriophage Al 18 genome at nucleotides 23500-23444 (GenBank Ace. No. AJ242593).
  • the present invention provides reagents and methods for catalyzing the integration of a nucleic acid, e.g., a plasmid, at an integration site in a Listeria genome.
  • the L. monocytogenes genome is disclosed (see, e.g., GenBank Ace. No. NC_003210; GenBank Ace. No. NC_003198, He and Luchansky (1997) Appl. Environ. Microbiol. 63:3480-3487, Nelson, et al. (2004) Nucl. Acids Res. 32:2386-2395; Buchrieser, et al. (2003) FEMS Immunol. Med. Microbiol. 35:207-213; Doumith, et al. (2004) Infect. Immun. 72:1072-1083; Glaser, et al. (2001) Science 294:849-852).
  • Suitable enzymes for catalyzing integration of a nucleic acid into a Listeria genome include, e.g., U153 integrase (see, e.g., complement of nucleotides 2741-4099 of GenBank Ace. No. AJ417488: Lauer. et al. (2002) J. Bact. 184:4177-4186)) and PSA integrase (see, e.g., complement of nucleotides 19,413-20,567 of PSA phage genome (37,618 bp genome) (GenBank Ace. No. NC_003291)).
  • a similar or identical nucleotide sequence for tRNA Arg gene, and for the core integration site that is found within this gene, has been disclosed for a number of strains of L. monocytogenes.
  • the L. monocytogenes strain EGD complete genome (2,944,528 bp total) (GenBank Ace. No. NC_003210) contains an integration site in the tRNA Arg gene.
  • the 74 nucleotide tRNA Arg gene is found at nucleotide 1,266,675 to 1,266,748 of GenBank Ace. No. NC_003210.
  • the tRNA Are gene occurs in L. monocytogenes strain 4bF265 (GenBank Ace. No.
  • Residence in a functional cluster establishes function of nucleic acids residing in that cluster.
  • the function of a bacterial gene, or bacteriophage gene can be identified according to its grouping in a functional cluster with other genes of known function, its transcriptional direction as relative to other genes of similar function, and occurrence on one operon with other genes of similar function (see, e.g., Bowers, et al. (2004) Genome Biology 5:R35.1-R35.13).
  • the gene encoding phage integrase has been identified in the genomes of a number of phages (or phages integrated into bacterial genomes), where the phage integrase gene resides in a lysogeny control cluster, where this cluster contains a very limited number of genes (three genes to nine genes) (see, e.g., Loessner, et al. (2000) MoI. Microbiol. 35:324-340; Zimmer, et al. (2003) MoI. Microbiol. 50:303-317; Zimmer, et al. (2002) J. Bacteriol. 184:4359-4368).
  • the phage attachment site (attPP') resides essentially immediately adjacent to the phage integrase gene.
  • the integrase gene (int) and attP are typically adjacent, facilitating their co-evolution (Zhao and Williams (2002) J. Bacteriol. 184:859-860).
  • phage integrase is encoded by nucleotide (nt): 38,447 to 40,264, while the attP site resides nearby at nt 38,346 to 38,429.
  • PhiC31 phage integrase does not require cofactors for catalyzing the integration reaction, and can function in foreign cellular environments, such as mammalian cells (see, e.g., Thorpe and Smith (1998) Proc. Natl. Acad. Sci. USA 95:5505-5510; Groth, et al. (2000) Proc. Natl. Acad. Sci. USA 97:5995-6000; GenBank Ace. No. AJ006589).
  • integrase gene and attP site are located immediately next to each other.
  • the integrase gene and attP site can occur together in small group of genes known as a "lysogeny control cluster.”
  • the present invention provides a vector for use in modifying a listerial genome, where the vector encodes phiC31 phage integrase, phiC31 attPP' site, and where the listerial genome was modified to include the phiC31 attBB' site.
  • a bacterial genome e.g., of Listeria or B. anthracis, can be modified to include an attBB' site by homologous recombination.
  • the phiC31 attBB' site is disclosed by Thorpe and Smith (1998) Proc. Natl. Acad. Sci. USA 95:5505-5510.
  • the amino acid sequence of phiC31 integrase is disclosed below (GenBank Ace. No. AJ414670):
  • the present invention provides the following relevant phiC31 target attBB' sites, and functional variants therof:
  • TGACGGTCTCGAAGCCGCGGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTAC TCCACCTCACCCATCTGGTCCA (SEQ ED NO:12) (see, e.g., Thorpe and Smith (1998) Proc. Natl. Acad. Sci. USA 95:5505-5510).
  • AAGGGGTTGTGACCGGGGTGGACACGTACGCGGGTGCTTACGACCGTCAGTCGC GCGAGCGCGAGAATTC (SEQ ID NO: 14) (see, e.g., GenBank Ace. Nos. X57036 and AJ006589; Thorpe and Smith (1998) Proc. Natl. Acad. Sci. USA 95:5505-5510).
  • the present invention encompasses a vector that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site of pPLl . Also encompassed is a vector that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site of pPL2. Moreover, the present invention encompasses a vector that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site of pPLl or of pPL2.
  • the present invention encompasses a vector useful for integrating a heterologous nucleic acid into a bacterial genome that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site of U 153 phage. Also encompassed is a vector, useful for integrating a heterologous nucleic acid into a bacterial genome, that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site of PSA phage.
  • the present invention encompasses a vector, useful for integrating a heterologous nucleic acid into a bacterial genome, that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site from any of Ul 53 phage and PSA phage.
  • the present invention encompasses a vector, useful for integrating a heterologous nucleic acid into a bacterial genome, that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site of Al 18 phage.
  • a vector useful for integrating a heterologous nucleic acid into a bacterial genome, that encodes a phage integrase and a functionally active attPP' site, but does not encode the phage integrase and attPP' site from any of Al 18 phage, U 153 phage, or PSA phage.
  • the target site for homologous recombination can be an open reading frame, a virulence gene, a gene of unknown function, a pseudogene, a region of DNA shown to have no function, a gene that mediates growth, a gene that mediates spread, a regulatory region, a region of the genome that mediates listerial growth or survival, a gene where disruption leads to attenuation, an intergenic region, and the like.
  • the invention provides a Listeria bacterium comprising an expression cassette, integrated via homologous recombination (or by allelic exchange, and the like), in a listerial virulence gene. Integration can be with or without deletion of a corresponding nucleic acid from the listerial genome.
  • the expression cassette can be operably linked with one or more promoters of the virulence gene (promoters already present in the parental or wild type Listeria).
  • the expression cassette can be operably linked with both: (1) One or more promoters supplied by the expression cassette; and (2) One or more promoters supplied by the parent or wild type
  • the expression cassette can be operably linked with one or more promoters supplied by the expression cassette, and not at all operably linked with any promoter of the Listeria.
  • the virulence factor gene can be one or more of actA, MB, both actA and inlB, as well as one or more of the genes disclosed in Table 3.
  • homologous recombination can be at the locus of one or more genes that mediate growth, spread, or both growth and spread.
  • the invention provides a Listeria bacterium having a polynucleotide, where the polynucleotide comprises a nucleic acid (encoding a heterologous antigen) integrated at the locus of a virulence factor.
  • integration is by homologous recombination.
  • the invention provides integration in a regulatory region of the virulence factor gene, in an open reading frame (ORP) of the virulence factor gene, or in both a regulatory region and the ORF of the virulence factor.
  • ORP open reading frame
  • Integration can be with deletion or without deletion of all or part of the virulence factor gene.
  • Expression of the nucleic acid encoding the heterologous antigen can be mediated by the virulence factor's promoter, where this promoter is operably linked and with the nucleic acid.
  • a nucleic acid integrated in the actA gene can be operably linked with the actA promoter.
  • a nucleic acid integrated at the locus of the inlB gene can be operably linked and in frame with the inlB promoter.
  • the regulation of expression of the open reading frame can be mediated entirely by a promoter supplied by the nucleic acid.
  • the expression cassette and the above- identified nucleic acid can provide one or more listerial promoters, one or more bacterial promoters that are non-listerial, an actA promoter, an inlB promoter, and any combination thereof.
  • the promoter mediates expression of the expression cassette.
  • the promoter mediates expression of the above- identified nucleic acid.
  • the promoter is operably linked with the ORP.
  • integration into the virulence gene, or integration at the locus of the virulence gene results in deletion of all or part of the virulence gene, and/or disruption of regulation of the virulence gene. In some embodiments, integration results in an attenuation of the virulence gene, or in inactivation of the virulence gene.
  • the invention provides a promoter that is prfA-dependent, a promoter that is prfA- independent, a promoter of synthetic origin, a promoter of partially synthetic origin, and so on.
  • a method for manufacturing the above-disclosed Listeria Also provided are methods of using the above -disclosed Listeria for expressing the expression cassette or for expressing the above -identified nucleic acid. Moreover, in some embodiments, what is provided are methods for stimulating a mammalian immune system, comprising administering the above -disclosed Listeria to a mammal.
  • the present invention provides a region of homology that is normally at least 0.01 kb, more normally at least 0.02 kb, most normally at least 0.04 kb, often at least 0.08 kb, more often at least 0.1 kb, most often at least 0.2 kb, usually at least 0.4 kb, most usually at least 0.8 kb, generally at least 1.0 kb, more generally at least 1.5 kb, and most generally at least 2.0 kb.
  • FIG. 2 demonstrates a strategy using pKSV7 in homologous recombination into a bacterial genome.
  • Step 1 the plasmid crosses over with a region of homology in the genome.
  • Step 2 the plasmid integrates into the genome, producing a merodiploid intermediate.
  • WXYZ represents any sequence in the pKSV7, such as an antibiotic-resistance encoding gene.
  • Step 3 shows a second crossover, while Step 4 shows elimination of the
  • Figure 3 shows a method for preparing an insert, where the insert is placed into pKSV7.
  • the insert mediates homologous recombination into a listerial genome, resulting in integration of various elements into the listerial geneome (nucleic acids encoding an antigen, loxP sites, and an antibiotic resistance gene). Subsequent treatment with Cre recombinase catalyzes removal of material between the loxP sites.
  • Figure 4 shows a method for preparing an insert, where the insert is placed into pKSV7.
  • the insert mediates homologous recombination into a listerial genome, resulting in integration of various elements into the listerial genome (nucleic acid encoding an antigen).
  • Nucleic acids encoding loxP sites and an antibiotic resistance gene are encoded by a modified pKSV7.
  • Subsequent treatment with Cre recombinase e.g., by transient expression of Cre recombination, catalyzes removal of material between the loxP sites.
  • Figure 5 discloses an embodiment that results in only integration with no deletion.
  • reagents and methods of the present invention are not limited to use of pKSV7, or to derivatives thereof.
  • Other vectors suitable for homologous recombination are available (see, e.g., Merlin, et al. (2002) J. Bacteriol. 184:4573-4581; Yu, et al. (2000) Proc. Natl. Acad. Sci. USA 97:5978-5983; Smith (1988) Microbiol. Revs.
  • bacteria are electroporated with a pKSV7, where the pKSV7 encodes a heterologous protein or where the pKSV7 contains an expression cassette.
  • Bacteria are selected by plating on BHI agar media (or media not based on animal proteins) containing a suitable antibiotic, e.g., chloramphenicol (0.01 mg/ml), and incubated at the permissive temperature of 3O 0 C.
  • a suitable antibiotic e.g., chloramphenicol (0.01 mg/ml
  • Single cross-over integration into the bacterial chromosome is selected by passaging several individual colonies for multiple generations at the non-permissive temperature of 41 0 C in medium containing the antibiotic.
  • plasm id excision and curing double cross-over is achieved by passaging several individual colonies for multiple generations at the permissive temperature of 30 0 C in BHI media not containing the antibiotic.
  • Homologous recombination can be used to insert a nucleic acid into a target DNA, with or without deletion of material from the target DNA.
  • a vector that mediates homologous recombination includes a first homologous arm (first nucleic acid), a second homologous arm (second nucleic acid), and a third nucleic acid encoding a heterologous antigen that resides in between the two homologous arms.
  • the target regions can abut each other or the target regions can be spaced apart from each other. Where the target regions abut each other, the event of homologous recombination merely results in insertion of the third nucleic acid. But where the target regions are spaced apart from each other, the event of homologous recombination results in insertion of the third nucleic acid and also deletion of the DNA residing in between the two target regions.
  • Homologous recombination at the inlB gene can be mediated by pKSV7, where the pKSV7 contains the following central structure.
  • the following central structure consists essentially of a first homologous arm (upstream of inlB gene in a L. monocytogenes genome), a region containing Kpnl and BamHI sites (underlined), and a second homologous arm (downstream of inlB gene in L. monocytogenes).
  • the region containing Kpnl and B ⁇ mHI sites is suitable for receiving an insert, where the insert also contains Kpnl and B ⁇ mHI sites at the 5 '-prime and 3 '-prime end (or 3 '-end and 5 '-end):
  • the upstream homologous arm is shown below (upstream of inlB gene).
  • the present sequences are from L. monocytogenes 10403S.
  • the following provides comparison with another listerial strain, L. monocytogenes 4bF2365.
  • the inlB gene resides at nt 196,241-198,133 (GenBank AE017323; segment 2 of 10 segments).
  • the upstream homologous arm, disclosed here for L. monocytogenes 10403S, has a corresponding sequence in L.
  • L. monocytogenes 4bF2365 at nt 194,932 to 196,240 (GenBank AE017323; segment 2 of 10 segments).
  • the downstream homologous arm, disclosed here for L. monocytogenes 10403S, has a corresponding (but not totally identical) sequence in L. monocytogenes 4bF2365 at nt 198,134 to 199,629 (GenBank AEO 17323; segment 2 of 10 segments).
  • downstream homologous arm is shown below (downstream ofinlB gene):
  • the present invention provides reagents and methods for mediating the rapid or efficient excision of a first nucleic acid from a bacterial genome.
  • the method depends on recombinase-mediated excision, where the recombinase recognizes heterologous recombinase binding sites that flank the first nucleic acid.
  • the heterologous recombinase binding sites can be, for example, a pair of loxP sites or a pair of fit sites.
  • the first nucleic acid can encode a selection marker such as an antibiotic resistance gene.
  • the reagents of this embodiment include plasmids comprising two heterologous recombinase binding sites that flank the first nucleic acid; a bacterial genome comprising two heterologous recombinase bindings sites that flank the first nucleic acid; and a bacterium containing a genome comprising two heterologous recombinase bindings sites that flank the first nucleic acid.
  • the method of this embodiment is set forth in the following steps: i. Transfect a bacterium with a plasm id, where the plasmid can mediate integration of a first nucleic acid (flanked by a pair of heterologous recombinase binding sites) into the bacterial genome; ii. Allow integration of the first nucleic acid (flanked by two heterologous recombinase binding sites) into the bacterial genome. Without implying any limitation as to the mechanism, integration can be by way of site-specific recombination or homologous recombination; iii. Select for the bacterium containing the integrated first nucleic acid.
  • selection can involve culturing the bacterium in a medium containing the antibiotic.
  • the selection step can result in a genotypically pure bacterium; iv. Treat the genotypically pure bacterium with conditions that facilitate recombinase-catalyzed excision of the first nucleic acid from the bacterial genome.
  • the pair of heterologous recombinase binding sites are loxP sites, the recombinase can be
  • Cre recombinase can be introduced into the bacterium by transfecting with a plasmid encoding this enzyme. In one embodiment, expression of Cre recombinase is transient. Cre recombinase and FLP recombinase use the same enzymatic reaction mechanism, and mediate precise site-specific excision between a pair of their specific target sequences; v. After allowing for Cre recombinase-catalyzed excision of the first nucleic, the bacterium can be cultured until the plasmid is lost by dilution or nuclease action; vi.
  • the resulting bacterium can be identified by the presence of the first nucleic acid in the genome. Also, the resulting bacterium can be identified by the loss of one of the two heterologous recombinase binding sites from the genome, that is, only one of the two sites will be left.
  • the above disclosure is not intended to limit the method to the recited steps, is not intended to limit the method to the disclosed order of steps, and is not intended to mean that all of these steps must occur.
  • the invention is not necessarily limited to two heterologous recombinase binding sites. Polynucleotides containing two loxP sites and two Fit sites can be used, for example, where the two loxP sites flank a first nucleic acid, and the two Frt sites flank a second nucleic acid, and where transient expression of Cre recombinase allows excision of the first nucleic acid, and where transient expression of FLP recombinase
  • the canonical DNA target site for site-specific recombinases consists of two recombinase binding sites, where the two recombinase binding sites flank a core region
  • the present invention provides two canonical DNA target sites (a pair of canonical DNA target sites), where the sites flank a first nucleic acid.
  • LoxP is one type of canonical DNA target site.
  • LoxP has two 13bp recombinase binding sites (13bp inverted repeats) that flank an 8bp core region or spacer.
  • each loxP site is a sequence of 34 continuous nucleotides (34bp).
  • Cre recombinase and FLP recombinase are members of the integrase family of site-specific recombinases. Cre and FLP recombinase utilize a tyrosine residue to catalyze
  • Cre recombinase recognizes lox sites, while FLP recombinase recognizes Frt sites.
  • Cre recombinase-mediated excision is likely to require identical spacer regions in the first lox site and the second lox site (see, e.g., Araki, et al. (2000) Nucleic Acids Res. 3O:elO3; Nagy
  • the present invention contemplates a polynucleotide comprising a first lox site and a second lox site, where the pair of lox sites flanks a first nucleic acid, and where the first nucleic acid can encode, e.g., a selection marker, antibiotic resistance gene, regulatory region, or antigen. Also contemplated is a polynucleotide comprising a first lox site and a second lox site, where the pair of lox sites flanks a first nucleic acid, and where the first nucleic acid can encode, e.g., a selection marker, antibiotic resistance gene, regulatory region, or antigen.
  • An alternate lox site, loxY is available, to provide a non-limiting example.
  • the present invention contemplates a polynucleotide comprising a first loxY site and a second loxY site, where the pair of lox Y sites flanks a first nucleic acid, and where the first nucleic acid can encode, e.g., a selection marker, an antibiotic resistance gene, a regulatory region, or an antigen, and so on.
  • the core region of loxP has alternating purine and pyrimidine bases.
  • the Fit site contains three 13bp symmetry elements and one 8bp core region (48bp altogether).
  • FLP recombinase recognizes Frt as a substrate, as well as variant Fit sites, including Frt sites as short as 34bp, and Frt site with variant core regions (see, e.g., Schweizer (2003) J. MoI. Microbiol. Biotechnol. 5:67-77; Bode, et al. (2000) Biol. Chem. 381 :801-813).
  • the present invention provides a polynucleotide containing a first loxP site and an operably linked second loxP site, wherein the first and second loxP sites flank a first nucleic acid, to provide a non-limiting example. It will be appreciated that the invention encompasses other heterologous recombinase binding sites, such as variants of loxP, as well as frt sites and frt site variants.
  • operably linked means that Cre recombinase is able to recognize the first loxP site and the second loxP site as substrates, and is able to catalyze the excision of the first nucleic acid from the bacterial genome.
  • operably linked is not to be limited to loxP sites, as it encompasses any "heterologous recombinase binding sites” such as other lox sites, or fit sites.
  • operably linked is not to be limited to recombinase-catalyzed excision, the term also embraces recombinase-catalyzed integration.
  • operably linked is not to be limited to nucleic acids residing in a genome — also encompassed are nucleic acids residing in plasmids, intermediates used in genetic engineering, and the like.
  • nucleic acids encoding recombinases are disclosed in Table 7 A, and nucleic acid target sites recognized by these recombinases appear in Table 7B.
  • Listeria e.g., chloramphenicol acetyltransferase (CAT) (Table 8).
  • a first nucleic acid encoding the antibiotic resistance factor is operably linked to a ribosome binding site, a promoter, and contains a translation start site, and/or a translation stop site, and is flanked by two heterologous recombinase binding sites.
  • the invention provides a polynucleotide containing a pair of operably linked loxP sites flanking a first nucleic acid, and a second nucleic acid (not flanked by the loxP sites), where the polynucleotide consists of a first strand and a second strand, and where the first nucleic acid has a first open reading frame (ORF) and the second nucleic acid has a second open reading frame (ORF).
  • ORF open reading frame
  • ORF second open reading frame
  • the first ORF is on the first strand
  • the second ORF is also on the first strand.
  • the first ORF is on the first strand and the second ORF is on the second strand.
  • the present invention provides a plasmid comprising the above-disclosed polynucleotide. Also provided is a Listeria containing the above-disclosed polynucleotide, where the polynucleotide can be on a plasmid and/or integrated in the genome.
  • Each of the above-disclosed embodiments can comprise heterologous recombinase binding sites other than loxP. For example, lox variants, Frt sites, Fit variants, and recombinas binding sites unrelated to lox or Frt are available.
  • ActA fusion protein partners and derivatives thereof.
  • the present invention in certain aspects, provides a polynucleotide comprising a first nucleic acid encoding a modified ActA, operably linked and in frame with a second nucleic acid encoding a heterologous antigen.
  • the invention also provides a Listeria containing the polynucleotide, where expression of the polynucleotide generates a fusion protein comprising the modified ActA and the heterologous antigen.
  • the modified ActA can include the natural secretory sequence of ActA, a secretory sequence derived from another listerial protein, a secretory sequence derived from a non-listerial bacterial protein, or the modified ActA can be devoid of any secretory sequence.
  • the ActA-derived fusion protein partner finds use in increasing expression, increasing stability, increasing secretion, enhancing immune presentation, stimulating immune response, improving survival to a tumor, improving survival to a cancer, increasing survival to an infectious agent, and the like.
  • the invention provides a polynucleotide comprising a promoter operably linked to a nucleic acid sequence encoding a fusion protein, wherein the fusion protein comprises (a) modified ActA and (b) a heterologous antigen.
  • the promoter is ActA promoter.
  • the modified ActA comprises at least the first 59 amino acids of ActA.
  • the modified ActA comprises more than the first 59 amino acids of ActA.
  • the modified ActA is a fragment of ActA comprising the signal sequence of ActA (or is derived from a fragment of ActA comprising the signal sequence of ActA).
  • the modified ActA comprises at least the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA. In some embodiments, the modified ActA comprises more than the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA. In other words, in some embodiments, the modified ActA sequence corresponds to an N-terminal fragment of ActA (including the ActA signal sequence) that is truncated somewhere between amino acid 59 and about amino acid 265 of the Act A sequence. In some embodiments, the modified ActA comprises the first 59 to 200 amino acids of ActA, the first 59 to 150 amino acids of ActA, the first 59 to 125 amino acids of ActA, or the first 59 to 110 amino acids of ActA.
  • the modified ActA consists of the first 59 to 200 amino acids of ActA, the first 59 to 150 amino acids of ActA, the first 59 to 125 amino acids of ActA, or the first 59 to 1 10 amino acids of ActA.
  • the modified ActA comprises about the first 65 to 200 amino acids of ActA, about the first 65 to 150 amino acids of ActA, about the first 65 to 125 amino acids of ActA, or about the first 65 to 110 amino acids of ActA.
  • the modified ActA consists of about the first 65 to 200 amino acids of ActA, about the first 65 to 150 amino acids of ActA, about the first 65 to 125 amino acids of ActA, or about the first 65 to 1 10 amino acids of ActA.
  • the modified ActA comprises the first 70 to 200 amino acids of ActA, the first 80 to 150 amino acids of ActA, the first 85 to 125 amino acids of ActA, the first 90 to 1 10 amino acids of ActA, the first 95 to 105 amino acids of ActA, or about the first 100 amino acids of ActA.
  • the modified ActA consists of the first 70 to 200 amino acids of ActA, the first 80 to 150 amino acids of ActA, the first 85 to 125 amino acids of ActA, the first 90 to 110 amino acids of ActA, the first 95 to 105 amino acids of ActA, or about the first 100 amino acids of ActA.
  • the modified ActA comprises amino acids 1-100 of ActA.
  • the modified ActA consists of amino acids 1-100 of ActA.
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is immunologically cross-reactive with, or shares at least one epitope with, the cancer, tumor, or infectious agent.
  • the heterologous antigen is a tumor antigen or is derived from a tumor antigen.
  • the heterologous antigen is, or is derived from, human mesothelin.
  • the nucleic acid sequence encoding the fusion protein is codon-optimized for expression in Listeria.
  • the invention provides plasmids and cells comprising the polynucleotide.
  • the invention further provides a Listeria bacterium e.g., Listeria monocytogenes ' ) comprising the polynucleotide, as well as vaccines comprising the Listeria.
  • the genomic DNA of the Listeria comprises the polynucleotide.
  • the polynucleotide is positioned in the genomic DNA at the site of the actA gene or the site of the inlB gene.
  • the Listeria comprises a plasmid comprising the polynucleotide.
  • the invention further provides immunogenic and pharmaceutical compositions comprising the Listeria.
  • the invention also provides methods for stimulating immune responses to the heterologous antigen in a mammal (e.g., a human), comprising administering an effective amount of the Listeria (or an effective amount of a composition comprising the Listeria) to the mammal.
  • a mammal e.g., a human
  • the invention also provides methods for stimulating immune responses to an antigen from, or derived from, a cancer or infectious agent, comprising administering an effective amount of the Listeria (or a composition comprising the Listeria) to a mammal having the cancer or infectious agent, wherein the heterologous antigen shares at least one epitope with or is immunologically cross-reactive with the antigen from, or derived from, the cancer or infectious agent.
  • the preferred embodiment of antigen expression cassettes utilizing ActA-N-100 heterologous antigen fusion partner configurations is to functionally link the said antigen fusion construct with the native actA promoter and 5' untranslated region (UTR) RNA.
  • PrfA-dependent transcription from the actA promoter results in synthesis of a 150 nucleotide 5' UTR RNA prior to the ActA protein GUG translation initiation site.
  • L. monocytogenes mutants deleted of the actA promoter 5' UTR express low levels of ActA, resulting in a phenotype characterized by absence of intracellular actin recruitment, inability to spread from cell-to-cell, and attenuated, as compared to the wild-type parent bacterium (Wong et. al. defective Cellular Microbiology 6: 155-166).
  • the promoter used to express the fusion protein comprising the modified ActA and a heterologous antigen is an hly promoter.
  • the promoter is an actA promoter.
  • These listerial promoters may, of instance, be derived from any strain of Listeria monocytogenes.
  • the hly or actA promoter may be derived from the L. monocytogenes strain EGD.
  • the EGD strain genome sequence is publicly available at GenBank Ace. No. AL591974 (complete genome segment 2/12) (hly promoter: nts 5581-5818; actA gene: nts 9456-1 1389), incorporated by reference herein in its entirety.
  • the sequences used may be from another strain such as the L. monocytogenes strain 10403 S.
  • the invention provides a polynucleotide comprising a first nucleic acid encoding a modified ActA, operably linked and in frame with, a second nucleic acid encoding a heterologous antigen.
  • the modified ActA comprises at least the first 59 amino acids of ActA, but less than about the first 265 amino acids of ActA.
  • the modified ActA comprises the first 59 to 200 amino acids of ActA, the first 59 to 150 amino acids of ActA, the first 59 to 125 amino acids of ActA, or the first 59 to 110 amino acids of ActA.
  • the modified ActA comprises the first 70 to 200 amino acids of ActA, the first 80 to 150 amino acids of ActA, the first 85 to 125 amino acids of ActA, the first 90 to 110 amino acids of ActA, the first 95 to 105 amino acids of ActA, or about the first 100 amino acids of ActA.
  • the first nucleic acid encodes amino acids 1-100 of ActA.
  • the polynucleotide is genomic. In some alternative embodiments, the polynucleotide is plasmid-based. In some embodiments, the polynucleotide is operably linked with a promoter.
  • the polynucleotide may be operably linked with one or more of the following: (a) actA promoter; or (b) a bacterial promoter that is not actA promoter.
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is immunologically cross-reactive with, or shares at least one epitope with, the cancer, tumor, or infectious agent.
  • the heterologous antigen is, or is derived from human mesothelin.
  • the invention further provides a Listeria bacterium e.g., Listeria monocytogenes) comprising the polynucleotide, as well as vaccines comprising the Listeria.
  • the Listeria is hMeso26 or hMeso38 (see Table 11 of Example VII, below).
  • the invention also provides methods for stimulating immune responses to an antigen from, or derived from, a cancer or infectious agent, comprising administering the Listeria to a mammal having the cancer or infectious agent, wherein the heterologous antigen shares at least one epitope with or is immunologically cross-reactive with the antigen from, or derived from, the cancer or infectious agent.
  • the L. monocytogenes native sequence encoding the first 100 amino acids of ActA is functionally linked in frame with a desired heterologous antigen sequence.
  • the heterologous antigen sequence is synthesized according to the optimal codon usage of L. monocytogenes, a low GC percentage organism.
  • compositions utilizing the actA promoter together with the 5' untranslated sequences are desired.
  • the invention provides a polynucleotide comprising a first nucleic acid encoding a modified actA, where the modified actA comprises (a) amino acids 1-59 of actA, (b) an inactivating mutation in, deletion of, or truncation prior to, at least one domain for actA-mediated regulation of the host cell cytoskeleton, wherein the first nucleic acid is operably linked and in frame with a second nucleic acid encoding a heterologous antigen.
  • the domain is the cofilin homology region (KKRR (SEQ ID NO:23)).
  • the domain is the phospholipid core binding domain (KVFKKIKDAGKWVRDKI (SEQ ID NO:20)). In some embodiments, at least one domain comprises all four proline-rich domains (FPPPP (SEQ ID NO:21), FPPPP (SEQ ID NO:21), FPPPP (SEQ ID NO:21), FPPIP (SEQ ID NO:22)) of ActA. In some embodiments, the modified actA is actA-NIOO. In some embodiments, the polynucleotide is genomic. In some embodiments, the polynucleotide is not genomic.
  • the polynucleotide is operably linked with one or more of the following: (a) actA promoter; or (b) a bacterial (e.g., listerial) promoter that is not actA promoter.
  • the invention further provides a Listeria bacterium (e.g., Listeria monocytogenes) comprising the polynucleotide, as well as vaccines comprising the Listeria.
  • the Listeria is is hMeso26 or hMeso38 (see Table 11 of Example VIl, below).
  • the invention also provides methods for stimulating immune responses to an antigen from, or derived from, a cancer or infectious agent, comprising administering the Listeria to a mammal having the cancer or infectious agent, wherein the heterologous antigen shares at least one epitope with or is immunologically cross-reactive with the antigen from, or derived from, the cancer or infectious agent.
  • the stimulating is relative to immune response without administering the Listeria.
  • the cancer comprises a tumor or pre-cancerous cell.
  • the infectious agent comprises a virus, pathogenic bacterium, or parasitic organism.
  • the heterologous antigen is, or is derived from, a cancer cell, tumor, or infectious agent.
  • the heterologous antigen is immunologically cross-reactive with, or shares at least one epitope with, the cancer, tumor, or infectious agent.
  • the heterologous antigen is, or is derived from, human mesothelin.
  • a polynucleotide comprising a first nucleic acid encoding a modified ActA comprising at least amino acids 1-59 of ActA, further comprising at least one modification in a wild type ActA sequence, wherein the at least one modification is an inactivating mutation in, deletion of, or truncation at or prior to, a domain specifically used for ActA-mediated regulation of the host cell cytoskeleton, wherein the first nucleic acid is operably linked and in frame with a second nucleic acid encoding a heterologous antigen.
  • the at least one modification is an inactivating mutation in, deletion of, or termination at, comprising the cofilin homology region KKRR (SEQ ID NO:23).
  • the at least one modification is an inactivating mutation in, deletion of, or termination at, comprising the phospholipid core binding domain (KVFKKIKDAGKWVRDKI (SEQ ID NO:20)).
  • the at least one modification comprises an inactivating mutation in, or deletion of, in each of the first proline-rich domain (FPPPP (SEQ ID NO:21)), the second proline-rich domain (FPPPP (SEQ ID NO:21)), the third proline-rich domain (FPPPP (SEQ ID NO:21)), and the fourth proline-rich domain (FPPIP (SEQ ID NO:22)), or a termination at the first proline-rich domain.
  • the modified ActA is ActA-NIOO.
  • a Listeria bacterium comprising one or more of the above polynucleotide.
  • the polynucleotide can be genomic, it can be plasmid-based, or it can reside on both a plasm id and the listeria! genome. Also provided is the above Listeria where the polynucleotide is not genomic, as well as the above Listeria where the polynucleotide is not plasmidic.
  • the Listeria can be Listeria monocytogenes, L. innocua, or some other listerial species.
  • a method of stimulating immune response to an antigen from, or derived from, a tumor, cancer cell, or infectious agent comprising administering to a mammal the above-disclosed Listeria and where the heterologous antigen is shares at least one epitope with the antigen derived from the tumor, cancer cell, or infectious agent.
  • the stimulating is relative to antigen-specific immune response in absence of the administering the Listeria (specific to the antigen encoded by the second nucleic acid).
  • the heterologous antigen can be identical to the antigen from (or derived from) the tumor, cancer cell, or infectious agent.
  • ActA-lMlOO encompasses a nucleic acid encoding amino acids 1 -100 of ActA, as well as the polypeptide expressed from this nucleic acid. (This numbering includes all of the secretory sequence of ActA.) What is provided is a polynucleotide comprising a first nucleic acid encoding ActA-NlOO operably linked and in frame with a second nucleic acid encoding a heterologous antigen.
  • a Listeria bacterium comprising one or more of the above polynucleotide.
  • the polynucleotide can be genomic, it can be plasmid-based, or it can reside on both a plasm id and the listerial genome. Also provided is the above Listeria where the polynucleotide is not genomic, as well as the above Listeria where the polynucleotide is not plasmidic.
  • the Listeria can be Listeria monocytogenes, L. innocua, or some other listerial species.
  • Methods for using ActA-N100 are also available.
  • a method for stimulating immune response to an antigen from, or derived from, a tumor, cancer cell, or infectious agent comprising administering to a mammal the above-disclosed Listeria, and wherein the heterologous antigen is shares at least one epitope with the antigen derived from the tumor, cancer cell, or infectious agent.
  • the stimulating is relative to antigen-specific immune response in absence of the administering the Listeria (specific to the antigen encoded by the second nucleic acid).
  • the heterologous antigen can be identical to the antigen from, or derived from, the tumor, cancer cell, or infectious agent.
  • the modified ActA consists of a fragment of ActA or other derivative of ActA in which the ActA signal sequence has been deleted.
  • the polynucleotides comprising nucleic acids encoding a fusion protein comprising such a modified ActA and the heterologous antigen further comprise a signal sequence that is not the ActA signal sequence.
  • the ActA signal sequence is MGLNRFMRAMMVVFITANCITINPDIIFA (SEQ ID NO: 125).
  • the modified ActA consists of amino acids 31-100 of ActA (i.e., ActA-N I OO deleted of the signal sequence).
  • the present invention provides a polynucleotide comprising a first nucleic acid encoding a modified ActA, operatively linked and in frame with a second nucleic acid encoding a heterologous antigen.
  • ActA contains a number of domains, each of which plays a part in binding to a component of the mammalian cytoskeleton, where the present invention contemplates removing one or more of these domains.
  • ActA contains a number of domains, including an N-terminal domain (amino acids 1-234), proline-rich domain (amino acids 235-393), and a C-terminal domain (amino acids 394-610).
  • the first two domains have distinct effects on the cytoskeleton (Cicchetti, et al. (1999) J. Biol. Chem. 274:33616-33626).
  • the proline-rich domain contains four proline-rich motifs.
  • the proline-rich motifs are docking sites for the Ena/VASP family of proteins. Deletion of proline-rich domains of ActA strongly reduces actin filament assembly (Cicchetti, et al. (1999) J. Biol. Chem.
  • Machner, et al. provides guidance for designing mutated proline-rich motifs that can no longer dock, where this guidance can be put to use for embodiments of the present invention (Machner, et al. (2001) J. Biol. Chem. 276:40096-40103).
  • the phenylalanine of the proline-rich motifs is critical.
  • the present invention in an alternate embodiment, provides a polynucleotide comprising a first nucleic acid encoding ActA, where the codons for the phenylalaline in each proline-rich motif is changed to an alanine codon, operably linked and in frame with a second nucleic acid encoding at least one heterologous antigen.
  • the first nucleic acid encoding ActA comprises a proline to alanine mutation in only the first proline-rich motif, in only the second proline-rich motif, in only the third proline-rich motif, in only the fourth proline-rich motif, or any combination thereof.
  • a nucleic acid encoding an altered ActA can encompass a mutation in a codon for one or more proline-rich motifs in combination with a mutation or deletion in, e.g., cofilin homology region and/or the core binding sequence for phospholipids interaction.
  • mutations of proline to another amino acid e.g., serine.
  • the above guidance in designing mutations is not to be limited to changing the proline-rich motifs, but applies as well to the cofilin homology region, the core binding sequence for phospholipids interaction, and any other motifs or domains that contribute to interactions of ActA with the mammalian cytoskeleton.
  • ActA contains a domain that is a "core binding sequence for phospholipids interaction" at amino acids 185-201 of ActA, where the function in phospholipids binding was demonstrated by binding studies (Cicchetti, et al. (1999) J. Biol. Chem. 274:33616- 33626). According to Cicchetti, et al., supra, phospholipids binding regulates the activities of actin-binding proteins.
  • ActA contains a cofilin homology region KKRR (SEQ ID NO:23). Mutations of the KKRR (SEQ ID NO:23) region abolishes the ActA's ability to stimulate actin polymerization (see, e.g., Baoujemaa-Paterski, et al. (2001) Biochemistry 40:1 1390-11404; Skoble, et al. (2000) J. Cell. Biol. 150:527-537; Pistor, et al. (2000) J. Cell Sci. 113:3277-3287). [0271] The following concerns expression, by L. monocytogenes, of truncated actA derivatives truncated down from amino acid 263 to amino acid 59.
  • actA N59 was not expressed whereas all of the longer ones were expressed (Skoble, J. (unpublished)).
  • the next longest derivative tested was actA-NIOl .
  • deletion constructs good expression was also found where the first fusion protein partner was soluble actA with amino acids 31-59 deleted.
  • good expression was found where the first fusion protein partner was soluble actA with amino acids 31-165 deleted (Skoble, J. (unpublished)).
  • the present invention provides a polynucleotide comprising a first nucleic acid encoding a modified ActA, comprising at least one modification, wherein the at least one modification is an inactivating mutation in, deletion of, or termination of the ActA polypeptide sequence at or prior to, a domain required for ActA-mediated regulation of the host cell cytoskeleton, and a second nucleic acid encoding a heterologous antigen.
  • the modified ActA can be one resulting in impaired motility and/or decreased plaque size, and includes a nucleic acid encoding one of the mutants 34, 39, 48, and 56 (Lauer, et al. (2001) MoI. Microbiol. 42:1 163-1177).
  • the present invention also contemplates a nucleic acid encoding one of the ActA mutants 49, 50, 51, 52, and 54. Also provides is a nucleic acid encoding one of the ActA mutants 40, 41, 42, 43, 44, 45, 45, and 47. Provided are mutants in the actin monomer binding region AB region, that is, mutants 41, 42, 43, and 44 (Lauer, et al. (2001) MoI. Microbiol. 42:1 163-1 177).
  • the modified ActA of the present invention can consist a deletion mutant, can comprise a deletion mutant, or can be derived from a deletion mutant ActA that is unable to polymerize actin in cells and/or unable to support plaque formation, or supported only sub-maximal plaque formation.
  • ActA deletion mutants include the nucleic acids encoding ⁇ 31-165; ⁇ 136-200; ⁇ 60-165; ⁇ 136-165; ⁇ 146-150, ⁇ 31-58; ⁇ 60-101 ; and ⁇ 202-263 and the like (Skoble, et al. (2000) J. Cell Biol. 150:527-537).
  • nucleic acids encoding ActA deletion mutants that have narrower deletions and broader deletions.
  • the following set of examples, which discloses deletions at the cofilin homology region, can optionally to each the ActA deletions set forth herein.
  • the present invention provides nucleic acids encoding these deletions at the cofilin homology region: ⁇ 146-150; ⁇ 145-150; ⁇ 144-150; ⁇ 143-150; ⁇ 142-150; ⁇ 141-150; ⁇ 140-150; ⁇ 139-150; ⁇ 138-150; ⁇ 137-150; ⁇ 136-150, and the like.
  • nucleic acids encoding ActA with the deletions ⁇ 146-150; ⁇ 146-151; ⁇ 146-152; ⁇ 146-153; ⁇ 146-154; ⁇ 146-155; ⁇ 146-156; ⁇ 146-157; ⁇ 146-158; ⁇ 146-159; ⁇ 146-160; and so on.
  • nucleic acids encoding the deletion mutants ⁇ 146-150; ⁇ 145-151; ⁇ 144-152; ⁇ 143-153; ⁇ 142-154; ⁇ 141-155; ⁇ 140-156; ⁇ 139-157; ⁇ 138-158; ⁇ 137-159; ⁇ 136-160, and the like. Where there is a deletion at both the N-terminal end of the region in question, and at the C-terminal end, the sizes of these two deletions need not be equal to each other.
  • Deletion embodiments are also provided, including but not limited to the following. What is provided is a nucleic acid encoding full length actA, an actA missing the transmembrane anchor, or another variant of actA, where the actA is deleted in a segment comprising amino acids (or in the alternative, consisting of the amino acids): 31-59, 31-60, 31-61, 31-62, 31-63, 31-64, 31-65, 31-66, 31-67, 31-68, 31-69, 31-70, 31-71, 31-72, 31 -73, 31 -74, 31-75, 31-76, 31-77, 31-78, 31-79, 31-80, 31-81, 31-82, 31-83, 31-84, 31-85, 31-86, 31-87, 31-88, 31-89, 31-90, 31-91, 31-92, 31-93, 31-94, 31-95, 31-96, 31-97, 31-98, 31-99, 31-100,
  • a polynucleotide comprising a first nucleic acid encoding an altered ActA, operably linked and in frame with a second nucleic acid, encoding a heterlogous antigen, where the first nucleic acid is derived from, for example, ⁇ ActA3 (amino acids 129-153 deleted); ⁇ ActA9 (amino acids 142-153 deleted); ⁇ ActA6 (amino acids 68-153 deleted); ⁇ ActA7 (amino acids 90-153 deleted); or ⁇ ActA8 (amino acids 110-153 deleted), and so on (see, e.g., Pistor, et al. (2000) J. Cell Science 113:3277-3287).
  • Fusion proteins (expressed from the ActA promoter) consisting of only the ActA signal sequence and a fusion protein partner, showed much less secretion than fusion proteins consisting of ActA-NlOO and a fusion protein partner.
  • the truncation, deletion, or inactivating mutation can reduce or eliminate the function of one or more of ActA's four FP 4 domains ((E/D)FPPPX(D/E) (SEQ ID NO: 135)).
  • ActA's FP 4 domains mediate binding to the following proteins: mammalian enabled (Mena); Ena/VASP-like protein (EvI); and vasodilator-stimulated phosphoprotein (VASP) (Machner, et al.
  • the nucleic acid of the present invention encodes a truncated ActA, deleted or mutated in one or more of its FP 4 domains, thereby reducing or preventing biding to Mena, EvI, and/or VASP.
  • a nucleic acid encoding a truncated, partially deleted or mutated ActA and a heterologous antigen, where the truncation, partial deletion, or mutation, occurs at amino acids 236-240; amino acids 270- 274; amino acids 306-310; and/or amino acids 351-355 of ActA (numbering of Machner, et al. (2001) J. Biol. Chem. 276:40096-40103).
  • the present invention provides a polynucleotide comprising a first nucleic acid encoding an ActA variant, and a second nucleic acid encoding at least one heterologous antigen, where the ActA variant is ActA deleted in or mutated in one "long repeat," two long repeats, or all three long repeats of ActA.
  • the long repeats of ActA are 24-amino acid sequences located in between the FP 4 domains (see, e.g., Smith, et al. (1996) J. Cell Biol. 135:647-660). The long repeats help transform actin polymerization to a force-generating mechanism.
  • nucleic acid encoding the following ActA-based fusion protein partner using consisting language: What is provided is a nucleic acid encoding a fusion protein partner consisting of amino acids 1-50 of human actA (for example, GenBank Ace. No.
  • AY512476 or its equivalent, where numbering begins with the start amino acid), amino acids 1-60; 1-61 ; 1-62; 1-63; 1-64; 1-65; 1-66; 1-67; 1 -68; 1-69; 1-70; 1-72; 1-73; 1-74; 1-75; 1-76; 1-77; 1-78; 1-79; 1-80; 1-81 ; 1-82; 1-83; 1-84; 1-85; 1-86; 1-87; 1-88; 1-89; 1-90; 1-91; 1-92; 1-93; 1-94; 1-95; 1-96; 1-97; 1-98; 1-99; 1-100; 1-101 ; 1-102; 1-103; 1-104; 1-105; 1-106; 1-107; 1-108; 1-109; 1-1 10; 1-111; 1-1 12; 1-113; 1-114; 1-115; 1-116; 1-117; 1-118; 1-119; 1-120; 1-121; 1-122; 1-123; 1-124; 1-125; 1-126; 1-127; 1-128; 1-129; 1-130; 1-131; 1-132; 1-133; 1-134; 1-135
  • nucleic acid encoding the following ActA-based fusion protein partner using comprising language: What is provided is a nucleic acid encoding a fusion protein partner comprising amino acids 1-50 of human actA (for example, GenBank Ace. No.
  • AY512476 or its equivalent, where numbering begins with the start amino acid), amino acids 1 -60; 1 -61 ; 1-62; 1-63; 1-64; 1-65; 1-66; 1-67; 1-68; 1-69; 1-70; 1-72; 1-73; 1-74; 1-75; 1-76; 1-77; 1-78; 1-79; 1-80; 1-81; 1-82; 1-83; 1-84; 1-85; 1-86; 1-87; 1-88; 1-89; 1-90; 1-91 ; 1-92; 1-93; 1-94; 1-95; 1-96; 1-97; 1-98; 1-99; 1-100; 1-101; 1-102; 1-103; 1-104; 1-105; 1-106; 1-107; 1 -108; 1-109; 1-110; 1-1 1 1 ; 1-112; 1-1 13; 1-114; 1-1 15; 1-1 16; 1-117; 1-118; 1-119; 1-120; 1-121; 1-122; 1-123; 1-124; 1-125; 1-126; 1-127; 1-128; 1-129; 1-130; 1-131 ; 1-132; 1-
  • the contemplated nucleic acids encoding an actA -based fusion protein partner include nucleic acids encoding the actA-based fusion protein partner, where one or more nucleotides is altered to provide one or more conservative amino acid changes. What is contemplated is one conservative amino acid change, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or more, conservative amino acid changes. Moreover, what is contemplated is a nucleic acid encoding the actA-based fusion protein partner, comprising at least one mutation encoding at least one short deletion, or at least one short insertion, or any combination thereof.
  • the codon for the start methionine can be a valine start codon.
  • Listeria uses a valine start codon to encode methionine.
  • the contemplated invention encompasses ActA, and ActA deleted in one or more cytoskeleton-binding domains, ActA-NlOO fusion protein partners, from all listeria! species, including L. monocytogenes and L. ivanovii (Gerstel, et al. (1996) Infection Immunity 64:1929-1936; GenBank Ace. No. X81 135; GenBank Ace. No. AY510073).
  • the modified ActA consists of a sequence having at least about 80% sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, or at least about 95% sequence identity to a fragment of ActA comprising more than the first 59 amino acids of ActA and less than the first 380 amino acids of ActA.
  • the modified ActA consists of a sequence having at least about 80% sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, or at least about 95% sequence identity to ActA-N100.
  • the nucleic acid molecule encoding the modified ActA hybridizes under stringent conditions to a nucleic acid molecule encoding the ActA-N100 sequence, or its complement.
  • the present invention in some embodiments, encompasses a polynucleotide comprising a first nucleic acid encoding actA-NlOO operably linked and in frame with a second nucleic acid encoding a heterologous antigen, such as human mesothelin, or a derivative thereof.
  • Human mesothelin was expressed from a number of constructs, where these constructs were created by site-directed integration or homologous integration into the Listeria genome. Some of these constructs are shown in Figure 6.
  • Figure 6 discloses naturally occurring human mesothelin, which contains a signal sequence and a GPI-sequence.
  • the signal sequence and GPI-sequence was deleted in the following examples, where the naturally occurring signal sequence was replaced with the Bacillus anthracis Protective Antigen secretory sequence (BaPA), with LLO-62, with LLO-60 CO don optimized (LLO-60 op t), or with ActA-NlOO ( Figure 6).
  • the sequence of ActA-NlOO includes the naturally occurring secretory sequence of ActA.
  • the modified ActA is changed to reduce or eliminate its interaction with the mammalian cytoskeleton. While the physiological function of ActA is to bind to the mammalian cytoskeleton and to allow actin-mediated movement of the Listeria bacterium through the cytoplasm, this binding is reduced or eliminated in the ActA component of the fusion protein.
  • Olazabal and Machesky overexpressing a protein demonstrated to be similar to ActA, the WASP protein, causes "defects in actin organization that lead to malfunctions of cells” (Olazabal and Machesky (2001) J. Cell Biol.
  • ActA a protein expressed by Listeria, sequesters or "highjacks” or utilizes various cytoskeleton related proteins, including the Arp2/3 complex and actin (Olazabal, et al. (2002) Curr. Biol. 12:1413-1418; Zalevsky, et al. (2001) J. Biol. Chem. 276:3468-3475; Brieher, et al. (2004) J. Cell Biol. 165:233-242).
  • the ActA-based fusion protein partner, of the present invention has a reduced polypeptide length when compared to ActA lacking the transmembrane domain.
  • the ActA-based fusion protein partner provides reduced disruption of actin-dependent activity such as immune presentation, host cell proliferation, cell polarity, cell migration, endocytosis, sealing of detached vesicles, movement of endocytotic vesicles, secretion, cell polarity, and response to wounds (wound healing) (see, e.g., Setterblad, et al. (2004) J. Immunol. 173: 1876-1886; Tskvitaria-Fuller, et al. (2003) J. Immunol. 171 :2287-2295).
  • Actin-dependent activities of the cell include immune cell functions, wound healing, capping, receptor internalization, phagocytosis, Fc-receptor clustering and Fc-receptor mediated phagocytosis, utilize actin (see, e.g., Kwiatkowska, et al. (2002) J. Cell Biol. 116:537-550; Ma, et al. (2001) J. Immunol. 166:1507-1516; Fukatsu, et al. (2004) J. Biol. Chem. 279:48976-48982; Botelho, et al. (2002) J. Immunol. 169:4423-4429; Krishnan, et al. (2003) J. Immunol.
  • ActA is degraded (in the mammalian cytoplasm) by way of the "N-end rule pathway.” (see, e.g., Moors, et al. (1999) Cellular Microbiol. 1 :249-257; Varshavsky (1996) Proc. Natl. Acad. Sci. USA 93:12142-12149).
  • the ActA coding region contains a number of codons that are non-optimal for L. monocytogenes. Of these, a number occur in the listerial genome at a frequency of 25% or less than that of the most commonly used codon. The following provides a codon analysis for L. monocytogenes 10403 S ActA.
  • rare codons for glutamate occur 12 times; rare codons for lysine (AAG) occurs three times; rare codons for isoleucine (ATA) occurs three times; rare codons for arginine (CGG) occurs once; rare codons for glutamine (CAG) occurs once; and rare codons for leucine (CTG; CTC) occurs three times.
  • the following commentary relates to non-optimal codons, not just to rare codons.
  • non-optimal codons occurs 152 times (out of 300 codons total).
  • ActA is a major target for immune response by humans exposed to L. monocytogenes (see, e.g., Grenningloh, et al. (1997) Infect. Immun. 65:3976-3980).
  • the present invention provides an ActA-based fusion protein partner, where the ActA-based fusion protein partner has reduced immunogenicity, e.g., contains fewer epitopes than full-length ActA or is modified to provide epitopes of reduced immunogenicity.
  • the reagents and methods of the present invention provide a nucleic acid encoding an ActA, a truncated ActA, and/or a mutated ActA (e.g., a point mutation or a deletion), having a reduced number of antigenic epitopes, or that lacks one or more regions of increased antigenicity.
  • Regions of increased antigenicity include amino acids 85-90; 140-150; 160-190; 220-230; 250-260; 270-280; 305-315; 350-370; 435- 445; 450-460; 490-520; 545-555; and 595-610, of GenBank Ace. No. X59723.
  • ActA has been identified as an immunogenic protein (see, e.g., Grenningloh, et al. (1997) Infection Immunity 65:3976-3980; Darji, et al. (1998) J. Immunol. 161 :2414-2420; Niebuhr, et al. (1993) Infect. Immun. 61 :2793-2802; Lingnau, et al. (1995) Infect. Immun. 63:3896-3903).
  • the immunogenic properties of ActA increase with expression of soluble forms of actin, e.g., actin lacking all or part of its C-terminal region (amino acids 394-610 using numbering of Mourrain, et al. (1997) Proc. Natl.
  • Assays for determining recruiting of actin, or other proteins, to ActA, or to variants of ActA, are available. Recruiting can reasonably be assessed by bacterial movement assays, that is, assays that measure actin-dependent rate of Listeria movement in eukaryotic cell extracts or inside a eukaryotic cell (see, e.g., Marchand, et al. (1995) J. Cell Biol. 130:331- 343). Bacterial movement assays can distinguish between Listeria expressing wild type ActA, and Listeria expressing mutant versions of ActA, for example, mutant ActA that lacks FP 4 domains (Smith, et al. (1996) J. Cell Biol. 135:647-660).
  • Recruitment can also be assessed by measuring local actin concentration at the surface of ActA-coated beads or at the surface of ActA-expressing bacteria.
  • Bead-based assays are described (see, e.g., Machner, et al. (2001) J. Biol. Chem. 276:40096-40103; Fradelizi, et al. (2001) Nature Cell Biol. 3:699-707; Theriot, et al. (1994) Cell 76:505-517; Smith, et al. (1995) MoI. Microbiol. 17:945-951; Cameron, et al. (1999) Proc. Natl. Acad. Sci. USA 96:4908-4913).
  • Ultracentrifugation can assess the number of cytoskeletal proteins bound to ActA (see, e.g., Machner, et al., supra).
  • Assays available to the skilled artisan include, e.g., the spontaneous actin polymerization assay; the elongation from the barbed end assay; and the elongation from the pointed end (see, e.g., Zalevsky, et al. (2001) J. Biol. Chem. 276:3468-3475). Methods are also available for assessing polarity of ActA-induced actin polymerization (see, e.g., Mogilner and Oster (2003) Biophys. J. 84: 1591-1605; Noireauz, et al. (2000) Biophys. J. 78: 1643-1654).
  • the present invention provides a family of SecA2 listeria! secretory proteins useful as fusion protein partners with a heterologous antigen.
  • the secretory protein-derived fusion protein partner finds use in increasing expression, increasing stability, increasing secretion, enhancing immune presentation, stimulating immune response, improving survival to a tumor, improving survival to a cancer, increasing survival to an infectious agent, and the like.
  • the contemplated listerial secretory proteins include p60 autolysin; N-acetyl-muramidase (NamA); penicillin-binding protein 2B (PBP-2B) (GenBank Ace. No.
  • p60 is encoded by an open reading frame of 1,452 bp, has an N-terminal signal sequence, an SH3 domain in the N-terminal region, a central region containig threonine-asparagine repeats, and a C-terminal region encompassing the autolysin catalytic site (see, e.g., Pilgrim, et al. (2003) Infect. Immun. 71 :3473-3484). p60 is also known as invasion-associated protein (iap) (GenBank Ace. No. X52268; NC_003210).
  • the present invention provides a polynucleotide comprising a first nucleic acid encoding p60, or a p60 derivative, and a second nucleic acid encoding a heterologous antigen.
  • the p60 or p60 derivatives encompass a full length p60 protein (e.g., from L. monocytogenes, L. innocua, L. ivanovii, L. seeligeri, L. welshimeri, L. murrayi, and/or L.
  • truncated p60 proteins consisting essentially of the N-terminal 70 amino acids; a truncated p60 protein deleted in the region that catalyses hydrolysis; signal sequences from a p60 protein; or a p60 protein with its signal sequence replaced with a different signal sequence (e.g., the signal sequence of ActA, LLO, PFO, or BaPA), and a second nucleic acid encoding a heterologous antigen.
  • the p60 signal sequence (27 amino acids) is: MNMKKATIAATAGIAVTAFAAPTIASA (SEQ ID NO:24) (Bubert, et al. (1992) J. Bacteriol. 174:8166-8171; Bubert, et al.
  • N-acetyl-muramidase signal sequence (52 amino acids) is: MDRKFIKPGIILL ⁇ VAFLVVSINVGAETGGSRTAQVNLTTSQQAFIDEILPA (SEQ ID NO:25) (nt 2679599 to 2681125 of GenBank Ace. No. NC_003210; GenBank Ace. No. AY542872; nt 2765101 to 2766627 of GenBank Ace. No. NC_003212; Lenz, et al. (2003) Proc. Natl. Acad. Sci. USA 100:12432-12437).
  • the present invention provides a p60 variant, for example, where the codons for amino acids 69 (L) and 70 (Q) are changed to provide a unique Pst I restriction site, where the Pst I site finds use in insertion a nucleic acid encoding a heterologous antigen.
  • Contemplated is nucleic acid encoding a fusion protein comprising a SecA2-pathway secreted protein and a heterologous antigen.
  • a nucleic acid encoding a fusion protein comprising a derivative or truncated version of a SecA2 -pathway secreted protein and a heterologous antigen.
  • a Listeria bacterium comprising a nucleic acid encoding a fusion protein comprising a SecA2-pathway secreted protein and a heterologous antigen, or comprising a nucleic acid encoding a fusion protein comprising a derivative or truncated version of a SecA2-pathway secreted protein and a heterologous antigen.
  • Human mesothelin cDNA is 2138 bp, contains an open reading frame of 1884 bp, and encodes a 69 kD protein.
  • the mesothelin precursor protein contains 628 amino acids, and a furin cleavage site (RPRFRR at amino acids 288-293). Cleavage of the 69 kd protein generates a 40 kD membrane-bound protein (termed “mesothelin”) plus a 31 kD soluble protein called megakaryocyte-potentiating factor (MPF).
  • Mesothelin has a lipophilic sequence at its C-terminus, which is removed and replaced by phosphatidyl inositol, which causes mesothelin to be membrane-bound.
  • Mesothelin contains a glycosylphosphatidyl inositol anchor signal sequence near the C-terminus.
  • Mesothelin's domains, expression of mesothelin by cancer and tumor cells, and antigenic properties of mesothelin are described (see, e.g., Hassan, et al. (2004) Clin. Cancer Res. 10:3937-3942; Ryu, et al. (2002) Cancer Res. 62:819-826; Thomas, et al. (2003) J. Exp. Med.
  • the present invention provides a polynucleotide comprising a first nucleic acid that mediates growth or spread in a wild type or parent Listeria, wherein the first nucleic acid is modified by integration of a second nucleic acid encoding at least one antigen.
  • the integration results in attenuation of the Listeria.
  • the integration does not result in attenuation of the Listeria.
  • the parent Listeria is attenuated, and the integration results in further attenuation.
  • the parent Listeria is attenuated, where the integration does not result in further measurable attenuation.
  • Embodiments further comprising modification by integrating in the first nucleic acid, a third nucleic acid encoding at least one antigen, a fourth nucleic acid encoding at least one antigen, a fifth nucleic acid encoding at least one antigen, or the like, are also provided.
  • the antigen can be a heterologous antigen (heterologous to the Listeria), a tumor antigen or an antigen derived from a tumor antigen, an infectious agent antigen or an antigen derived from an infectious agent antigen, and the like.
  • the first nucleic acid can be the actA gene or inlB gene.
  • Integration can be at a promoter or regulatory region of actA or inlB, and/or in the open reading frame of actA or inlB, where the integration attenuates the Listeria, as determinable under appropriate conditions. Integration can be accompanied by deletion of a part or all of the promoter or regulatory region of actA or inlB, or with deletion of part or all of the open reading frame of actA or inlB, or with deletion of both the promoter or regulatory region plus part or all of the open reading frame of actA or inlB, where the integration attenuates the Listeria, as determinable under appropriate conditions.
  • the present invention provides a Listeria bacterium containing the polynucleotide.
  • the polynucleotide can be genomic.
  • the first nucleic acid that is modified by integration of a second nucleic acid encoding at least one antigen mediates growth or spread in a wild type or parent Listeria.
  • the first nucleic acid that is modified mediates cell to cell spread.
  • the first nucleic acid is actA.
  • the first nucleic acid that is modified by integration of a second nucleic acid encoding at least one antigen comprises a gene identified as one of the following: hly gene (encodes listeriolysin O; LLO); internalin A; internalin B; actA; SvpA; pi 04 (a.k.a.
  • LAP LAP
  • IpIA phosphatidylinositol-specific phospholipase C
  • Pl-PLC phosphatidylinositol-specific phospholipase C
  • PC-PLC phosphatidylcholine-specific phospholipase C
  • MpI gene zinc metalloprotease precursor
  • p60 protein 60; invasion associated protein (iap); sortase; listeriolysin positive regulatory protein (PrfA gene); Prf ⁇ gene; FbpA gene; Auto gene; Ami (amidase that mediates adhesion); dlt operon (dltA; dltB; dltC; dltD); any prfA boxe; or Htp (sugar-P transporter).
  • a Listeria comprising the above polynucleotide.
  • the polynucleotide can be genomic.
  • the Listeria can be Listeria monocytogenes.
  • the integration results in attenuation of the Listeria, as determinable under appropriate conditions.
  • the integration does not result in attenuation of the Listeria, as determinable under appropriate conditions.
  • the parent Listeria is attenuated, and the integration results in further attenuation.
  • the parent Listeria is attenuated, where the integration does not result in further measurable attenuation.
  • first nucleic acid can be genomic.
  • the integration can be mediated by homologous recombination, where the integration does not result in any deletion of the first nucleic acid, where the integration results in deletion of all or part of the first nucleic acid, where the first nucleic acid contains a promoter or other regulatory region and where the second nucleic acid is operably linked and/or in frame with the promoter or other regulatory region, and where the first nucleic acid contains a promoter or other regulatory region and where the second nucleic acid is not at all operably linked and/or in frame with the promoter or other regulatory region.
  • gene modified by integration encompasses, but is not limited to, "a locus of integration that is the gene.”
  • a polynucleotide comprising a first nucleic acid that mediates growth or spread in a wild type or parent Listeria, where the first nucleic acid comprises all or part of a pathogenicity island or virulence gene cluster, wherein the all or part of the pathogenicity island or virulence gene cluster is modified by integration of a second nucleic acid encoding at least one antigen, wherein the integration results in attenuation of the Listeria, as determinable under appropriate conditions.
  • Pathogenicity islands and virulence gene clusters are disclosed (see, e.g., Chakraborty, et al. (2000) Int. J. Med. Microbiol.
  • the gene that mediates growth and spread is not limited to a gene that specifically mediates virulence, but encompasses growth-mediating genes such those that mediate energy production (e.g., glycolysis, Krebs cycle, cytochromes), anabolism and/or catabolism of amino acids, sugars, lipids, minerals, purines, and pyrimidines, and genes that mediate nutrient transport, transcription, translation, and/or replication, and the like.
  • a polynucleotide comprising a first nucleic acid that mediates growth or spread in a wild type or parent Listeria, wherein the nucleic acid is modified by integration of a plurality of nucleic acids encoding an antigen or antigens.
  • the integration can be within the second nucleic acid without any corresponding deletion of the second nucleic acid.
  • the integration can be within the second nucleic acid with a corresponding deletion of the second nucleic acid, or a portion thereof.
  • the first nucleic acid in the wild type or parent Listeria comprises a promoter and/or other regulatory site
  • the integration can be in the promoter and/or regulatory site.
  • the present invention provides an integrated second nucleic acid, where the second nucleic acid comprises a coding region that is operably linked and in-frame with the promoter and/or regulatory site.
  • the present invention provides an integrated second nucleic acid, where the second nucleic acid comprises a coding region that is not operably linked and in-frame with the promoter and/or regulatory site.
  • the integrated nucleic acid comprises a promoter and/or regulatory site
  • the promoter and/or regulatory site can take the place of, or alternatively can operate in addition to, a promoter and/or other regulatory site present in the first nucleic acid.
  • the first nucleic acid comprises (or in the alternative, consists of) a promoter or other regulatory element, and the second nucleic acid is operably linked with the promoter and/or other regulatory element.
  • the second nucleic encoding an antigen further comprises a promoter and/or other regulatory element.
  • the first nucleic acid need not encode any polypeptide, as the first nucleic acid can be a regulatory region or box. The following concerns integration as mediated by, for example, homologous integration.
  • the invention provides the above polynucleotide, wherein the second nucleic acid is integrated without deletion of any of the first nucleic acid.
  • the first nucleic acid mediates growth but not spread.
  • the first nucleic acid mediates spread but not growth. In yet another embodiment, the first nucleic acid mediates both growth and spread. In one aspect, the integration reduces or eliminates the growth, reduces or eliminates the spread, or reduces or eliminates both growth and spread.
  • the first nucleic acid has the property that its inactivation results in at least 10% reduction of growth, sometimes in at least 20% reduction of growth, typically in at least 30% reduction of growth, more typically in least 40% reduction of growth, most typically in at least 50% reduction in growth, often in at least 60% reduction in growth, more often in at least 70% reduction in growth, most often in at least 80% reduction in growth, conventionally at least 85% reduction in growth, more conventionally at least 90% reduction in growth, and most conventionally in at least 95% reduction in growth, and sometimes in at least 99% reduction in growth.
  • the growth can be measured in a defined medium, in a broth medium, in agar, within a host cell, in the cytoplasm of a host cell, and the like.
  • the first nucleic acid has the property that its inactivation results in at least 10% reduction of cell-to-cell spread, sometimes in at least 20% reduction of spread, typically in at least 30% reduction of spread, more typically in least 40% reduction of spread, most typically in at least 50% reduction in spread, often in at least 60% reduction in spread, more often in at least 70% reduction in spread, most often in at least 80% reduction in spread, conventionally at least 85% reduction in spread, more conventionally at least 90% reduction in spread, and most conventionally in at least 95% reduction in spread, and sometimes in at least 99% reduction in spread.
  • the growth can be measured in a defined medium, in a broth medium, in agar, within a host cell, in the cytoplasm of a host cell, and the like.
  • a Listeria bacterium comprising each of the above-disclosed polynucleotides.
  • the Listeria is Listeria monocytogenes.
  • the present invention contemplates each of the above polynucleotides that is genomic, plasmid based, or that is present in both genomic and plasmid based forms.
  • integration can be mediated by site-specific integration. Site-specific integration involves a plasmidic attPP' site, which recognizes a genomic attBB' site. In certain embodiments, the attBB' site can be naturally present in a gene that mediates growth or spread.
  • the attBB' site can be integrated, e.g., by homologous integration, in the gene that mediates growth or spread, followed by site-specific integration of the above-disclosed second nucleic acid.
  • the present invention provides a Listeria containing a polynucleotide comprising a first nucleic acid that, in the wild type Listeria or parent Listeria, mediates growth or spread, or both growth and spread, wherein the nucleic acid is modified by integration of a second nucleic acid encoding an antigen.
  • Yet one further example of each of the embodiments disclosed herein provides an integration that reduces or eliminates growth, reduces or eliminates spread, or reduces or eliminates both growth and spread.
  • a polynucleotide comprising a first nucleic acid that mediates growth or spread of a wild type or parental Listeria, and where the first nucleic acid comprises a signal sequence or secretory sequence, wherein the first nucleic acid is modified by integration of a second nucleic acid encoding at least one antigen, and wherein the integration results an in attenuation of the Listeria, and where the integration operably links the signal or secretory sequence (encoded by the first nucleic acid) with an open reading frame encoding by the second nucleic acid.
  • the above integration results in deletion of all of the polypeptide encoded by the first nucleic acid, except for the signal or secretory sequence encoded by the first nucleic acid (where the signal or secretory sequence remains intact).
  • Genomes comprising each of the polynucleotide embodiments described herein are further contemplated. Moreover, what is provided is a listeria! genome comprising each of the above embodiments. Furthermore, the invention supplies a Listeria bacterium comprising each of the polynucleotide embodiments described herein.
  • the invention provides Listeria (e.g., Listeria monocytogenes ' ) in which the genome comprises a polynucleotide comprising a nucleic acid encoding a heterologous antigen.
  • the nucleic acid encoding the heterologous antigen has been integrated into the genome by site-specific recombination or homologous recombination.
  • the presence of the nucleic acid in the genome attenuates the Listeria.
  • the nucleic acid encoding the heterologous antigen has been integrated into the locus of a virulence gene.
  • the nucleic acid encoding the heterologous antigen has been integrated into the actA locus. In some embodiments, the nucleic acid encoding the heterologous antigen has been integrated into the inlB locus. In some embodiments, the genome of the Listeria comprises a first nucleic acid encoding a heterologous antigen that has been integrated into a first locus (e.g., the actA locus) and a second nucleic acid encoding a second heterologous antigen that has been integrated into a second locus (e.g., the inlB locus). The first and second heterologous antigens may be identical to each other or different.
  • the first and second heterologous antigens differ from each other, but are derived from the same tumor antigen or infectious agent antigen. In some embodiments, the first and second heterologous antigens are each a different fragment of an antigen derived from a cancer cell, tumor, or infectious agent.
  • the integrated nucleic acid encodes a fusion protein comprising a modified ActA and the heterologous antigen. In some embodiments, at least two, at least three, at least four, at least five, at least six, or at least seven nucleic acid sequences encoding heterologous antigens have been integrated into the Listerial genome.
  • a polynucleotide (or nucleic acid) described herein has been integrated into a virulence gene in the genome of the Listeria, wherein the integration of the polynucleotide (a) disrupts expression of the virulence gene; and/or (b) disrupts a coding sequence of the virulence gene.
  • the Listeria is attenuated by the disruption of the expression of the virulence gene and/or the disruption of the coding sequence of the virulence gene attenuates the Listeria.
  • the virulence gene is necessary for mediating growth or spread. In other embodiments, the virulence gene is not necessary for mediating growth or spread.
  • the virulence gene is a prfA -dependent gene. In some embodiments, the virulence gene is not a prfA-dependent gene. In some embodiments, the virulence gene is actA or inlB. In some embodiments, the expression of the virulence gene in which the polynucleotide/nucleic acid is integrated is disrupted at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or about 100% (relative to the expression of the virulence gene in the absence of the integrated polynucleotide/nucleic acid, as determined by measuring expression levels.
  • Disruption of the coding sequence of the virulence gene encompasses alterations of the coding sequence of any kind including frame-shift mutations, truncations, insertions, deletions, or replacements/substitutions.
  • all or part of the virulence gene is deleted during integration of the polynucleotide into the virulence gene.
  • none of the virulence gene is deleted during integration of the polynucleotide.
  • part or all of the coding sequence of the virulence gene is replaced by the integrated polynucleotide.
  • multiple polynucleotides described herein have been integrated into the Listeria genome at one or more different sites.
  • the multiple polynucleotides may be the same or different.
  • a first polynucleotide described herein has been integrated into the actA locus and/or a second polynucleotide described herein has been integrated into the MB locus.
  • a first polynucleotide described herein has been integrated into the actA locus and a second polynucleotide described herein has been integrated into the inlB locus.
  • the heterologous antigen encoded by the first polynucleotide may be the same or different as that encoded by the second polynucleotide.
  • the two heterologous antigens encoded by the integrated antigens differ, but are derived from the same antigen.
  • the attenuated Listeria, vaccines, small molecules, biological reagents, and adjuvants that are provided herein can be administered to a host, either alone or in combination with a pharmaceutically acceptable excipient, in an amount sufficient to induce an appropriate immune response to an immune disorder, cancer, tumor, or infection.
  • the immune response can comprise, without limitation, specific immune response, non-specific immune response, both specific and non-specific response, innate response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, and cytokine expression.
  • “Pharmaceutically acceptable excipient” or “diagnosticaHy acceptable excipient” includes but is not limited to, sterile distilled water, saline, phosphate buffered solutions, amino acid-based buffers, or bicarbonate buffered solutions.
  • An excipient selected and the amount of excipient used will depend upon the mode of administration. Administration may be oral, intravenous, subcutaneous, dermal, intradermal, intramuscular, mucosal, parenteral, intraorgan, intralesional, intranasal, inhalation, intraocular, intramuscular, intravascular, intranodal, by scarification, rectal, intraperitoneal, or any one or combination of a variety of well-known routes of administration.
  • the administration can comprise an injection, infusion, or a combination thereof.
  • Administration of the Listeria of the present invention by a non-oral route can avoid tolerance (see, e.g., Lecuit, et al. (2001) Science 292:1722-1725; Kirk, et al. (2005) Transgenic Res. 14:449-462; Faria and Weiner (2005) Immunol. Rev. 206:232-259; Kraus, et al. (2005) J. Clin. Invest. 115:2234-2243; Mucida, et al. (2005) J. Clin. Invest. 115:1923-1933).
  • Methods are available for administration of Listeria, e.g., intravenously, subcutaneously, intramuscularly, intraperitoneal Iy, orally, mucosal, by way of the urinary tract, by way of a genital tract, by way of the gastrointestinal tract, or by inhalation (Dustoor, et al. (1977) Infection Immunity 15:916-924; Gregory and Wing (2002) J. Leukoc. Biol. 72:239-248; Hof, et al. (1997) Clin. Microbiol. Revs. 10:345-357; Schluter, et al. (1999) Immunobiol. 201 : 188-195; Hof (2004) Expert Opin. Pharmacother.
  • the invention provides immunogenic compositions comprising any of the Listeria described herein.
  • the invention further provides pharmaceutical compositions comprising any of the Listeria described herein and a pharmaceutically acceptable excipient.
  • the immunogenic compositions or pharmaceutical compositions are vaccines.
  • the composition comprising the Listeria is a vaccine that further comprises an adjuvant.
  • an administered reagent that is pure or purified for example where the administered reagent can be administered to a mammal in a pure or purified form, i.e., alone, as a pharmaceutically acceptable composition, or in an excipient.
  • the following also can apply, optionally, to each of the embodiments disclosed herein.
  • an administered reagent that is pure or purified where the administered reagent can be administered in a pure or purified form, i.e., alone, as a pharmaceutically acceptable composition, or in an excipient, and where the reagent is not generated after administration (not generated in the mammal).
  • each of the reagents disclosed herein is a polypeptide reagent that is administered as a pure or purified polypeptide (e.g., alone, as a pharmaceutically acceptable composition, or in an excipient), where the administered polypeptide reagent is not administered in the form of a nucleic acid encoding that polypeptide, and as a consequence, there is no administered nucleic acid that can generate the polypeptide inside the mammal.
  • the Listeria of the present invention can be stored, e.g., frozen, lyophilized, as a suspension, as a cell paste, or complexed with a solid matrix or gel matrix.
  • An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the route and dose of administration and the severity of side affects.
  • An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the route and dose of administration and the severity of side affects.
  • Guidance for methods of treatment and diagnosis is available (see, e.g., Maynard, et al. (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, FL; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).
  • the Listeria of the present invention can be administered in a dose, or dosages, where each dose comprises at least 1000 Listeria cells/kg body weight; normally at least 10,000 cells; more normally at least 100,000 cells; most normally at least 1 million cells; often at least 10 million cells; more often at least 100 million cells; typically at least 1 billion cells; usually at least 10 billion cells; conventionally at least 100 billion cells; and sometimes at least 1 trillion Listeria cells/kg body weight.
  • the present invention provides the above doses where the units of Listeria administration is colony forming units (CFU), the equivalent of CFU prior to psoralen-treatment, or where the units are number of Listeria cells.
  • CFU colony forming units
  • the Listeria of the present invention can be administered in a dose, or dosages, where each dose comprises between 10 and 10 Listeria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); 2 x 10 7 and 2 x 10 8 Listeria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); 5 x 10 7 and 5 x 10 8 Listeria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); 10 and 10 Listeria per 70 kg body weight (or per 1.7 square meters surface area; or per 1.5 kg liver weight); between 2.0 x 10 8 and 2.0 x 10 9 Listeria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 5.0 x 10 8 to 5.0 x 10 9 Listeria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 10 9 and 10 10 Listeria per 70 kg (or per 1.7 square meters surface area, or per 1.5 kg liver weight); between 2 x 10
  • the dose is administered by way of one injection every day, one injection every two days, one injection every three days, one injection every four days, one injection every five days, one injection every six days, or one injection every seven days, where the injection schedule is maintained for, e.g., one day only, two days, three days, four days, five days, six days, seven days, two weeks, three weeks, four weeks, five weeks, or longer.
  • the invention also embraces combinations of the above doses and schedules, e.g., a relatively large initial dose of Listeria, followed by relatively small subsequent doses of Listeria, or a relatively small initial dose followed by a large dose.
  • a dosing schedule of, for example, once/week, twice/week, three times/week, four times/week, five times/week, six times/week, seven times/week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, and the like, is available for the invention.
  • the dosing schedules encompass dosing for a total period of time of, for example, one week, two weeks, three weeks, four weeks, five weeks, six weeks, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, and twelve months.
  • cycles of the above dosing schedules can be repeated about, e.g., every seven days; every 14 days; every 21 days; every 28 days; every 35 days; 42 days; every 49 days; every 56 days; every 63 days; every 70 days; and the like.
  • An interval of non-dosing can occur between a cycle, where the interval can be about, e.g., seven days; 14 days; 21 days; 28 days; 35 days; 42 days; 49 days; 56 days; 63 days; 70 days; and the like.
  • the term "about” means plus or minus one day, plus or minus two days, plus or minus three days, plus or minus four days, plus or minus five days, plus or minus six days, or plus or minus seven days.
  • the present invention encompasses a method of administering Listeria that is oral. Also provided is a method of administering Listeria that is intravenous. Moreover, what is provided is a method of administering Listeria that is intramuscular.
  • the invention supplies a Listeria bacterium, or culture or suspension of Listeria bacteria, prepared by growing in a medium that is meat based, or that contains polypeptides derived from a meat or animal product.
  • Also supplied by the present invention is a Listeria bacterium, or culture or suspension of Listeria bacteria, prepared by growing in a medium that does not contain meat or animal products, prepared by growing on a medium that contains vegetable polypeptides, prepared by growing on a medium that is not based on yeast products, or prepared by growing on a medium that contains yeast polypeptides.
  • the present invention encompasses a method of administering Listeria that is not oral. Also provided is a method of administering Listeria that is not intravenous. Moreover, what is provided is a method of administering Listeria that is not intramuscular.
  • the invention supplies a Listeria bacterium, or culture or suspension of Listeria bacteria, prepared by growing in a medium that is not meat based, or that does not contain polypeptides derived from a meat or animal product. Also supplied by the present invention is a Listeria bacterium, or culture or suspension of Listeria bacteria, prepared by growing in a medium based on vegetable products, that contains vegetable polypeptides, that is based on yeast products, or that contains yeast polypeptides.
  • an additional therapeutic agent e.g., a small molecule, antibiotic, innate immunity modulating agent, tolerance modulating agent, cytokine, chemotherapeutic agent, or radiation
  • an additional therapeutic agent e.g., a small molecule, antibiotic, innate immunity modulating agent, tolerance modulating agent, cytokine, chemotherapeutic agent, or radiation
  • the present invention provides reagents for administering in conjunction with an attenuated Listeria.
  • These reagents include biological reagents such as: (1) Cytokines, antibodies, dendritic cells, attenuated tumor cells cells; (2) Small molecule reagents such as 5-fluorouracil, methotrexate, paclitaxel, docetaxel, cis-platin, gemcitabine; (3) Reagents that modulate regulatory T cells, such as cyclophosphamide, anti-CTLA4 antibody, anti-CD25 antibody (see, e.g., Hawryfar, et al. (2005) J. Immunol.
  • the reagents can be administered with the Listeria or independently (before or after) the Listeria.
  • the reagent can be administered immediately before (or after) the Listeria, on the same day as, one day before (or after), one week before (or after), one month before (or after), or two months before (or after) the Listeria, and the like.
  • Bioreagents or macromolecules of the present invention encompass an agonist or antagonist of a cytokine, a nucleic acid encoding an agonist or antagonist of a cytokine, a cell expressing a cytokine, or an agonistic or antagonistic antibody.
  • Biological reagents include, without limitation, a TH-I cytokine, a TH-2 cytokine, IL-2, IL- 12, FLT3-ligand, GM-CSF, IFNgamma, a cytokine receptor, a soluble cytokine receptor, a chemokine, tumor necrosis factor (TNF), CD40 ligand, or a reagent that stimulates replacement of a proteasome subunit with an immunoproteasome subunit.
  • TNF tumor necrosis factor
  • the present invention encompasses biological reagents, such cells engineered to express at least one of the following: GM-CSF, IL-2, IL-3, TL-4, TL-12, IL-18, tumor necrosis factor-alpha (TNF-alpha), or inducing protein- 10.
  • biological reagents include agonists of B7-1, B7-2, CD28, CD40 ligand, or OX40 ligand (OX40L), and novel forms engineered to be soluble or engineered to be membrane-bound (see, e.g., Karnbach, et al. (2001) J. Immunol. 167:2569-2576; Greenfield, et al. (1998) Crit. Rev. Immunol.
  • the present invention provides the following biological s.
  • MCP-I, MIPl -alpha, TNF-alpha, and interleukin-2 are effective in treating a variety of tumors (see, e.g., Nakamoto, et al. (2000) Anticancer Res. 20(6A):4087- 4096; Kamada, et al. (2000) Cancer Res. 60:6416-6420; Li, et al. (2002) Cancer Res. 62:4023-4028; Yang, et al. (2002) Zhonghua Wai Ke Za Zhi 40:789-791 ; Hoving, et al.
  • the present invention provides reagents and methods encompassing an FH3-ligand agonist, and an Flt3-ligand agonist in combination with Listeria.
  • Flt3-Iigand Fms-like thyrosine kinase 3 ligand
  • a cytokine that can generate an antitumor immune response (see, e.g., Dranoff (2002) Immunol. Revs. 188:147-154; Mach, el al. (2000) Cancer Res. 60:3239- 3246; Furumoto, et al. (2004) J. Clin. Invest. 1 13:774-783; Freedman, et al. (2003) Clin. Cancer Res. 9:5228-5237; Mach, et al.
  • the present invention contemplates administration of a dendritic cell (DC) that expresses at least one tumor antigen, or infectious disease antigen.
  • DC dendritic cell
  • Expression by the DC of an antigen can be mediated by way of, e.g., peptide loading, tumor cell extracts, fusion with tumor cells, transduction with mRNA, or transfected by a vector (see, e.g., Klein, et al. (2000) J. Exp. Med. 191:1699-1708; Conrad and Nestle (2003) Curr. Opin. MoI. Ther. 5:405-412; Gilboa and Vieweg (2004) Immunol. Rev. 199:251-263; Paczesny, et al. (2003) Semin. Cancer Biol. 13:439-447; Westermann, et al. (1998) Gene Ther. 5:264-271).
  • the methods and reagents of the present invention also encompass small molecule reagents, such as 5-fluorouracil, methotrexate, irinotecan, doxorubicin, prednisone, dolostatin-10 (DlO), combretastatin A-4, mitomycin C (MMC), vincristine, colchicines, vinblastine, cyclophosphamide, fungal beta-glucans and derivatives therof, and the like (see, e.g., Hurwitz, et al. (2004) New Engl. J. Med. 350:2335-2342; Pelaez, et al. (2001) J. Immunol.
  • small reagents such as 5-fluorouracil, methotrexate, irinotecan, doxorubicin, prednisone, dolostatin-10 (DlO), combretastatin A-4, mitomycin C (MMC), vincristine, colchicines
  • compositions that are not molecules, e.g., salts and ions.
  • CpG oligonucleotides that stimulate innate immune response
  • imiquimod e.g., imiquimod
  • alphaGalCer e.g., alphaGalCer
  • CpG oligonucleotides mediate immune response via TLR9 (see, e.g., Chagnon, et al. (2005) Clin. Cancer Res. 11 : 1302-131 1 ; Whyr, et al. (2005) J. Clin. Invest. Feb.3 (epub ahead of print); Mason, et al. (2005) CHn. Cancer Res. 1 1 :361-369; Suzuki, et al. (2004) Cancer Res. 64:8754-8760; Taniguchi, et al. (2003) Annu.
  • the invention includes reagents and methods for modulating activity of T regulatory cells (Tregs; suppressor T cells). Attenuation or inhibition of Treg cell activity can enhance the immune system's killing of tumor cells.
  • T regulatory cells T regulatory cells
  • a number of reagents have been identified that inhibit Treg cell activity. These reagents include, e.g., cyclophosphamide (a.k.a. Cytoxan®; CTX), anti-CD25 antitobody, modulators of GITR-L or GITR, a modulator of Forkhead-box transcription factor (Fox), a modulator of LAG-3, anti-IL-2R, and anti-CTLA4 (see, e.g., Pardoll (2003) Annu. Rev. Immunol.
  • CTX shows a bimodal effect on the immune system, where low doses of CTX inhibit Tregs (see, e.g., Lutsiak, et al. (2005) Blood 105:2862-2868).
  • CTLA4-blocking agents such as anti-CTLA4 blocking antibodies
  • can enhance immune response to cancers, tumors, pre-cancerous disorders, infections, and the like see, e.g., Zubairi, et al. (2004) Eur. J. Immunol. 34:1433-1440; Espen Kunststoff, et al. (2003) J. Immunol. 170:3401-3407; Davila, et al. (2003) Cancer Res. 63:3281-3288; Hodi, et al.
  • Lymphocyte activation gene-3 (LAG-3) blocking agents such as anti-LAG-3 antibodies or soluble LAG-3 (e.g., LAG-3 Ig), can enhance immune response to cancers or infections.
  • Anti-LAG-3 antibodies reduce the activity of Tregs (see, e.g., Huang, et al.
  • Vaccines comprising a tumor antigen, a nucleic acid encoding a tumor antigen, a vector comprising a nucleic acid encoding a tumor antigen, a cell comprising a tumor antigen, a tumor cell, or an attenuated tumor cell, are encompassed by the invention.
  • reagents derived from a nucleic acid encoding a tumor antigen e.g., a codon optimized nucleic acid, or a nucleic acid encoding two or more different tumor antigens, or a nucleic acid expressing rearranged epitopes of a tumor antigen, e.g., where the natural order of epitopes is ABCD and the engineered order is ADBC, or a nucleic acid encoding a fusion protein comprising at least two different tumor antigens.
  • an appropriate dose can be one where the therapeutic effect outweighs the toxic effect.
  • an optimal dosage of the present invention is one that maximizes therapeutic effect, while limiting any toxic effect to a level that does not threaten the life of the patient or reduce the efficacy of the therapeutic agent.
  • Signs of toxic effect, or anti-therapeutic effect include, without limitation, e.g., anti-idiotypic response, immune response to a therapeutic antibody, allergic reaction, hematologic and platelet toxicity, elevations of aminotransferases, alkaline phosphatase, creatine kinase, neurotoxicity, nausea, and vomiting (see, e.g., Huang, et al. (1990) Clin. Chem. 36:431-434).
  • An effective amount of a therapeutic agent is one that will decrease or ameliorate the symptoms normally by at least 10%, more normally by at least 20%, most normally by at least 30%, typically by at least 40%, more typically by at least 50%, most typically by at least 60%, often by at least 70%, more often by at least 80%, and most often by at least 90%, conventionally by at least 95%, more conventionally by at least 99%, and most conventionally by at least 99.9%.
  • the reagents and methods of the present invention provide a vaccine comprising only one vaccination; or comprising a first vaccination; or comprising at least one booster vaccination; at least two booster vaccinations; or at least three booster vaccinations.
  • Guidance in parameters for booster vaccinations is available (see, e.g., Marth (1997) Biologicals 25:199-203; Ramsay, et al. (1997) Immunol. Cell Biol. 75:382-388; Gherardi, et al. (2001) Histol. Histopathol. 16:655-667; Leroux-Roels, et al. (2001) ActA Clin. BeIg. 56:209-219; Greiner, et al. (2002) Cancer Res.
  • a first reagent that comprises a Listeria bacterium (or Listeria vaccine), and a second reagent that comprises, e.g., a cytokine, a small molecule such as cyclophosphamide or methotrexate, or a vaccine, such as an attenuated tumor cell or attenuated tumor cell expressing a cytokine.
  • a second reagent that comprises, e.g., a cytokine, a small molecule such as cyclophosphamide or methotrexate, or a vaccine, such as an attenuated tumor cell or attenuated tumor cell expressing a cytokine.
  • the Listeria and the second reagent can be administered concomitantly, that is, where the administering for each of these reagents can occur at time intervals that partially or fully overlap each other.
  • the Listeria and second reagent can be administered during time intervals that do not overlap each other.
  • Formulations of therapeutic and diagnostic agents may be prepared for storage by mixing with physiologically acceptable carriers, excipients, or stabilizers in the form of, e.g., Iyophilized powders, slurries, aqueous solutions or suspensions (see, e.g., Hardman, et al.
  • the invention also provides a kit comprising a Listeria cell, a listerial cell culture, or a Iyophilized cell preparation, and a compartment.
  • the present invention provides a kit comprising a Listeria cell, listerial cell culture, or a Iyophilized cell preparation and a reagent.
  • a kit comprising a Listeria cell, a listerial cell culture, or a Iyophilized cell preparation and instructions for use or disposal.
  • kits comprising a Listeria cell, a listerial cell culture, or Iyophilized cell preparation, and compartment and a reagent.
  • a kit comprising Listeria bacteria, and instructions for using the Listeria bacteria with a small molecule anti-cancer agent, and/or small molecule immunomodulating agent (e.g., cyclophosphamide), and/or a small molecule anti-infection agent, and the like.
  • a kit comprising Listeria bacteria, and/or instructions for administering the Listeria, and/or instructions for monitoring immune response to the administered Listeria, and/or instructions for monitoring immune response to a heterologous antigen encoded by the administered Listeria.
  • the invention provides, in certain embodiments, a modified Listeria bacterium, e.g., L. monocytogenes, engineered to express at least one heterologous antigen.
  • the invention is useful for enhancing immune response, stimulating immune response, enhancing immune presentation, increasing stability of an expressed mRNA or polypeptide, increasing proteolytic processing of an expressed polypeptide, increasing immune response to a mutated self antigen, increasing survival to a cancer or infection, and/or for treating a cancer or infection.
  • the invention is also useful for enhanced expression of a heterologous antigen, e.g., for industry, agriculture, or medicine.
  • an increase can occur with administration of a. Listeria containing a nucleic acid encoding a heterologous antigen.
  • the increase can be relative to response with administration of & Listeria not containing a nucleic acid encoding that particular heterologous antigen.
  • the increase can be relative to response with administering a Listeria not containing any nucleic acid that encodes a heterologous antigen, e.g., a parental or wild type Listeria.
  • the increase can be relative to response without administering any Listeria.
  • an increase can occur with administration of a Listeria (containing or not containing a nucleic acid encoding a heterologous antigen) with an immune modulator, such as an agonist antibody, a cytokine, or an antibody that specifically binds to an antigen of the cancer, tumor, or infectious agent.
  • an immune modulator such as an agonist antibody, a cytokine, or an antibody that specifically binds to an antigen of the cancer, tumor, or infectious agent.
  • the increase can be relative to response with administration of a Listeria but without administering the immune modulator.
  • the increase can be relative to any response with administering the immune modulator, but without administering any Listeria.
  • the increase can be relative to response without administering any Listeria and without administering the immune modulator.
  • the invention provides methods of stimulating an immune response to an antigen in a mammal, comprising administering an effective amount of a Listeria bacterium described herein, or an effective amount of a composition comprising the Listeria, to the mammal.
  • the invention provides methods of stimulating an immune response to an antigen from, or derived from, a cancer or infectious agent, comprising administering an effective amount of a Listeria bacterium described herein, or an effective amount of a composition comprising the Listeria, to the mammal.
  • the heterologous antigen expressed by the Listeria shares at least one epitope with, or is immunologically cross-reactive with, the antigen from, or derived from, the cancer or infectious agent.
  • the immune response is a CD8+ T-cell immune response.
  • the immune response is a CD4+ T-cell immune response.
  • An inactivating mutation in at least one DNA repair gene e.g., ⁇ uvrAB
  • a nucleic acid cross-linking agent e.g., psoralen
  • concentrations of a nucleic acid cross-linking agent e.g., psoralen
  • concentrations of a nucleic acid cross-linking agent e.g., psoralen
  • concentrations of a nucleic acid cross-linking agent e.g., psoralen
  • concentrations e.g., psoralen
  • UVA light and/or of treatment with a nucleic acid cross- linking agent that is highly specific for making interstrand genomic cross links, is that the bacterial cells are killed but remain metabolically active.
  • the present invention results in the reduction of the number of abnormally proliferating cells, reduction in the number of cancer cells, reduction in the number of tumor cells, reduction in the tumor volume, reduction of the number of infectious organisms or pathogens per unit of biological fluid or tissue (e.g., serum), reduction in viral titer (e.g., serum), where it is normally reduced by at least 5%, more normally reduced by at least 10%, most normally reduced by at least 15%, typically reduced by at least 20%, more typically reduced by at least 25%, most typically reduced by at least 30%, usually reduced by at least 40%, more usually reduced by at least 50%, most usually reduced by at least 60%, conventionally reduced by at least 70%, more conventionally reduced by at least 80%, most conventionally reduced by at least 90%, and still most conventionally reduced by at least 99%.
  • biological fluid or tissue e.g., serum
  • viral titer e.g., serum
  • the unit of reduction can be, without limitation, number of tumor cells/mammalian subject; number of tumor cells/liver; number of tumor cells/spleen; mass of tumor cells/mammalian subject; mass of tumor cells/liver; mass of tumor cells/spleen; number of viral particles or viruses or titer per gram of liver; number of viral particles or viruses or titer per cell; number of viral particles or viruses or titer per ml of blood; and the like.
  • the growth medium used to prepare a Listeria can be characterized by chemical analysis, high pressure liquid chromatography (HPLC), mass spectroscopy, gas chromatography, spectroscopic methods, and the like.
  • the growth medium can also be characterized by way of antibodies specific for components of that medium, where the component occurs as a contaminant with the Listeria, e.g., a contaminant in the listerial powder, frozen preparation, or cell paste.
  • Antibodies, specific for peptide or protein antigens, or glycol ipid, glycopeptide, or lipopeptide antigens can be used in ELISA assays formulated for detecting animal-origin contaminants.
  • Antibodies for use in detecting antigens, or antigenic fragments, of animal origin are available (see, e.g., Fukuta, et al. (1977) Jpn. Heart J. 18:696-704; DeVay and Adler (1976) Ann. Rev. Microbiol.
  • the invention supplies kits and diagnostic methods that facilitate testing the Listeria's influence on the immune system. Testing can involve comparing one strain of Listeria with another strain of Listeria, or a parent Listeria strain with a mutated Listeria strain.
  • Methods of testing comprise, e.g., phagocytosis, spreading, antigen presentation, T cell stimulation, cytokine response, host toxicity, LD 5O , and efficacy in ameliorating a pathological condition.
  • the present invention provides methods to increase survival of a subject, host, patient, test subject, experimental subject, veterinary subject, and the like, to a cancer, a tumor, a precancerous disorder, an immune disorder, and/or an infectious agent.
  • the infectious agent can be a virus, bacterium, or parasite, or any combination thereof.
  • the method comprises administering an attenuated Listeria, for example, as a suspension, bolus, gel, matrix, injection, or infusion, and the like.
  • the administered Listeria increases survival, as compared to an appropriate control (e.g., nothing administered or an administered placebo, and the like) by usually at least one day; more usually at least four days; most usually at least eight days, normally at least 12 days; more normally at least 16 days; most normally at least 20 days, often at least 24 days; more often at least 28 days; most often at least 32 days, conventionally at least 40 days, more conventionally at least 48 days; most conventionally at least 56 days; typically by at least 64 days; more typically by at least 72 days; most typically at least 80 days; generally at least six months; more generally at least eight months; most generally at least ten months; commonly at least 12 months; more commonly at least 16 months; and most commonly at least 20 months, or more.
  • an appropriate control e.g., nothing administered or an administered placebo, and the like
  • the subject/host/patient to which the Listeria is administered is a mammal.
  • the mammal is a primate.
  • the primate is a human.
  • Each of the above disclosed methods contemplates admininstering a composition comprising a Listeria and an excipient, a Listeria and a carrier, a Listeria and buffer, a Listeria and a reagent, a Listeria and a pharmaceutically acceptable carrier, a Listeria and an agriculturally acceptable carrier, a Listeria and a veterinarily acceptable carrier, a Listeria and a stabilizer, a Listeria and a preservative, and the like.
  • the present invention provides reagents and methods for treating conditions that are both cancerous (neoplasms, malignancies, cancers, tumors, and/or precancerous disorders, dysplasias, and the like) and infectious (infections).
  • infections with certain viruses such as papillomavirus and polyoma virus, the result can be a cancerous condition, and here the condition is both cancerous and infectious.
  • a condition that is both cancerous and infectious can be detected, as a non-limiting example, where a viral infection results in a cancerous cell, and where the cancerous cell expresses a viral-encoded antigen.
  • a condition that is both cancerous and infectious is one where immune response against a tumor cell involves specific recognition against a viral-encoded antigen (See, e.g., Montesano, et al. (1990) Cell 62:435-445; Ichaso and Dilworth (2001) Oncogene 20:7908-7916; Wilson, et al. (1999) J. Immunol. 162:3933-3941; Daemen, et al. (2004) Antivir. Ther.
  • the Listeria described herein that express a heterologous antigen are used to induce immune responses against cells in a subject that express the antigen.
  • the Listeria, vaccines, and other compositions described herein are used to treat cancerous disorders, precancerous disorders, tumors, infections, and/or angiogenesis of tumors and cancers.
  • the Listeria, vaccines, and other compositions described herein are used to treat cancer in a subject.
  • the Listeria (or compositions comprising the Listeria) described herein that express EphA2 antigenic peptides (or fusion proteins comprising EphA2 antigenic peptides) are used to treat hyperproliferative disorders of
  • EphA2-expressing cells EphA2-expressing cells.
  • the present invention in certain embodiments, comprises a method of stimulating the immune system against an infectious disorder, where the infectious disorder is a Listeria infection. Also comprised, is a method of stimulating the immune system against an infectious disorder, where the infectious disorder is not a Listeria infection, that is, excludes
  • Each of the embodiments encompasses, as an alternate or additional reagent, a
  • each of the embodiments encompasses, as an alternate or additional reagent, a Listeria that is attenuated.
  • Each of the embodiments encompasses, as an alternate or additional method, using a Listeria that is not attenuated.
  • each of the embodiments encompasses, as an alternate or additional method, using a Listeria that is attenuated.
  • Each of the embodiments disclosed herein encompasses methods and reagents using a Listeria that comprises a nucleic acid encoding at least one tumor antigen, a Listeria that comprises a nucleic acid encoding at least one cancer antigen, a Listeria that comprises a nucleic acid encoding at least one heterologous antigen, as well as a Listeria that expresses at least one tumor antigen, cancer antigen, and/or heterologous antigen.
  • Each of the embodiments disclosed herein encompasses methods and reagents using a Listeria that does not comprise a nucleic acid encoding a tumor antigen, a Listeria that does not comprise a nucleic acid encoding a cancer antigen, a Listeria that does not comprise a nucleic acid encoding a heterologous antigen, as well as a Listeria that does not express a tumor antigen, cancer antigen, and/or a heterologous antigen.
  • Each of the embodiments disclosed herein encompasses methods and reagents using a Listeria that comprises a nucleic acid encoding an antigen from a non-listerial infectious organism.
  • Each of the above-disclosed embodiments encompasses methods and reagents using a Listeria that comprises a nucleic acid encoding at least one antigen from a virus, parasite, bacterium, tumor, self-antigen derived from a tumor, or non-self antigen derived from a tumor.
  • Each of the embodiments disclosed herein encompasses methods and reagents using a Listeria that does not comprise a nucleic acid encoding an antigen from a non-listerial infectious organism.
  • Each of the above-disclosed embodiments encompasses methods and reagents using a Listeria that does not comprise a nucleic acid encoding at least one antigen from a virus, parasite, bacterium, tumor, self-antigen derived from a tumor, or non-self antigen derived from a tumor.
  • Each of the embodiments disclosed herein also encompasses a Listeria that is not prepared by growing on a medium based on animal protein, but is prepared by growing on a different type of medium.
  • Each of the above-disclosed embodiments also encompasses a Listeria that is not prepared by growing on a medium containing peptides derived from animal protein, but is prepared by growing on a different type of medium.
  • each of the above-disclosed embodiments encompasses administration of a Listeria by a route that is not oral or that is not enteral.
  • each of the above-disclosed embodiments includes administration of a Listeria by a route that does not require movement from the gut lumen to the lymphatics or bloodstream.
  • Each of the embodiments disclosed herein further comprises a method wherein the Listeria are not injected directly into the tumor or are not directly injected into a site that is affected by the cancer, precancerous disorder, tumor, or infection.
  • each of the embodiments disclosed herein encompasses administering the Listeria by direct injection into a tumor, by direct injection into a cancerous lesion, and/or by direct injection into a lesion of infection.
  • the invention includes each of the above embodiments, where administration is not by direct injection into a tumor, not by direct injection into a cancerous lesion, and/or not by direct injection into a lesion of infection.
  • a vaccine where the heterologous antigen, as in any of the embodiments disclosed herein, is a tumor antigen or is derived from a tumor antigen.
  • heterologous antigen as in any of the embodiments disclosed herein, is a cancer antigen, or is derived from a cancer antigen.
  • a further embodiment provides a nucleic acid where the heterologous antigen, as in any of the embodiments disclosed herein, is a tumor antigen or derived from a tumor antigen. Also provided is a nucleic acid where the heterologous antigen, as in any of the embodiments disclosed herein, is a cancer antigen, or is derived from a cancer antigen. Moreover, what is provided is a nucleic acid, where the heterologous antigen, as in any of the embodiments disclosed herein, is an antigen of an infectious organism, or is derived from an antigen of an infectious organism, e.g., a virus, bacterium, or multi-cellular organism.
  • Each of the above-disclosed embodiments also encompasses an attenuated Listeria that is not prepared by growing on a medium based on animal or meat protein, but is prepared by growing on a different type of medium.
  • an attenuated Listeria not prepared by growing on a medium based on meat or animal protein, but is prepared by growing on a medium based on yeast and/or vegetable derived protein.
  • each of the embodiments disclosed herein encompasses a bacterium that does not contain a nucleic acid encoding a heterologous antigen. Also, unless specified otherwise, each of the embodiments disclosed herein encompasses a bacterium that does not contain a nucleic acid encoding a heterologous regulatory sequences. Optionally, every one of the embodiments disclosed herein encompasses a bacterium that contains a nucleic acid encoding a heterologous antigen and/or encoding a heterologous regulatory sequence.
  • bacterial embodiments e.g., of Listeria, Bacillus anthracis, or another bacterium, that encode secreted antigens, non-secreted antigens, secreted antigens that are releasable from the bacterium by a mechanism other than secretion, and non-secreted antigens that are releasable by a mechanism other than secretion.
  • a bacterium containing a polynucleotide comprising a nucleic acid, where the nucleic acid encodes a polypeptide that contains a secretory sequence and is secreted under appropriate conditions; where the nucleic acid encodes a polypeptide that does not contain a secretory sequence; where the nucleic acid does contain a secretory sequence and where the polypeptide is releasable by some other mechanism such as enzymatic damage or perforation to the cell membrane or cell wall; and where the nucleic acid encodes a polypeptide that does not contain any secretory sequence but where the polypeptide is releasable by some other mechanism, such as enzymatic damage or perforation to the cell membrane and/or cell wall.
  • Extracellular growth 0.1%; 0.5%; 1.0%; 5%; 10%; 15%; 20%; 25%; 30%; as compared of the Listeria strain 35%; 40%; 45%; 50%; 55%; 60%; 65%; 70%; 75%; with of the present 80%; 85%; 90%; 95%; 99%; 99.5%; or greater than intracellular invention is at least 99.5%, 100%, 2-fold greater; 5-fold greater; or growth of the 10-fold greater, same Listeria strain.
  • Extracellular growth 0-0.1%; 0.1-0.5%; 0.5-1.0%; 1.0-5%; 5-10%; as compared of the Listeria strain 10-15%; 15-20%; 20-25%; 25-30%; 30-35%; with of the present 35-40%; 40-45%; 45-50%; 50-55%; 55-60%; intracellular invention is 60-65%; 65-70%; 70-75%; 75-80%; 80-85%; growth of the 85-90%; 90-95%; 95-99%; 99-99.5%; 99.5-100%, same Listeria 100-200%; 200-500%; 500-1000%; or greater than strain. 1000%,
  • a growth related gene of the present invention can include, but is not necessarily limited in narrowness or in breadth, by the following.
  • a growth related the same amunt by at least 10% greater; by at least than the rate the gene embraces one 20% greater; by at least 30% greater; by at least 40% gene stimulates that stimulates the greater; by at least 50% greater; by at least 60% extracellular rate of intracellular greater; by at least 70% greater; by at least 80% growth. growth by greater; by at least 90% greater; by at least 100% (2-fold) greater; by at least 3-fold greater; by at least 4-fold greater; by at least 10-fold greater; by at least 20-fold greater; by at least 40-fold greater,
  • Growth of a Listeria strain of the present invention can be compared with a parent, or suitable control, Listeria strain, where only intracellular growth is compared.
  • Growth of a Listeria strain of the present invention can be compared with a parent, or suitable control, Listeria strain, where only extracellular growth is compared.
  • Growth of a Listeria strain of the present invention can be compared with a parent, or suitable control, Listeria strain, where intracellular growth of the present invention strain is compared with extracellular growth of a parent or suitable control strain.
  • Growth of a Listeria strain of the present invention can be compared with a parent, or suitable control, Listeria strain, where extracellular growth of the present invention strain is compared with intracellular growth of a parent or suitable control strain.
  • a "killed but metabolically active" (KMBA) bacterium is a Listeria bacterium that is unable to form colonies and where metabolism is, e.g., 10-fold to 5-fold (an indicator of metabolism occurring at a level higher than normally found); 5-fold to 4-fold; 4-fold to 2-fold; 2-fold to 100%; essentially 100%; 100% to 95%; 95% to 90%; 90% to 80%; 80% to 70%; 70% to 60%; 60% to 50%; 50% to 40%; 40% to 30; 30 to 20%; 20 to 10%; or 10 to 5%, that of a control or parent Listeria bacterium.
  • 10-fold to 5-fold an indicator of metabolism occurring at a level higher than normally found
  • 5-fold to 4-fold 4-fold to 2-fold
  • 2-fold to 100% essentially 100%; 100% to 95%; 95% to 90%; 90% to 80%; 80% to 70%; 70% to 60%; 60% to 50%; 50% to 40%; 40% to 30; 30 to 20%; 20 to 10%; or 10 to 5%, that of a control or parent Listeria bacterium.
  • a KBMA bacterium is a Listeria bacterium where the rate of colony formation is under 1% that of a control or parent Listeria bacterium, and where metabolism is, e.g., 10-fold to 5-fold; 5-fold to 4-fold; 4-fold to 2-fold; 2-fold to 100%; essentially 100%; 100% to 95%; 95% to 90%; 90% to 80%; 80% to 70%; 70% to 60%; 60% to 50%; 50% to 40%; 40% to 30; 30 to 20%; 20 to 10%; or 10 to 5%, that of the control or parent Listeria bacterium.
  • a KBMA bacterium is a Listeria bacterium where the rate of colony formation is under 2% that of a control or parent Listeria bacterium, and where metabolism is, e.g., 10-fold to 5-fold; 5-fold to 4-fold; 4-fold to 2-fold; 2-fold to 100%; essentially 100%; 100% to 95%; 95% to 90%; 90% to 80%; 80% to 70%; 70% to 60%; 60% to 50%; 50% to 40%; 40% to 30; 30 to 20%; 20 to 10%; or 10 to 5%, that of the control or parent Listeria bacterium.
  • a KBMA bacterium is a Listeria bacterium where the rate of colony formation is under 5% that of a control or parent Listeria bacterium, and where metabolism is, e.g., 10-fold to 5-fold; 5-fold to 4-fold; 4-fold to 2-fold; 2-fold to 100%; essentially 100%; 100% to 95%; 95% to 90%; 90% to 80%; 80% to 70%; 70% to 60%; 60% to 50%; 50% to 40%; 40% to 30; 30 to 20%; 20 to 10%; or 10 to 5%, that of the control or parent Listeria bacterium.
  • the rate of metabolism can be measured by various indicia, e.g., translation, respiration, secretion, transport, fermentation, glycolysis, amino acid metabolism, or the Krebs cycle.
  • various indicia of metabolism for L. monocytogenes are disclosed (see, e.g., Karlin, et al. (2004) Proc. Natl. Acad. Sci. USA 101:6182-6187; Gilbreth, et al. (2004) Curr. Microbiol. 49:95-98).
  • metabolism is assessed with intact bacteria by way of radioactive, heavy isotope, or fluorescent tagged metabolites.
  • the skilled artisan can choose a suitable gene for measuring translation, or a suitable enzyme for measuring glycolysis, amino acid metabolism, or the Krebs cycle.
  • a heat-killed bacterium generally is essentially or totally metabolically inactive. Residual apparent metabolic activity of an essentially or totally metabolically inactive bacterium can be due, e.g., to oxidation of lipids, oxidation of sulfhydryls, reactions catalyzed by heavy metals, or to enzymes that are stable to heat- treatment.
  • Reagents and methods useful for determining, assessing, monitoring, and/or diagnosing immune response are available.
  • the present invention provides the following methods for diagnosing a mammalian subject administered with the compositions of the present invention.
  • what is provided are the following methods for assessing immune response to one or more of the administered compositions of the present invention.
  • These methods which can be applied, e.g., in vivo, in vitro, ex vivo, in utero; to living or deceased mammals; to cells; to recombinant, chimeric, or hybrid cells; to biological fluids, to isolated nucleic acids, and the like, include: i. Methods for measuring cellular parameters.
  • What can be measured includes effector T cells; central memory T cells (T CM ); effector memory T cells (T EM ). and constituents thereof. What can be measured are biological functions of these cells including cytotoxic function, expression of markers, affinity for antigen, number of cells in a biological compartment such as serum, preferred location in the body such as in lymph node or spleen, and rate of response when exposed or re-exposed to antigen. ii. Methods for measuring antibodies. What can be measured is affinity maturation of antibodies (see, e.g., McHeyzer-Williams and McHeyzer-Williams (2005) Ann. Rev. Immunol.
  • antibody titer or isotype including IgG (IgGi; IgG ⁇ ; IgG3; IgG.»); IgA (IgAi; IgA 2 ); IgM; IgD; IgE; isotype switching of antibodies, for example, decreases in IgM and increases in IgG (see, e.g., Hasbold, et al. (2004) Nature Immunol. 5:55-63; Ryffel, et al. (1997) J. Immunol. 158:2126-2133; Lund, et al. (2002) J. Immunol. 169:5236-5243; Palladino, et al. (1995) J. Virol.
  • What can be measured includes naive B cells (high in membrane IgD and low in CD27), memory B cells (low in IgD and high in CD27), and constituents of these cells (see, e.g., Fecteau and Neron (2003) J. Immunol. 171 :4621-4629). What can be measured is formation of memory B cells within germinal centers (see, e.g., Ohkubo, etal. (2005) J. Immunol. 174:7703-7710). What can be measured includes terminally differentiated B cells, for example, cell's ability to respond to CXCL12 (see, e.g., Roy, et al. (2002) J. Immunol. 169:1676-1682).
  • What can be measured includes commitment antibody-secreting cells (ASCs) (see, e.g., Hasbold, et al. (2004) Nature Immunol. 5:55-63). iv. Parameters of T cells. What can be measured is affinity of a peptide for T cell receptor, affinity maturation of T cell receptor (see, e.g., Rees, et al. (1999) Proc. Natl. Acad. Sci. USA 96:9781-9786; McKinney, et al. (2004) J. Immunol. 173: 1941-1950). What can be measured is affinity of a cytotoxic T cell for a target cell (see, e.g., Montoya and Del VaI (1999) J.
  • ASCs commitment antibody-secreting cells
  • T EM effector memory T cells
  • T CM Central memory T cells
  • Other available markers include, e.g., CCL4, CCL5, XCLl, granulysin, granzyme A, granzyme B, and so on (see, e.g., Chtanova, et al. (2005) J. Immunol.
  • APCs antigen presenting cells
  • DCs dendritic cells
  • Plasmids suitable for introducing a nucleic acid into a bacterium include, e.g., pPLl (GenBank assession no:AJ417488), pPL2 (Ace. No. AJ417449), pLUCH80, pLUCH88, and derivatives thereof (see, e.g., Lauer, et al. (2002) J. Bact. 184:4177-4186: Wilson, et al. (2001) Infect. Immunity 69:5016-5024; Chesneau, et al. (1999) FEMS Microbiol. Lett.
  • CDS coding sequences
  • a suitable APC is murine DC 2.4 cell line, while suitable T cell is the B3Z T cell hybridoma (see, e.g., U.S. Provisional Pat. Appl. Ser. No. 60/490,089 filed July 24, 2003; Shen, et al. (1997) J. Immunol. 158:2723-2730; Kawamura, et al. (2002 J. Immunol. 168:5709-5715; Geginat, et al. (2001) J. Immunol. 166:1877-1884; Skoberne, et al. (2001) J. Immunol. 167:2209-2218; Wang, et al. (1998) J. Immunol.
  • DCs dendritic cells
  • ex vivo modification of the DCs e.g., for the treatment of a cancer, pathogen, or infective agent
  • administration of the modified DCs e.g., for the treatment of a cancer, pathogen, or infective agent.
  • Plaque diameter is a function of a bacterium's ability to grow, to move from from cell to cell, and to escape from a secondary vesicle formed in an adjacent cell (see, e.g., Lauer, et al.
  • Elisp ⁇ t assays and intracellular cytokine staining (ICS) for characterizing immune cells are available (see, e.g., Lalvani, et al. (1997) J. Exp. Med. 186:859-865; Waldrop, el al. (1997) J. Clin. Invest. 99: 1739-1750; Hudgens, et al. (2004) J. Immunol. Methods 288:19-34; Goulder, et al. (2001) J. Virol. 75:1339-1347; Goulder, et al. (2000) J. Exp. Med.
  • ICS intracellular cytokine staining
  • TAP-deficient mice with administration of cells (from another source) that contain an antigen of interest.
  • Another method involves preparing a mouse genetically deficient in an MHC Class I or Class II molecule that is re ⁇ uired for Dresenting a specific epitope, e.g., MHC Class I H-2 b , and administering H-2 b -expressing antigen presenting cells (APCs) (from another source) that contain the antigen of interest (or that were pulsed with an epitope of interest) (see, e.g., van Mierlo, et al. (2004) J. Immunol. 173:6753-6759; Pozzi, et al. (2005) J. Immunol. 175:2071- 2081).
  • APCs antigen presenting cells
  • the present invention provides methods for stimulating and/or diagnosing affinity maturation, as it applies to, e.g., maturation of antibodies and/or of T cells (see, e.g., Chen, et al. (2004) J. Immunol. 173:5021-5027; Rees, et al. (1999) Proc. Natl. Acad. Sci. USA 96:9781-9786; Busch and Pamer (1999) J. Exp. Med. 189:701-709; Ploss, et al. (2005) J. Immunol. 175:5998-6005; Brams, et al. (1998) J. Immunol. 160:2051-2058; Choi, et al. (2003) J. Immunol. 171 :51 16-5123).
  • Colorectal cancer hepatic metastases can be generated using primary hepatic injection, portal vein injection, or whole spleen injection of tumor cells (see, e.g., Suh, et al. (1999) J. Surgical Oncology 72:218-224; Dent and Finley-Jones (1985) Br. J. Cancer 51 :533- 541; Young, et al. (1986) J. Natl. Cancer Inst. 76:745-750; Watson, et al. (1991) J. Leukoc. Biol. 49:126-138).
  • EXAMPLE II Vectors for use in mediating site-specific recombination and homologous recombination.
  • ⁇ ActA ⁇ inlB also known as DP-L4029inlB was deposited with the American Type Culture
  • accession number PTA-5562 L. monocytogenes ⁇ ActA ⁇ uvrAB (also known as DP-L4029uvrAB) was deposited with the ATCC, on October 3, 2003, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and designated with accession number PTA-5563.
  • Yeast medium without glucose contained 25 grams/L yeast extract (Bacto ⁇ yeast extract) (BD Biosciences, Sparks, MD); 9 grams/L potassium phosphate monobasic, pH 7.2.
  • Homologous recombination can be mediated by pKSV7 (SEQ ID NO:3) (see also, Smith and Youngman (1992) Biochimie 74:705-71 1; Camilli, et al. (1993) MoI. Microbiol. 8:143-157; Camilli (1992) Genetic analysis of Listeria monocytogenes Determinants of Pathogenesis, Univ. of Pennsylvania, Doctoral thesis).
  • Site-specific integration can be mediated by pPLl , pPL2, pINT, or variants thereof (see, e.g., Lauer, et al. (2002) J. Bacterid. 184:4177-4186; Int. Appl. No. PCT/US03/13492 (Int. Publ. No. WO 03/092600) of Portnoy, Calendar, and Lauer).
  • the pINT plasm id has loxP sites that allow the specific removal of most of the plasm id from the listerial chromosome, leaving behind the attP and MCS (multiple cloning site), and the contents of the multi-cloning site (MCS) (e.g., an antigen cassette).
  • MCS multi-cloning site
  • pINT can work differently from pPL2 as follows. Up to a 100 microliters aliquot of a 10:1 dilution of a pPL2 conjugation can be plated on double selection plates. Plating up to a 100 microliters aliquot of a 10: 1 dilution of a pPL2 conjugation generally results in 50-100 colonies.
  • pINT can be plated without diluting and even concentrating the conjugation mix because erythromycin (Erm) is more selective than chloramphenicol against E. coli.
  • Erm erythromycin
  • the use of pINT broadens the dynamic range for successful integration by approximately 2 logs.
  • EXAMPLE III ActA-based fusion protein partners, including ActA derivatives that are truncated or deleted in one or more motifs.
  • the present invention provides reagents and methods comprising a first nucleic acid encoding an ActA-based fusion protein partner operably linked to and in frame with a second nucleic acid encoding at least one heterologous antigen.
  • a nucleic acid that can hybridize under stringent conditions to any of the disclosed nucleic acids.
  • first nucleic acid and second nucleic acid that are operably linked with each other, and in frame with each other.
  • operably linked with each other means that any construct comprising the first and second nucleic acids encode a fusion protein.
  • the second nucleic acid can be embedded in the first nucleic acid.
  • the ActA-based fusion protein partner can comprise one or more of the following. "Consisting" embodiments are also available, and here the ActA-based fusion protein partner can consist of one or more of the following embodiments:
  • ActA-NlOO amino acids 1-100 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence.
  • a truncated ActA that normally supports less than 90% the activity of nucleating the Arp2/3 complex, as compared with the activity of full length ActA; conventionally supports less than 80% the nucleating activity of full length ActA; characteristically supports less than 70% the nucleating activity of full length ActA; typically supports less than 60% the nuceating activity of full length ActA; more typically supports less than 50% the nucleating activity of full length ActA; most typically supports less than 40% the nucleating activity of full length ActA; often supports less than 30% the nucleating activity of full length ActA; more often supports less than 20% the nucleating activity of full length ActA; most often supports less than 10% the nucleating activity of full length ActA; usually supports less than 5% the nucleating activity of full length ActA; more usually supports less than 2% the nucleating activity of full length ActA; and most usually is undetectable in any ability to nucleate the Arp2/3 complex.
  • ActA is truncated at about amino acid-40; truncated at about amino acid-45; truncated at about amino acid-50; truncated at about amino acid-55; truncated at about amino acid-60; truncated at about amino acid-65; truncated at about amino acid-70; truncated at about amino acid-75; truncated at about amino acid-80; truncated at about amino acid-85; truncated at about amino acid-90; truncated at about amino acid-95; truncated at about amino acid- 100; truncated at about amino acid-IOS; truncated at about amino acid-1 10; truncated at about amino acid- 1 IS; truncated at about amino acid- 120; truncated at about amino acid-125; truncated at about amino acid-130; truncated at about amino acid- 1
  • ActA secretory sequence amino acids 1-29 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence.
  • ActA secretory sequence and the mature N-terminal domain (amino acids 1-263 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence).
  • ActA sequence with reduced ability to directly stimulate actin polymerization can be, e.g., normally at most 90% maximal, more normally at most 80% maximal, most normally at most 70% maximal, usually at most 60% maximal, more usually at most 50% maximal, most usually at most 40% maximal, often at most 30% maximal, more often at most 20% maximal, most often at most 10% maximal, and typically at most 5% maximal.
  • ActA sequence with a reduced ability to bind to a member of the Ena/VASP family of proteins (mammalian Enabled (Mena); Ena/VASP-like protein (EvI); vasodilator-stimulated phosphoprotein (VASP) (see, e.g., Machner, et al. (2001) J. Biol. Chem. 276:40096-40103).
  • the reduced ability can be, e.g., normally at most 90% maximal, more normally at most 80% maximal, most normally at most 70% maximal, usually at most 60% maximal, more usually at most 50% maximal, most usually at most 40% maximal, often at most 30% maximal, more often at most 20% maximal, most often at most 10% maximal, and typically at most 5% maximal.
  • ActA that is truncated at the point of, deleted in, or mutated in amino acids 93-98 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (LKEKAE (SEQ ID NO: 124)) (homologous to actin binding domain of caldesmon (see, e.g., Pistor, et al. (2000) J. Cell Science 113:3277-3287; Lasa, et al. (1997) EMBO J. 16:1531-1540).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 126-155 (PAIQ, etc.) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence, that are critical for ActA dimer formation (see, e.g., Mourrain, et al. (1997) Proc. Natl. Acad. Sci. USA 94:10034-10039).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 121-170 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (minimal ARP2/3 activating domain) (see, e.g., Zalevsky, et al. (2001) J. Biol. Chem. 276:3468-3475).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 146-150 KKRRK (SEQ ID NO:30)) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (a region essential for recruiting Arp2/3 complex) (Lasa, et al. (1997) EMBO J. 16:1531-1540; Pistor, et al. (2000) J. Cell Science 113:3277-3287).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 41-46 DEWEEE (SEQ ID NO:31) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (a region involved in Arp2/3 complex binding) (see, e.g., Boujemaa-Paterski, et al. (2001) Biochemisty 40: 1 1390-1 1404).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 481-492 (DRLADLRDRGTG (SEQ ID NO:32)), which is a vinculin homology region. Vinculin mediates cell-to-cell spread ofS.flexneri (see, e.g., Kocks, et al. (1992) Cell 68:521-531).
  • ActA that is truncated at the point of, deleted in, or mutated in, the cofilin homology domain (IKKKRRKAIASSD (SEQ ID NO:33)) (amino acids 145-156 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence) (see, e.g., Skoble, et al. (2000) J. Cell Biol. 150:527-537).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 50-125 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (continuity of filament elongation region) (see, e.g., Lasa, et al. (1997) EMBO J. 16:1531-1540).
  • ActA that is truncated at the point of, deleted in, or mutated in, the first FP 4 motif (amino acids 265-269. or 264-269. and the like), second FP 4 motif (amino acids 300-304, or 299-304, and the like), third FP 4 motif (amino acids 335-339, or 334-339, and the like), fourth FP 4 "motif (amino acids 380-384, or 379-384, and the like), all four FP 4 motifs, or any combination of the above, where the amino acids refer to GenBank Ace. No. X59723, or a similar or homologous ActA sequence (see, e.g., Machner, et al. (2001) J.
  • the FP 4 motifs enhance actin polymerization and bacterial motility by recruiting focal contact proteins (e.g., VASP and Mena) and profilin, which promote elongation of filaments nucleated by interactions between motifs at the N-terminal region of ActA and Arp2/3 complex (see, e.g., Welch, et al. (1998) Science 281:105-108; Skoble, et al. (2000) J. Cell Biol. 150:527-537); Pistor, et al. (2000) J. Cell Science 113:3277-3287).
  • focal contact proteins e.g., VASP and Mena
  • profilin which promote elongation of filaments nucleated by interactions between motifs at the N-terminal region of ActA and Arp2/3 complex
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 136-165 of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (cofilin homology region, a region that stimulates Arp2/3 complex) (see, e.g., Lauer, et al. (2001 ) MoI/ Microbiol. 42:1163-1177).
  • ActA that is truncated at the point of, deleted in, or mutated in, the "acidic stretch," that is, amino acids 31-58 (TDSED (SEQ ID NO:34), etc.) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence.
  • the acidic stretch contributes to actin polymerization, movement of Listeria in the host cell cytoplasm, cell to cell spreading, and to plaque size (see, e.g., Skoble, et al. (2000) J. Cell Biol. 150:527-537; Lauer, et al. (2001) MoI. Microbiol. 42:1163-1 177).
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 60-101 (AB region, an actin binding domain) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (see, e.g., Lauer, et al. (2001) MoI. Microbiol. 42: 1 163-1177).
  • ActA that is truncated at the point of, deleted in, or containing the mutation of mutant 34 (no movement; no plaque) amino acids 117-121 (KKRRK (SEQ ID NO:30)) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (Lauer, et al. (2001) MoI. Microbiol. 42:1163-1177.
  • ActA that is truncated at the point of, deleted in, or containing the mutation of mutant 34 (no movement; no plaque) amino acids 244-249 (DKSAGLID (SEQ ID NO: 123)) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence.
  • the mutation can be, e.g., replacement of the D, K, and D by alanines (Lauer, et al. (2001) MoI. Microbiol. 42:1163-1177).
  • ActA that is truncated at the point of, deleted in, or containing the mutation of mutants 39, 47-52, 54 and/or 48 (reduced movement) (Lauer, et al. (2001) MoI. Microbiol. 42:1163- 1177V
  • ActA that is truncated at the point of, deleted in, or mutated in, amino acids 264-390 (central repeat region) of GenBank Ace. No. X59723, or of a similar or homologous ActA sequence (see, e.g., Lauer, et al. (2001) MoI. Microbiol. 42:1 163-1177; Skoble, et al. (2000) J. Cell Biol.
  • the present invention provides an ActA-based fusion protein partner that can comprise any one, or any combination of, the above-disclosed embodiments.
  • "Consisting" embodiments are also available, and here the ActA-based fusion protein partner can consist of one or more of the above-disclosed embodiments.
  • fusion protein partner encompasses, but is not limited to, a nucleic acid encoding a polypeptide, or the polypeptide itself, that occurs as a fusion protein with a heterologous antigen, where the fusion protein partner enhances, e.g., transcription, translation, stability, processing by an antigen presenting cell (APC), presentation by an APC, immune presentation, cytotoxic T cell response, CD8 + T cell response, CD4 "1" T cell response, reduction in tumor size, number, or metastasis, increase in survival to a tumor or infective agent, and the like.
  • APC antigen presenting cell
  • APC antigen presenting cell
  • CD8 + T cell response CD4 "1" T cell response
  • reduction in tumor size, number, or metastasis increase in survival to a tumor or infective agent, and the like.
  • the present invention provides nucleic acids and polypeptides of ActA-NlOO, and fusion proteins thereof, including fusion proteins that comprise at least one antigen.
  • the at least one antigen can comprise mesothelin, H-ras, a mesothelin derivative, a H-ras derivative, or any combination thereof.
  • the nucleic acid encoding at least one antigen can be operably linked to, and in frame with, the N-terminus of an ActA-based fusion protein partner.
  • the nucleic acid encoding the at least one antigen can be operably linked to, and in frame with, the C-terminus of the ActA fusion protein partner.
  • the nucleic acid encoding the at least one antigen can be operably linked with, and reside within a nucleic acid encoding an ActA-based fusion protein partner.
  • EXAMPLE rv Building blocks used for assembling nucleic acids encoding ActA fusion proteins.
  • the following discloses nucleic acids and polypeptides used for making constructs that contain ActA-NlOO as a fusion protein partner. Sequences codon optimized for expression in L. monocytogenes, and non-codon optimized sequences, are identified.
  • EXAMPLE V Building blocks used for assembling Iisteriolysin (LLO; hly gene) fusion proteins.
  • EXAMPLE VI Building blocks used for assembling p60 fusion proteins and fusion proteins other polypeptides that mediate SecA2-dependent secretion.
  • the present invention provides a polynucleotide comprising a first nucleic acid encoding a protein secreted by a SecA2-dependent pathway and a second nucleic acid encoding a heterologous antigen.
  • Autolysins such as p60 and NamA
  • the fusion protein partner e.g., p60 or NamA
  • the fusion protein partner retains its enzymatic or structural activity.
  • the fusion protein partner lacks its enzymatic or structural activity.
  • nucleic acids encoding fusion proteins comprising p60 and human mesothelin (hMeso).
  • Mesothelin was inserted into Listeria's p60 protein as follows.
  • a nucleic acid encoding mesothelin was inserted into a nucleic acid encoding p60, so that when expressed, mesothelin would be inserted into p60 at amino acid 70.
  • a polynucleotide encoding the resulting fusion protein was prepared for use in expression by a Listeria bacterium.
  • protein chimera contained optimal codons for expression in Listeria in the p60 amino acids 1-70 as well as in the entire mesothelin coding sequence.
  • the p60-human mesothelin protein chimera was functionally linked to the L. monocytogenes hly promoter, incorporated into the pPL2 vector, which was used subsequently to generate recombinant L. monocytogenes strains expressing and secreting human mesothelin.
  • the synthesized DNA sequence corresponding to the My promoter-70 N-terminal p60 amino acids is shown below.
  • the 5' end of the synthesized sub-fragment contains a unique Kpnl enzyme recognition sequence.
  • nucleic acid sequence corresponds to the following: hly promoter-p60 (70 N-terminai amino acids of p60).
  • CTGCAG The unique Pstl site (CTGCAG) is visible at the 3 '-end.
  • the 447 bp Kpnl and Pstl digested sub-fragment is ligated into the corresponding Kpnl and Pstl sites of the pPL2 vector, treated by digestion with Kpnl and Pstl enzymes and digestion with calf intestinal alkaline phosphatase (CIAP).
  • This plasmid is known as pPL2- hlyP-Np60 CodOp.
  • the remainder of the native p60 gene was cloned into the pPL2-hlyP-Np60 CodOp plasmid, between the unique Pst I and B ⁇ mHI sites.
  • the remainder of the p60 gene was cloned by PCR, using a proof-reading containing thermostable polymerase, and the following primer pair:
  • Reverse primer 5'-CGCGGATCCTTAATTATACGCGACCGAAG (SEQ ID NO:64)
  • the 1241 bp amplicon is digested with Pstl and BamHI, and the purified 1235 bp is ligated into the pPL2-hlyP-Np60 CodOp plasmid, digested with Pstl and BamHI, and treated with CIAP.
  • the resulting plasmid contains the full p60 gene with optimal codons corresponding to amino acids 1-77, and native codons corresponding to amino acids 78-478.
  • the full p60 gene is linked functional to the L. monocytogenes hly promoter.
  • nucleic acid sequence corresponds to the following: hly promoter-p60-
  • the construct has not yet received a nucleic acid encoding a heterologous antigen.
  • the unique Pstl site will receive a nucleic acid encoding a heterologous antigen (mesothelin).
  • This plasmid which contains full length p60, but with the N-terminal region codon optimized, and the C-terminal region non-codon optimized, is known as: pPL2-hlyP-Np60 CodOp (1-77).
  • the sequence of the Kpnl-BamHI sub-fragment that contains the hlyP linked functionally to the p60 encoding sequence is shown below (SEQ ID NO:65).
  • the expected sequence of the pPL2-hlyP-Np60 Cod ⁇ p(l- 77) plasmid was confirmed by sequencing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une bactérie contenant un polynucléotide qui comporte un acide nucléique codant pour un antigène hétérologue, de même que des partenaires protéiques de fusion. L'invention concerne également des vecteurs permettant d'induire une recombinaison spécifique d'un site et des vecteurs comportant des gènes de résistance aux antibiotiques susceptibles d'être supprimés.
PCT/US2007/005455 2006-03-01 2007-03-01 Listeria de fabrication humaine et ses procédés d'utilisation WO2007117371A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77847106P 2006-03-01 2006-03-01
US60/778,471 2006-03-01
US78491506P 2006-03-21 2006-03-21
US60/784,915 2006-03-21
US78855806P 2006-03-30 2006-03-30
US60/788,558 2006-03-30

Publications (2)

Publication Number Publication Date
WO2007117371A2 true WO2007117371A2 (fr) 2007-10-18
WO2007117371A3 WO2007117371A3 (fr) 2008-12-18

Family

ID=38581544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005455 WO2007117371A2 (fr) 2006-03-01 2007-03-01 Listeria de fabrication humaine et ses procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2007117371A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143085A1 (fr) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comportant un mutant prfa de listeria, et leurs procédés d'utilisation
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2014106123A1 (fr) 2012-12-27 2014-07-03 Aduro Biotech, Inc. Partenaires de fusion de type peptides signal favorisant l'expression de séquences antigéniques dans les bactéries du genre listeria et leurs procédés de préparation et d'utilisation
US9200057B2 (en) 2010-11-17 2015-12-01 Providence Health & Services-Oregon Methods and compositions for inducing an immune response to EGFRvIII
US9511129B2 (en) 2012-11-06 2016-12-06 Aduro Biotech, Inc. Facultatively attenuated bacterial species and methods of preparation and use thereof
US9808516B2 (en) 2015-04-13 2017-11-07 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
US10105427B2 (en) 2015-04-13 2018-10-23 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
KR20200096955A (ko) * 2017-12-13 2020-08-14 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
US10774390B2 (en) 2015-09-02 2020-09-15 The Regents Of The University Of California Methods and compositions for modulating PrfA mediated virulence gene activation in Listeria spp
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020079768A (ko) * 2000-01-04 2002-10-19 에이브이아이 바이오파마 인코포레이티드 안티센스 항박테리아 세포분열 조성물 및 방법
US7056728B2 (en) * 2000-07-06 2006-06-06 Xenogen Corporation Compositions and methods for use thereof in modifying the genomes of microorganisms

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US8580939B2 (en) 2006-03-01 2013-11-12 Aduro Biotech Engineered Listeria and methods of use thereof
WO2009143085A1 (fr) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comportant un mutant prfa de listeria, et leurs procédés d'utilisation
US9200057B2 (en) 2010-11-17 2015-12-01 Providence Health & Services-Oregon Methods and compositions for inducing an immune response to EGFRvIII
US9511129B2 (en) 2012-11-06 2016-12-06 Aduro Biotech, Inc. Facultatively attenuated bacterial species and methods of preparation and use thereof
WO2014106123A1 (fr) 2012-12-27 2014-07-03 Aduro Biotech, Inc. Partenaires de fusion de type peptides signal favorisant l'expression de séquences antigéniques dans les bactéries du genre listeria et leurs procédés de préparation et d'utilisation
US9663557B2 (en) 2012-12-27 2017-05-30 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US9808516B2 (en) 2015-04-13 2017-11-07 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
US10105427B2 (en) 2015-04-13 2018-10-23 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10774390B2 (en) 2015-09-02 2020-09-15 The Regents Of The University Of California Methods and compositions for modulating PrfA mediated virulence gene activation in Listeria spp
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
KR20200096955A (ko) * 2017-12-13 2020-08-14 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
KR102637862B1 (ko) * 2017-12-13 2024-02-19 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
US11986517B2 (en) 2017-12-13 2024-05-21 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
WO2007117371A3 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
DK1991263T3 (en) Prepared listeria and methods of use thereof
US9764013B2 (en) Engineered Listeria and methods of use thereof
WO2007117371A2 (fr) Listeria de fabrication humaine et ses procédés d'utilisation
US20070207171A1 (en) Engineered listeria and methods of use thereof
US7700104B2 (en) Attenuated Salmonella SP12 mutants as antigen carriers
JP5530065B2 (ja) 抗生物質耐性欠失ワクチンの作成方法
US7794728B2 (en) Attenuated Listeria spp. and methods for using the same
AU2013341242B2 (en) Facultatively attenuated bacterial species and methods of preparation and use thereof
JP5713523B2 (ja) エンドソームエスケープ能力増強組み換えｂｃｇ株類
AU2013341242A1 (en) Facultatively attenuated bacterial species and methods of preparation and use thereof
US7829104B2 (en) Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
AU2016369580A1 (en) Listeria-based immunotherapy and methods of use thereof
US20120121643A1 (en) Engineered listeria and methods of use thereof
WO2005037222A2 (fr) Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci
US10226521B2 (en) Genetically modified Yersinia as vaccines against Yersinia species
EP3381931A1 (fr) Anatoxine de cyclase d'adénylate avec réduction de l'activité cytolytique
Tiner Induction of Long-Term Immune Responses to Protect Mice against Pneumonic Plague: Development and Testing of Novel Live-Attenuated Mutants of Yersinia pestis CO92

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07794330

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07794330

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载